{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:10:48Z","timestamp":1792609848564,"version":"4.5.0"},"reference-count":991,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100011840","name":"Shantou University Medical College","doi-asserted-by":"publisher","award":["0001408"],"award-info":[{"award-number":["0001408"]}],"id":[{"id":"10.13039\/501100011840","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172917"],"award-info":[{"award-number":["82172917"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32571076"],"award-info":[{"award-number":["32571076"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.drup.2026.101355","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:41:45Z","timestamp":1768264905000},"page":"101355","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["The hallmarks of oncogenic signaling: From pathways to resistance in cancer therapy"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3442-7216","authenticated-orcid":false,"given":"Muhammad","family":"Tufail","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunxiang","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bushra","family":"Ijaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3416-8931","authenticated-orcid":false,"given":"Harsh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4717-4473","authenticated-orcid":false,"given":"Weng-Onn","family":"Lui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiumei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drup.2026.101355_bib1","author":"Elranatamab (Elrexfio) for Multiple Myeloma","year":"2023","journal-title":"Med. Lett. Drugs Ther."},{"key":"10.1016\/j.drup.2026.101355_bib2","first-page":"1717","volume":"66","author":"Isatuximab (Sarclisa) for multiple myeloma","year":"2024","journal-title":"Med. Lett. Drugs Ther."},{"key":"10.1016\/j.drup.2026.101355_bib3","article-title":"Elotuzumab in Multiple Myeloma","volume":"9","author":"Mechanisms of NK cell activation and clinical activity of the therapeutic SLAMF7 antibody","year":"2018","journal-title":"Front. Immunol."},{"issue":"26","key":"10.1016\/j.drup.2026.101355_bib4","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2017-05-782292","volume":"129","author":"Midostaurin approved for FLT3-mutated AML","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101355_bib5","doi-asserted-by":"crossref","unstructured":"Sunitinib in the Treatment of Thyroid Cancer, Current medicinal chemistry 26 6 (2019), pp. 963-972.","DOI":"10.2174\/0929867324666171006165942"},{"key":"10.1016\/j.drup.2026.101355_bib6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10549-008-9908-5","article-title":"Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer","volume":"113","author":"Aaltonen","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.drup.2026.101355_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2021.109450","article-title":"Nuclear factor-\u03baB signaling inhibitors revert multidrug-resistance in breast cancer cells","volume":"340","author":"Abdin","year":"2021","journal-title":"Chem. -Biol. Interact."},{"key":"10.1016\/j.drup.2026.101355_bib8","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3892\/mco.2021.2413","article-title":"Expression of VEGF, EGF and HGF in early- and late-stage colorectal cancer","volume":"15","author":"Abdulla","year":"2021","journal-title":"Mol. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.drup.2026.101355_bib9","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.clbc.2016.05.016","article-title":"Neratinib, a novel HER2-targeted tyrosine kinase inhibitor","volume":"16","author":"Abraham","year":"2016","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib10","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/s12276-022-00863-4","article-title":"DNA damage response revisited: the p53 family and its regulators provide endless cancer therapy opportunities","volume":"54","author":"Abuetabh","year":"2022","journal-title":"Exp. Mol. Med"},{"key":"10.1016\/j.drup.2026.101355_bib11","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1517\/14712598.7.2.257","article-title":"Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity","volume":"7","author":"Aglietta","year":"2007","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.drup.2026.101355_bib12","doi-asserted-by":"crossref","first-page":"11542","DOI":"10.1002\/cam4.5577","article-title":"Autophagy: a challengeable paradox in cancer treatment","volume":"12","author":"Ahmadi-Dehlaghi","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.drup.2026.101355_bib13","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s00423-016-1483-3","article-title":"Loss of APAF-1 expression is associated with early recurrence in stage I, II, and III colorectal cancer","volume":"401","author":"Ahn","year":"2016","journal-title":"Lange 'S. Arch. Surg."},{"key":"10.1016\/j.drup.2026.101355_bib14","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.3748\/wjg.v29.i32.4883","article-title":"Different oncological features of colorectal cancer codon-specific KRAS mutations: not codon 13 but codon 12 have prognostic value","volume":"29","author":"Ahn","year":"2023","journal-title":"World J. Gastroenterol."},{"issue":"6","key":"10.1016\/j.drup.2026.101355_bib15","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2217\/fon.13.68","article-title":"Ramucirumab: a novel antiangiogenic agent","volume":"9","author":"Ajani","year":"2013","journal-title":"Future Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib16","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1007\/s00018-016-2146-9","article-title":"Reactivation of telomerase in cancer","volume":"73","author":"Akincilar","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.drup.2026.101355_bib17","article-title":"Tumor angiogenesis: current challenges and therapeutic opportunities","volume":"28","author":"Al-Ostoot","year":"2021","journal-title":"Cancer Treat. Res. Commun."},{"key":"10.1016\/j.drup.2026.101355_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15010038","article-title":"A review of margetuximab-based therapies in patients with HER2-positive metastatic breast cancer","volume":"15","author":"Alasmari","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2026.101355_bib19","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/humu.20234","article-title":"Spectrum of gross deletions and insertions in the RB1 gene in patients with retinoblastoma and association with phenotypic expression","volume":"26","author":"Albrecht","year":"2005","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.drup.2026.101355_bib20","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2174\/1574362418666230810094626","article-title":"Mutation S249C of FGFR3b promotes bladder cancer through downstream signaling proteins FRS2 and FRS3: a computational approach","volume":"18","author":"Ali","year":"2023","journal-title":"Curr. Signal Transduct. Ther."},{"key":"10.1016\/j.drup.2026.101355_bib21","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s12935-022-02706-8","article-title":"Recent advances and limitations of mTOR inhibitors in the treatment of cancer","volume":"22","author":"Ali","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.drup.2026.101355_bib22","doi-asserted-by":"crossref","first-page":"42295","DOI":"10.1038\/s41598-025-23435-8","article-title":"Transfer learning with multiomics integration and deep neural networks reveals drug resistance mechanisms in cancer","volume":"15","author":"Alpsoy","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drup.2026.101355_bib23","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.3390\/cancers13194820","article-title":"Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia\u2014from molecular mechanisms to clinical relevance","volume":"13","author":"Alves","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2026.101355_bib24","doi-asserted-by":"crossref","first-page":"E10869","DOI":"10.1073\/pnas.1808314115","article-title":"p53 mutants cooperate with HIF-1 in transcriptional regulation of extracellular matrix components to promote tumor progression","volume":"115","author":"Amelio","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.semcancer.2015.02.005","article-title":"Evasion of anti-growth signaling: a key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds","volume":"35","author":"Amin","year":"2015","journal-title":"Semin Cancer Biol."},{"key":"10.1016\/j.drup.2026.101355_bib26","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s10616-017-0134-z","article-title":"MiR-221\/222 promote chemoresistance to cisplatin in ovarian cancer cells by targeting PTEN\/PI3K\/AKT signaling pathway","volume":"70","author":"Amini-Farsani","year":"2018","journal-title":"Cytotechnology"},{"key":"10.1016\/j.drup.2026.101355_bib27","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3892\/or.2022.8296","article-title":"p53 reactivating small molecule PRIMA\u20111MET\/APR\u2011246 regulates genomic instability in MDA\u2011MB\u2011231 cells","volume":"47","author":"Amirtharaj","year":"2022","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.drup.2026.101355_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102224","article-title":"Recent advancements of antiangiogenic combination therapies in ovarian cancer","volume":"98","author":"An","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.drup.2026.101355_bib29","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.drup.2026.101355_bib30","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor\u2013positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.drup.2026.101355_bib31","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101355_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.01275","article-title":"TERT promoter mutation C228T increases risk for tumor recurrence and death in head and neck cancer patients","volume":"10","author":"Arantes","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib33","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3390\/cells12071002","article-title":"Role of basic fibroblast growth factor in cancer: biological activity, targeted therapies, and prognostic value","volume":"12","author":"Ardizzone","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.drup.2026.101355_bib34","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/annonc\/mds245","article-title":"Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck","volume":"24","author":"Argiris","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib35","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1158\/1535-7163.MCT-19-0208","article-title":"ATM dysfunction in pancreatic adenocarcinoma and associated therapeutic implications","volume":"18","author":"Armstrong","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drup.2026.101355_bib36","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.devcel.2020.04.016","article-title":"Hedgehog signaling regulates epithelial morphogenesis to position the ventral embryonic midline","volume":"53","author":"Arraf","year":"2020","journal-title":"Dev. Cell"},{"key":"10.1016\/j.drup.2026.101355_bib37","doi-asserted-by":"crossref","DOI":"10.1590\/1678-4685-gmb-2018-0160","article-title":"Targeting STAT-3 signaling pathway in cancer for development of novel drugs: advancements and challenges","volume":"43","author":"Arshad","year":"2020","journal-title":"Genet Mol. Biol."},{"key":"10.1016\/j.drup.2026.101355_bib38","first-page":"115","article-title":"Spotlight on patritumab deruxtecan (HER3-DXd) from HERTHENA Lung01. Is a median PFS of 5.5 months enough in light of FLAURA-2 and MARIPOSA?","volume":"15","author":"Arter","year":"2024","journal-title":"Lung Cancer (Auckl. )"},{"key":"10.1016\/j.drup.2026.101355_bib39","doi-asserted-by":"crossref","first-page":"589","DOI":"10.4161\/cc.6.5.3900","article-title":"Apaf1 in chronic myelogenous leukemia (CML) progression: reduced Apaf1 expression is correlated with a H179R p53 mutation during clinical blast crisis","volume":"6","author":"Ashur-Fabian","year":"2007","journal-title":"Cell Cycle"},{"key":"10.1016\/j.drup.2026.101355_bib40","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.lungcan.2019.04.005","article-title":"Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer","volume":"132","author":"Assoun","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib41","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026062","article-title":"Tumor-suppressor functions of the TP53 pathway","volume":"6","author":"Aubrey","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med"},{"key":"10.1016\/j.drup.2026.101355_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.931774","article-title":"Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation","volume":"12","author":"Avery","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib43","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRASG12C inhibition in cancer","volume":"384","author":"Awad Mark","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101355_bib44","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRASG12C inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101355_bib45","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41419-023-06391-x","article-title":"Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy","volume":"15","author":"Babamohamadi","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.drup.2026.101355_bib46","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.drup.2026.101355_bib47","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41421-023-00523-5","article-title":"Structure and dynamics of the EGFR\/HER2 heterodimer","volume":"9","author":"Bai","year":"2023","journal-title":"Cell Discov."},{"key":"10.1016\/j.drup.2026.101355_bib48","doi-asserted-by":"crossref","first-page":"21","DOI":"10.18632\/genesandcancer.221","article-title":"CDK4: a master regulator of the cell cycle and its role in cancer","volume":"13","author":"Baker","year":"2022","journal-title":"Genes Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib49","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.3390\/cells11091502","article-title":"Crocin inhibits angiogenesis and metastasis in colon cancer via TNF-\u03b1\/NF-kB\/VEGF pathways","volume":"11","author":"Bakshi","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.drup.2026.101355_bib50","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1002\/eji.201343448","article-title":"Hypoxia downregulates the expression of activating receptors involved in NK-cell-mediated target cell killing without affecting ADCC","volume":"43","author":"Balsamo","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.drup.2026.101355_bib51","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012374","article-title":"Artificial intelligence-powered spatial analysis of tumor microenvironment in patients with non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitor","volume":"13","author":"Bang","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib52","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.canlet.2013.05.007","article-title":"MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT\/ERK pathways","volume":"337","author":"Bao","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.drup.2026.101355_bib53","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1111\/jcmm.17303","article-title":"Effect of Glut-1 and HIF-1\u03b1 double knockout by CRISPR\/CAS9 on radiosensitivity in laryngeal carcinoma via the PI3K\/Akt\/mTOR pathway","volume":"26","author":"Bao","year":"2022","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.drup.2026.101355_bib54","article-title":"Abstract CT179: telisotuzumab vedotin (teliso-v) monotherapy in patients with previously treated c-Met+advanced non-small cell lung cancer","author":"Bar","year":"2021","journal-title":"Clin. Trials"},{"key":"10.1016\/j.drup.2026.101355_bib55","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/1541-7786.MCR-20-0687","article-title":"The MEK\/ERK network as a therapeutic target in human cancer","volume":"19","author":"Barbosa","year":"2021","journal-title":"Mol. Cancer Res"},{"key":"10.1016\/j.drup.2026.101355_bib56","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1200\/JCO.23.01708","article-title":"Phase II, single-arm trial of induction and concurrent vismodegib with curative-intent radiation therapy for locally advanced, unresectable basal cell carcinoma","volume":"42","author":"Barker","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib57","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/path.971","article-title":"Evaluating HER2 amplification and overexpression in breast cancer","volume":"195","author":"Bartlett","year":"2001","journal-title":"J. Pathol.: A J. Pathol. Soc. Gt. Br. Irel."},{"key":"10.1016\/j.drup.2026.101355_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.adcanc.2021.100005","article-title":"miR-221 regulates proliferation, invasion, apoptosis and progression of prostate cancer cells by modulating E-cadherin\/Wnt\/\u03b2 catenin axis","volume":"2","author":"Baruah","year":"2021","journal-title":"Adv. Cancer Biol. - Metastas-.-."},{"key":"10.1016\/j.drup.2026.101355_bib59","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming growth factor-\u03b2 signaling in immunity and cancer","volume":"50","author":"Batlle","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.drup.2026.101355_bib60","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1002\/1878-0261.13224","article-title":"Resistance to DNA repair inhibitors in cancer","volume":"16","author":"Baxter","year":"2022","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib61","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1093\/oncolo\/oyac261","article-title":"Combining sunitinib and bevacizumab for the management of advanced renal cell carcinoma: a phase I\/II trial","volume":"28","author":"Bazarbashi","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.drup.2026.101355_bib62","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10739-008-9171-y","article-title":"Scientific discovery and scientific reputation: the reception of Peyton Rous' discovery of the chicken sarcoma virus","volume":"43","author":"Becsei-Kilborn","year":"2010","journal-title":"J. Hist. Biol."},{"key":"10.1016\/j.drup.2026.101355_bib63","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/bjc.2016.255","article-title":"Transforming growth factor \u03b2 as regulator of cancer stemness and metastasis","volume":"115","author":"Bellomo","year":"2016","journal-title":"Br. J. Cancer"},{"issue":"12","key":"10.1016\/j.drup.2026.101355_bib64","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","article-title":"Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study","volume":"19","author":"Besse","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib65","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10555-024-10172-z","article-title":"Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance","volume":"43","author":"Bhat","year":"2024","journal-title":"Cancer Metastas-.-. Rev."},{"key":"10.1016\/j.drup.2026.101355_bib66","article-title":"Antibody\u2013drug conjugates for the treatment of acute pediatric leukemia","volume":"10","author":"Bhojwani","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.drup.2026.101355_bib67","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.gene.2017.11.017","article-title":"AJUBA increases the cisplatin resistance through hippo pathway in cervical cancer","volume":"644","author":"Bi","year":"2018","journal-title":"Gene"},{"key":"10.1016\/j.drup.2026.101355_bib68","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1158\/2159-8290.CD-18-0710","article-title":"IL1-induced JAK\/STAT signaling is antagonized by TGF\u03b2 to shape CAF heterogeneity in pancreatic ductal adenocarcinoma","volume":"9","author":"Biffi","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drup.2026.101355_bib69","doi-asserted-by":"crossref","first-page":"15259","DOI":"10.1073\/pnas.1521145112","article-title":"Discovery of oncogenes: the advent of molecular cancer research","volume":"112","author":"Bister","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.drup.2026.101355_bib70","doi-asserted-by":"crossref","first-page":"6422","DOI":"10.1038\/s41467-023-42156-y","article-title":"Oncogenic context shapes the fitness landscape of tumor suppression","volume":"14","author":"Blair","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101355_bib71","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1517\/13543784.12.8.1395","article-title":"Erlotinib: a new therapeutic approach for non-small cell lung cancer","volume":"12","author":"Bonomi","year":"2003","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.drup.2026.101355_bib72","article-title":"Abstract 1555: enhanced HER2-dependent immune activation by margetuximab, an investigational Fc-engineered anti-HER2 mAb, supports combination with checkpoint blockade","author":"Bonvini","year":"2021","journal-title":"Immunology"},{"key":"10.1016\/j.drup.2026.101355_bib73","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1158\/0008-5472.CAN-23-0519","article-title":"Obesogenic high-fat diet and MYC cooperate to promote lactate accumulation and tumor microenvironment remodeling in prostate cancer","volume":"84","author":"Boufaied","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2026.101355_bib74","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/s41467-021-21615-4","article-title":"Inter-and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling","volume":"12","author":"Brady","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101355_bib75","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11101618","article-title":"A comprehensive review on MAPK: a promising therapeutic target in cancer","volume":"11","author":"Braicu","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drup.2026.101355_bib76","article-title":"Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase fusion\u2013positive lung cancers","volume":"6","author":"Brega","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib77","doi-asserted-by":"crossref","first-page":"495","DOI":"10.32604\/or.2023.029309","article-title":"mTORC2 promotes pancreatic cancer progression and parp inhibitor resistance","volume":"31","author":"Bu","year":"2023","journal-title":"Oncol. Res"},{"key":"10.1016\/j.drup.2026.101355_bib78","doi-asserted-by":"crossref","first-page":"7357","DOI":"10.1038\/s41388-019-0921-4","article-title":"\u00e9r\u00e9, T-cell acute lymphoblastic leukemia displays autocrine production of Interleukin-7","volume":"38","author":"Buffi\u00e8re","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.drup.2026.101355_bib79","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1038\/s41467-024-46811-w","article-title":"Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer","volume":"15","author":"Bulle","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101355_bib80","first-page":"90","article-title":"Is telomerase a viable target in cancer?","volume":"730","author":"Buseman","year":"2012","journal-title":"Mutat. Res. \/Fundam. Mol. Mech. Mutagen."},{"key":"10.1016\/j.drup.2026.101355_bib81","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12885-023-10561-7","article-title":"IGF-1R down regulates the sensitivity of hepatocellular carcinoma to sorafenib through the PI3K\/akt and RAS\/raf\/ERK signaling pathways","volume":"23","author":"Cai","year":"2023","journal-title":"BMC Cancer"},{"issue":"16","key":"10.1016\/j.drup.2026.101355_bib82","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1200\/JCO.18.02236","article-title":"ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer","volume":"37","author":"Camidge","year":"2019","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib83","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1158\/1535-7163.MCT-13-0731","article-title":"Hedgehog pathway inhibition in chondrosarcoma using the smoothened inhibitor IPI-926 directly inhibits sarcoma cell growth","volume":"13","author":"Campbell","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drup.2026.101355_bib84","article-title":"Trastuzumab deruxtecan in breast cancer","author":"Cano","year":"2024","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"key":"10.1016\/j.drup.2026.101355_bib85","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.7150\/thno.21477","article-title":"Twist promotes tumor metastasis in basal-like breast cancer by transcriptionally upregulating ROR1","volume":"8","author":"Cao","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.drup.2026.101355_bib86","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1282996","article-title":"ATF5 promotes malignant T cell survival through the PI3K\/AKT\/mTOR pathway in cutaneous T cell lymphoma","volume":"14","author":"Cao","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.drup.2026.101355_bib87","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s13277-013-1171-7","article-title":"miR-34a regulates cisplatin-induce gastric cancer cell death by modulating PI3K\/AKT\/survivin pathway","volume":"35","author":"Cao","year":"2014","journal-title":"Tumor Biol."},{"key":"10.1016\/j.drup.2026.101355_bib88","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.4161\/15592294.2014.971608","article-title":"TGF-\u03b2 induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells","volume":"9","author":"Cardenas","year":"2014","journal-title":"Epigenetics"},{"issue":"4","key":"10.1016\/j.drup.2026.101355_bib89","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1535-6108(04)00083-2","article-title":"Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex","volume":"5","author":"Carey","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2026.101355_bib90","first-page":"3994","article-title":"The microRNA\u2011200 family acts as an oncogene in colorectal cancer by inhibiting the tumor suppressor RASSF2","volume":"18","author":"Carter","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.drup.2026.101355_bib91","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1073\/pnas.0730640100","article-title":"Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells","volume":"100","author":"Castriconi","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.drup.2026.101355_bib92","doi-asserted-by":"crossref","DOI":"10.3892\/or.2023.8496","article-title":"Modulating epigenetic modifications for cancer therapy (Review)","volume":"49","author":"Castro-Mu\u00f1oz","year":"2023","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.drup.2026.101355_bib93","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","article-title":"Mechanisms controlling PD-L1 expression in cancer","volume":"76","author":"Cha","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.drup.2026.101355_bib94","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.1038\/ncomms6811","article-title":"Constitutive and ligand-induced EGFR signalling triggers distinct and mutually exclusive downstream signalling networks","volume":"5","author":"Chakraborty","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101355_bib95","doi-asserted-by":"crossref","DOI":"10.3390\/biom12030358","article-title":"Anti-GD2 directed immunotherapy for high-risk and metastatic neuroblastoma","volume":"12","author":"Chan","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.drup.2026.101355_bib96","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/s43018-024-00772-7","article-title":"LORIS robustly predicts patient outcomes with immune checkpoint blockade therapy using common clinical, pathologic and genomic features","volume":"5","author":"Chang","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib97","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1002\/cam4.2174","article-title":"Activated hippo signal pathway inhibits cell proliferation and promotes apoptosis in NK\/T cell lymphoma cells","volume":"8","author":"Chang","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.drup.2026.101355_bib98","article-title":"Focus on ROS1-positive non-small cell lung cancer (NSCLC): crizotinib, resistance mechanisms and the newer generation of targeted therapies","volume":"12","author":"Chapman","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2026.101355_bib99","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.578418","article-title":"The double-edge sword of autophagy in cancer: from tumor suppression to pro-tumor activity","volume":"10","author":"Chavez-Dominguez","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2020.113388","article-title":"Kanglaite enhances the efficacy of cisplatin in suppression of hepatocellular carcinoma via inhibiting CKLF1 mediated NF-\u03baB pathway and regulating transporter mediated drug efflux","volume":"264","author":"Chen","year":"2021","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.drup.2026.101355_bib101","doi-asserted-by":"crossref","first-page":"13595","DOI":"10.1074\/jbc.C200694200","article-title":"Direct interactions between HIF-1 alpha and Mdm2 modulate p53 function","volume":"278","author":"Chen","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drup.2026.101355_bib102","first-page":"2025","article-title":"Multi-omics dissection of tumor microenvironment-mediated drug resistance: mechanisms and therapeutic reprogramming","volume":"16","author":"Chen","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.drup.2026.101355_bib103","doi-asserted-by":"crossref","first-page":"987","DOI":"10.7150\/jca.63410","article-title":"Activation of the Hedgehog pathway mediates resistance to epidermal growth factor receptor inhibitors in non-small cell lung cancer","volume":"13","author":"Chen","year":"2022","journal-title":"J. Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib104","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/s41419-020-02989-7","article-title":"Circular RNA GLIS2 promotes colorectal cancer cell motility via activation of the NF-\u03baB pathway","volume":"11","author":"Chen","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.drup.2026.101355_bib105","doi-asserted-by":"crossref","first-page":"7291","DOI":"10.7150\/jca.46429","article-title":"VEGF promotes migration and invasion by regulating EMT and MMPs in nasopharyngeal carcinoma","volume":"11","author":"Chen","year":"2020","journal-title":"J. Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib106","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41392-020-0196-9","article-title":"Regulating tumor suppressor genes: post-translational modifications","volume":"5","author":"Chen","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.drup.2026.101355_bib107","first-page":"2023","article-title":"Unveiling tumor immune evasion mechanisms: abnormal expression of transporters on immune cells in the tumor microenvironment","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.drup.2026.101355_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.biocel.2024.106637","article-title":"Tumor-derived exosomal ICAM1 promotes bone metastasis of triple-negative breast cancer by inducing CD8+ T cell exhaustion","volume":"175","author":"Chen","year":"2024","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.drup.2026.101355_bib109","doi-asserted-by":"crossref","first-page":"9319","DOI":"10.2147\/OTT.S227220","article-title":"BANCR regulates the cell invasion and migration in esophageal squamous cell carcinoma through Wnt\/\u03b2-catenin signaling pathway","volume":"12","author":"Chen","year":"2019","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.drup.2026.101355_bib110","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.3892\/ol.2017.6823","article-title":"Long non-coding RNA PTENP1 inhibits proliferation and migration of breast cancer cells via AKT and MAPK signaling pathways","volume":"14","author":"Chen","year":"2017","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.drup.2026.101355_bib111","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1059995","article-title":"PD-1\/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1\/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: a real-world retrospective cohort study","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.drup.2026.101355_bib112","article-title":"Tumor-derived exosomal circFARSA mediates M2 macrophage polarization via the PTEN\/PI3K\/AKT pathway to promote non-small cell lung cancer metastasis","volume":"28","author":"Chen","year":"2021","journal-title":"Cancer Treat. Res. Commun."},{"key":"10.1016\/j.drup.2026.101355_bib113","doi-asserted-by":"crossref","DOI":"10.3390\/metabo10070289","article-title":"Metabolic reprogramming of chemoresistant cancer cells and the potential significance of metabolic regulation in the reversal of cancer chemoresistance","volume":"10","author":"Chen","year":"2020","journal-title":"Metabolites"},{"key":"10.1016\/j.drup.2026.101355_bib114","doi-asserted-by":"crossref","first-page":"S806","DOI":"10.1016\/j.annonc.2021.08.1319","article-title":"909P A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy: updated results","volume":"32","author":"Chen","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib115","first-page":"3423","article-title":"Long non-coding RNA ZFAS1 promotes nasopharyngeal carcinoma through activation of Wnt\/\u03b2-catenin pathway","volume":"22","author":"Chen","year":"2018","journal-title":"Eur. Rev. Med Pharm. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib116","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41419-022-05408-1","article-title":"Mutant p53 in cancer: from molecular mechanism to therapeutic modulation","volume":"13","author":"Chen","year":"2022","journal-title":"Cell death Dis."},{"key":"10.1016\/j.drup.2026.101355_bib117","first-page":"349","article-title":"Long non\u2011coding RNA GHET1 promotes osteosarcoma development and progression via Wnt\/\u03b2\u2011catenin signaling pathway","volume":"44","author":"Chen","year":"2020","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.drup.2026.101355_bib118","first-page":"625","article-title":"Hedgehog signaling regulates drug sensitivity by targeting ABC transporters ABCB1 and ABCG2 in epithelial ovarian cancer","volume":"53","author":"Chen","year":"2014","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.drup.2026.101355_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2021.108728","article-title":"Atezolizumab and blockade of LncRNA PVT1 attenuate cisplatin resistant ovarian cancer cells progression synergistically via JAK2\/STAT3\/PD-L1 pathway","volume":"227","author":"Chen","year":"2021","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.drup.2026.101355_bib120","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41419-024-06712-8","article-title":"Research progress on morphology and mechanism of programmed cell death","volume":"15","author":"Chen","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.drup.2026.101355_bib121","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.3892\/mmr.2013.1403","article-title":"miRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherin-mediated PTEN\/Akt signaling","volume":"7","author":"Chen","year":"2013","journal-title":"Mol. Med Rep."},{"key":"10.1016\/j.drup.2026.101355_bib122","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1111\/1759-7714.13603","article-title":"Circular RNA CirCHIPK3 promotes cell proliferation and invasion of breast cancer by sponging miR-193a\/HMGB1\/PI3K\/AKT axis","volume":"11","author":"Chen","year":"2020","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib123","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","article-title":"Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.drup.2026.101355_bib124","doi-asserted-by":"crossref","first-page":"2254976","DOI":"10.1080\/15592294.2023.2254976","article-title":"DNMT1 expression partially dictates 5-Azacytidine sensitivity and correlates with RAS\/MEK\/ERK activity in gastric cancer cells","volume":"18","author":"Chen","year":"2023","journal-title":"Epigenetics"},{"key":"10.1016\/j.drup.2026.101355_bib125","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/cncr.10231","article-title":"Expression of nucleotide excision repair genes and the risk for squamous cell carcinoma of the head and neck","volume":"94","author":"Cheng","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib126","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12013-023-01205-5","article-title":"Hypoxia potentiated lung cancer cell migration and invasion by up-regulating HIF1\u03b1\/JAK2\/STAT3 axis and activating MMP13 transcription","volume":"82","author":"Cheng","year":"2024","journal-title":"Cell Biochem. Biophys."},{"key":"10.1016\/j.drup.2026.101355_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114529","article-title":"DTX3 suppresses bladder cancer cell invasion and metastasis by inhibiting the Notch signaling pathway","volume":"153","author":"Cheng","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.drup.2026.101355_bib128","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.molcel.2010.01.025","article-title":"The BCL-2 family reunion","volume":"37","author":"Chipuk","year":"2010","journal-title":"Mol. Cell"},{"key":"10.1016\/j.drup.2026.101355_bib129","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.128834","article-title":"Necroptosis: a crucial pathogenic mediator of human disease","volume":"4","author":"Choi","year":"2019","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.drup.2026.101355_bib130","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.critrevonc.2010.02.012","article-title":"Pazopanib: clinical development of a potent anti-angiogenic drug","volume":"77","author":"Choueiri","year":"2011","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"issue":"10","key":"10.1016\/j.drup.2026.101355_bib131","article-title":"A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities","volume":"18","author":"Christensen","year":"2007","journal-title":"Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib132","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/nsmb.3275","article-title":"One-way membrane trafficking of SOS in receptor-triggered Ras activation","volume":"23","author":"Christensen","year":"2016","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.drup.2026.101355_bib133","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.965492","article-title":"Endostatin induces normalization of blood vessels in colorectal cancer and promotes infiltration of CD8+ T cells to improve anti-PD-L1 immunotherapy","volume":"13","author":"Chu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.drup.2026.101355_bib134","doi-asserted-by":"crossref","first-page":"31277","DOI":"10.1074\/jbc.M110.158485","article-title":"Stabilization of hypoxia-inducible factor-1alpha protein in hypoxia occurs independently of mitochondrial reactive oxygen species production","volume":"285","author":"Chua","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drup.2026.101355_bib135","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1517\/14712598.2013.810717","article-title":"Targeted inhibition of VEGF receptor 2: an update on ramucirumab","volume":"13","author":"Clarke","year":"2013","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.drup.2026.101355_bib136","doi-asserted-by":"crossref","first-page":"7538","DOI":"10.1038\/ncomms8538","article-title":"Suppression of the alternative lengthening of telomere pathway by the chromatin remodelling factor ATRX","volume":"6","author":"Clynes","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101355_bib137","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.immuni.2017.11.016","article-title":"Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA","volume":"47","author":"Coelho","year":"2017","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.drup.2026.101355_bib138","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1634\/theoncologist.12-5-577","article-title":"FDA drug approval summary: panitumumab (Vectibix)","volume":"12","author":"Cohen","year":"2007","journal-title":"oncologist"},{"key":"10.1016\/j.drup.2026.101355_bib139","first-page":"7163","article-title":"Fibroblast growth factors are required for efficient tumor angiogenesis1","volume":"60","author":"Compagni","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2026.101355_bib140","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071760","article-title":"MHC class I downregulation in cancer: underlying mechanisms and potential targets for cancer immunotherapy","author":"Cornel","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2026.101355_bib141","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1186\/s12885-023-11266-7","article-title":"TP53 mutation prevalence in normal airway epithelium as a biomarker for lung cancer risk","volume":"23","author":"Craig","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib142","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.746707","article-title":"Osimertinib rechallenge with bevacizumab vs. chemotherapy plus bevacizumab in EGFR-Mutant NSCLC patients with osimertinib resistance","volume":"12","author":"Cui","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.drup.2026.101355_bib143","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1086\/426403","article-title":"CHEK2 is a multiorgan cancer susceptibility gene","volume":"75","author":"Cybulski","year":"2004","journal-title":"Am. J. Hum. Genet"},{"key":"10.1016\/j.drup.2026.101355_bib144","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/sj.bjc.6602092","article-title":"Reduced Apaf-1 expression in human cutaneous melanomas","volume":"91","author":"Dai","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib145","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.2147\/CMAR.S243796","article-title":"LncRNA MALAT1 regulates the cell proliferation and cisplatin resistance in gastric cancer via PI3K\/AKT pathway","volume":"12","author":"Dai","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.drup.2026.101355_bib146","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.7150\/jca.43446","article-title":"LncRNA UCA1 promotes cisplatin resistance in gastric cancer via recruiting EZH2 and activating PI3K\/AKT pathway","volume":"11","author":"Dai","year":"2020","journal-title":"J. Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib147","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3892\/ijmm.2021.4922","article-title":"The potential role of necroptosis in clinical diseases (Review)","volume":"47","author":"Dai","year":"2021","journal-title":"Int J. Mol. Med"},{"key":"10.1016\/j.drup.2026.101355_bib148","first-page":"1","article-title":"Overcoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor-kappa B","volume":"1","author":"Dai","year":"2009","journal-title":"Am. J. Transl. Res"},{"key":"10.1016\/j.drup.2026.101355_bib149","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0092-8674(00)80405-5","article-title":"Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery","volume":"91","author":"Datta","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.drup.2026.101355_bib150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.176013","article-title":"Cancer chemotherapy resistance: mechanisms and recent breakthrough in targeted drug delivery","volume":"958","author":"Davodabadi","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.drup.2026.101355_bib151","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1042\/bj20031886","article-title":"Molecular and functional consequences of Smad4C-terminal missense mutations in colorectal tumour cells","volume":"379","author":"De Bosscher","year":"2004","journal-title":"Biochem J."},{"key":"10.1016\/j.drup.2026.101355_bib152","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1158\/1535-7163.MCT-21-0035","article-title":"Belantamab mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated antitumor responses in vivo","volume":"20","author":"De Oca","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drup.2026.101355_bib153","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth","volume":"41","author":"de Visser","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2026.101355_bib154","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/cdd.2015.50","article-title":"The BCL-2 protein family, BH3-mimetics and cancer therapy","volume":"22","author":"Delbridge","year":"2015","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.drup.2026.101355_bib155","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1080\/21655979.2021.2023983","article-title":"Enabled homolog (ENAH) regulated by RNA binding protein splicing factor 3b subunit 4 (SF3B4) exacerbates the proliferation, invasion and migration of hepatocellular carcinoma cells via Notch signaling pathway","volume":"13","author":"Deng","year":"2022","journal-title":"Bioengineered"},{"key":"10.1016\/j.drup.2026.101355_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2022.153849","article-title":"LncRNA SNHG11 accelerates the progression of lung adenocarcinoma via activating Notch pathways","volume":"234","author":"Deng","year":"2022","journal-title":"Pathol. - Res. Pract."},{"key":"10.1016\/j.drup.2026.101355_bib157","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41392-024-01764-w","article-title":"TGF-\u03b2 signaling in health, disease and therapeutics","volume":"9","author":"Deng","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.drup.2026.101355_bib158","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20160470","article-title":"CAF-derived HGF promotes cell proliferation and drug resistance by up-regulating the c-Met\/PI3K\/Akt and GRP78 signalling in ovarian cancer cells","volume":"37","author":"Deying","year":"2017","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.drup.2026.101355_bib159","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41571-021-00549-2","article-title":"The MYC oncogene - the grand orchestrator of cancer growth and immune evasion","volume":"19","author":"Dhanasekaran","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib160","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s40265-023-01954-w","article-title":"Elranatamab: first approval","volume":"83","author":"Dhillon","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.drup.2026.101355_bib161","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s40265-020-01311-1","article-title":"Isatuximab: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.drup.2026.101355_bib162","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202300306R","article-title":"LAMA5 promotes cell proliferation and migration in ovarian cancer by activating Notch signaling pathway","volume":"37","author":"Diao","year":"2023","journal-title":"FASEB J."},{"key":"10.1016\/j.drup.2026.101355_bib163","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13205059","article-title":"Progress on Ras\/MAPK signaling research and targeting in blood and solid cancers","author":"Dillon","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2026.101355_bib164","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21061960","article-title":"The roles of cyclin-dependent kinases in cell-cycle progression and therapeutic strategies in human breast cancer","volume":"21","author":"Ding","year":"2020","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib165","first-page":"453","article-title":"Upregulation of circ_001569 predicts poor prognosis and promotes cell proliferation in non\u2011small cell lung cancer by regulating the Wnt\/\u03b2\u2011catenin pathway","volume":"16","author":"Ding","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.drup.2026.101355_bib166","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3233\/CBM-170777","article-title":"LncRNA SNHG12 promotes the proliferation and metastasis of papillary thyroid carcinoma cells through regulating wnt\/\u03b2-catenin signaling pathway","volume":"22","author":"Ding","year":"2018","journal-title":"Cancer Biomark."},{"key":"10.1016\/j.drup.2026.101355_bib167","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12935-024-03282-9","article-title":"RGS20 promotes non-small cell lung carcinoma proliferation via autophagy activation and inhibition of the PKA-Hippo signaling pathway","volume":"24","author":"Ding","year":"2024","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.drup.2026.101355_bib168","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1080\/09553002.2024.2327395","article-title":"Epigenetic regulation of TGF-\u03b2 pathway and its role in radiation response","volume":"100","author":"Ding","year":"2024","journal-title":"Int. J. Radiat. Biol."},{"key":"10.1016\/j.drup.2026.101355_bib169","first-page":"8349","article-title":"MiR-34a affects G2 arrest in prostate cancer PC3 cells via Wnt pathway and inhibits cell growth and migration","volume":"24","author":"Dong","year":"2020","journal-title":"Eur. Rev. Med Pharm. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib170","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13046-021-02229-6","article-title":"ROS\/PI3K\/Akt and Wnt\/\u03b2-catenin signalings activate HIF-1\u03b1-induced metabolic reprogramming to impart 5-fluorouracil resistance in colorectal cancer","volume":"41","author":"Dong","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101355_bib171","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/s41388-018-0505-8","article-title":"Hypoxia-induced TUFT1 promotes the growth and metastasis of hepatocellular carcinoma by activating the Ca2+\/PI3K\/AKT pathway","volume":"38","author":"Dou","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.drup.2026.101355_bib172","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2020.112290","article-title":"CiRS-7 functions as a ceRNA of RAF-1\/PIK3CD to promote metastatic progression of oral squamous cell carcinoma via MAPK\/AKT signaling pathways","volume":"396","author":"Dou","year":"2020","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.drup.2026.101355_bib173","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.589929","article-title":"TERT\u2014regulation and roles in cancer formation","volume":"11","author":"Dratwa","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.drup.2026.101355_bib174","article-title":"hsa_circ_0000285 sponging miR-582-3p promotes neuroblastoma progression by regulating the Wnt\/\u03b2-catenin signaling pathway","volume":"18","author":"Du","year":"2023"},{"key":"10.1016\/j.drup.2026.101355_bib175","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1186\/s12885-024-12364-w","article-title":"Methylation-regulated tumor suppressor gene PDE7B promotes HCC invasion and metastasis through the PI3K\/AKT signaling pathway","volume":"24","author":"Du","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib176","unstructured":"L. Duan, K.M. Ohara and C. Maki, Creb1 Promotes Dormancy Exit and is a Target to Overcome Endocrine Therapy Resistance in ER+ Breast Cancer Cells, Available at SSRN 5345806."},{"key":"10.1016\/j.drup.2026.101355_bib177","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102154","article-title":"MYC as a target for cancer treatment","volume":"94","author":"Duffy","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.drup.2026.101355_bib178","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/PGP.0b013e3181b64ec3","article-title":"Cytoplasmic p27 expression is an independent prognostic factor in ovarian cancer","volume":"29","author":"Duncan","year":"2010","journal-title":"Int J. Gynecol. Pathol."},{"key":"10.1016\/j.drup.2026.101355_bib179","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41698-024-00612-y","article-title":"Pharmacological inhibition of the LIF\/LIFR autocrine loop reveals vulnerability of ovarian cancer cells to ferroptosis","volume":"8","author":"Ebrahimi","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib180","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s00018-023-04729-4","article-title":"Receptor tyrosine kinase inhibitors in cancer","volume":"80","author":"Ebrahimi","year":"2023","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.drup.2026.101355_bib181","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1161\/CIRCRESAHA.120.316851","article-title":"Basic and therapeutic aspects of angiogenesis updated","volume":"127","author":"Eelen","year":"2020","journal-title":"Circ. Res."},{"key":"10.1016\/j.drup.2026.101355_bib182","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1093\/annonc\/12.suppl_1.S57","article-title":"Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data","volume":"12","author":"Eiermann","year":"2001","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib183","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155161","article-title":"The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia","volume":"254","author":"El-Tanani","year":"2024","journal-title":"Pathol. - Res. Pract."},{"key":"10.1016\/j.drup.2026.101355_bib184","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201754","article-title":"The road from Rous sarcoma virus to precision medicine","volume":"218","author":"Elemento","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.drup.2026.101355_bib185","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/s41568-021-00399-1","article-title":"Artificial intelligence in cancer research, diagnosis and therapy","volume":"21","author":"Elemento","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib186","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/nm.1890","article-title":"Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers","volume":"14","author":"Engelman","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2026.101355_bib187","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a Novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Engst","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drup.2026.101355_bib188","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/PGP.0000000000000812","article-title":"HER2 protein overexpression and gene amplification in tubo-ovarian high-grade serous carcinomas","volume":"41","author":"Ersoy","year":"2022","journal-title":"Int. J. Gynecol. Pathol."},{"key":"10.1016\/j.drup.2026.101355_bib189","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202201159","article-title":"Paradoxical roles of caspase-3 in regulating cell survival, proliferation, and tumorigenesis","volume":"221","author":"Eskandari","year":"2022","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.drup.2026.101355_bib190","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/2040620716636541","article-title":"Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential","volume":"7","author":"Evans","year":"2016","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.drup.2026.101355_bib191","doi-asserted-by":"crossref","unstructured":"C.E. Eyler and J.N. Rich, Survival of the Fittest: Cancer Stem Cells in Therapeutic Resistance and Angiogenesis, Journal of Clinical Oncology 26, pp. 2839-2845.","DOI":"10.1200\/JCO.2007.15.1829"},{"key":"10.1016\/j.drup.2026.101355_bib192","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.cr.7290060","article-title":"Apoptosis in oncology","volume":"11","author":"Fan","year":"2001","journal-title":"Cell Res."},{"key":"10.1016\/j.drup.2026.101355_bib193","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s12672-023-00626-1","article-title":"Upregulated GPRC5A disrupting the Hippo pathway promotes the proliferation and migration of pancreatic cancer cells via the cAMP-CREB axis","volume":"14","author":"Fang","year":"2023","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib194","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41392-020-0134-x","article-title":"Molecular principles of metastasis: a hallmark of cancer revisited","volume":"5","author":"Fares","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.drup.2026.101355_bib195","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.657965","article-title":"Regulation of Hippo, TGF\u03b2\/SMAD, Wnt\/\u03b2-Catenin, JAK\/STAT, and NOTCH by long non-coding RNAs in pancreatic cancer","volume":"11","author":"Farooqi","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib196","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11060-014-1456-8","article-title":"Alternative lengthening of telomeres in neuroblastoma cell lines is associated with a lack of MYCN genomic amplification and with p53 pathway aberrations","volume":"119","author":"Farooqi","year":"2014","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.drup.2026.101355_bib197","doi-asserted-by":"crossref","unstructured":"M.A. Feitelson, A. Arzumanyan, R.J. Kulathinal, S.W. Blain, R.F. Holcombe, J. Mahajna, M. Marino, M.L. Martinez-Chantar, R. Nawroth and I. Sanchez-Garcia, Sustained proliferation in cancer: Mechanisms and novel therapeutic targets. Elsevier, pp. S25-S54.","DOI":"10.1016\/j.semcancer.2015.02.006"},{"issue":"4 12","key":"10.1016\/j.drup.2026.101355_bib198","first-page":"60","article-title":"Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)","volume":"26","author":"Fendly","year":"1999","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib199","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-4598-13-209","article-title":"Survivin expression promotes VEGF-induced tumor angiogenesis via PI3K\/Akt enhanced \u03b2-catenin\/Tcf-Lef dependent transcription","volume":"13","author":"Fern\u00e1ndez","year":"2014","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib200","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s43042-020-00089-x","article-title":"Exploring the multiple roles of guardian of the genome: P53","volume":"21","author":"Feroz","year":"2020","journal-title":"Egypt. J. Med. Hum. Genet."},{"key":"10.1016\/j.drup.2026.101355_bib201","doi-asserted-by":"crossref","first-page":"790","DOI":"10.3324\/haematol.2021.280201","article-title":"The mitochondrial anti-apoptotic dependencies of hematologic malignancies: from disease biology to advances in precision medicine","volume":"107","author":"Ferrarini","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.drup.2026.101355_bib202","doi-asserted-by":"crossref","DOI":"10.3390\/cells11142183","article-title":"Crucial role of oncogenic KRAS mutations in apoptosis and autophagy regulation: therapeutic implications","volume":"11","author":"Ferreira","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.drup.2026.101355_bib203","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1053\/j.seminoncol.2017.06.002","article-title":"A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab","volume":"44","author":"Fessas","year":"2017","journal-title":"Semin Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib204","doi-asserted-by":"crossref","unstructured":"T. Flaherty Keith, R. Infante Jeffery, A. Daud, R. Gonzalez, F. Kefford Richard, J. Sosman, O. Hamid, L. Schuchter, J. Cebon, N. Ibrahim, R. Kudchadkar, A. Burris Howard, G. Falchook, A. Algazi, K. Lewis, V. Long Georgina, I. Puzanov, P. Lebowitz, A. Singh, S. Little, P. Sun, A. Allred, D. Ouellet, B. Kim Kevin, K. Patel and J. Weber, Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations, New England Journal of Medicine 367, pp. 1694-1703.","DOI":"10.1056\/NEJMoa1210093"},{"key":"10.1016\/j.drup.2026.101355_bib205","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11523-023-01026-9","article-title":"Tremelimumab: a review in advanced or unresectable hepatocellular carcinoma","volume":"19","author":"France","year":"2024","journal-title":"Target. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib206","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.dnarep.2015.03.002","article-title":"BRCA1 and BRCA2 protect against oxidative DNA damage converted into double-strand breaks during DNA replication","volume":"30","author":"Fridlich","year":"2015","journal-title":"DNA Repair (Amst. )"},{"key":"10.1016\/j.drup.2026.101355_bib207","doi-asserted-by":"crossref","first-page":"7596","DOI":"10.1158\/0008-5472.CAN-04-1627","article-title":"RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo","volume":"64","author":"Friese","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101355_bib208","doi-asserted-by":"crossref","DOI":"10.1172\/JCI171154","article-title":"PD-1 or CTLA-4 blockade promotes CD86-driven Treg responses upon radiotherapy of lymphocyte-depleted cancer in mice","volume":"134","author":"Frijlink","year":"2024","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.drup.2026.101355_bib209","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13023-022-02206-y","article-title":"LncRNA HOTAIR facilitates proliferation and represses apoptosis of retinoblastoma cells through the miR-20b-5p\/RRM2\/PI3K\/AKT axis","volume":"17","author":"Fu","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.drup.2026.101355_bib210","doi-asserted-by":"crossref","first-page":"7600","DOI":"10.1111\/jcmm.15396","article-title":"miR-126 reduces trastuzumab resistance by targeting PIK3R2 and regulating AKT\/mTOR pathway in breast cancer cells","volume":"24","author":"Fu","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.drup.2026.101355_bib211","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/cas.13177","article-title":"MicroRNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K\/Akt pathway","volume":"108","author":"Fu","year":"2017","journal-title":"Cancer Sci."},{"key":"10.1016\/j.drup.2026.101355_bib212","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1111\/cas.15914","article-title":"Potential therapeutic target secretogranin II might cooperate with hypoxia-inducible factor 1\u03b1 in sunitinib-resistant renal cell carcinoma","volume":"114","author":"Fukumoto","year":"2023","journal-title":"Cancer Sci."},{"key":"10.1016\/j.drup.2026.101355_bib213","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.3892\/ijo.2014.2792","article-title":"5-azacytidine enhances efficacy of multiple chemotherapy drugs in AML and lung cancer with modulation of CpG methylation","volume":"46","author":"F\u00fcller","year":"2015","journal-title":"Int J. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib214","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s11523-023-01007-y","article-title":"Durvalumab: a review in advanced biliary tract cancer","volume":"18","author":"Fung","year":"2023","journal-title":"Target. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib215","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000335533","article-title":"Fas Ligand has a greater impact than TNF-\u03b1 on apoptosis and inflammation in ischemic acute kidney injury","volume":"2","author":"Furuichi","year":"2012","journal-title":"Nephron Extra"},{"key":"10.1016\/j.drup.2026.101355_bib216","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3389\/fphar.2012.00009","article-title":"Defective cell cycle checkpoints as targets for anti-cancer therapies","volume":"3","author":"Gabrielli","year":"2012","journal-title":"Front Pharm."},{"issue":"1","key":"10.1016\/j.drup.2026.101355_bib217","doi-asserted-by":"crossref","first-page":"80","DOI":"10.2174\/156800910790980241","article-title":"Cetuximab: from bench to bedside","volume":"10","author":"Galluzzo","year":"2010","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.drup.2026.101355_bib218","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40364-018-0122-2","article-title":"Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential","volume":"6","author":"Gan","year":"2018","journal-title":"Biomark. Res"},{"key":"10.1016\/j.drup.2026.101355_bib219","doi-asserted-by":"crossref","first-page":"357","DOI":"10.20517\/2394-4722.2016.08","article-title":"Function of cancer cell-derived extracellular matrix in tumor progression","volume":"2","author":"Gao-Feng","year":"2016","journal-title":"J. Cancer Metastas-.-. Treat."},{"key":"10.1016\/j.drup.2026.101355_bib220","doi-asserted-by":"crossref","first-page":"8001","DOI":"10.2147\/OTT.S172379","article-title":"Long noncoding RNA H19 mediated the chemosensitivity of breast cancer cells via Wnt pathway and EMT process","volume":"11","author":"Gao","year":"2018","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.drup.2026.101355_bib221","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.biopha.2017.01.014","article-title":"Long non-coding RNA ZFAS1 is an unfavourable prognostic factor and promotes glioma cell progression by activation of the Notch signaling pathway","volume":"87","author":"Gao","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.drup.2026.101355_bib222","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s13046-019-1260-6","article-title":"PTENP1\/miR-20a\/PTEN axis contributes to breast cancer progression by regulating PTEN via PI3K\/AKT pathway","volume":"38","author":"Gao","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101355_bib223","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.3389\/fonc.2019.00849","article-title":"Distinguishing features of cetuximab and panitumumab in colorectal cancer and other solid tumors","volume":"9","author":"Garc\u00eda-Foncillas","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib224","series-title":"Stabilization of GTSE1 by cyclin D1-CDK4\/6 promotes cell proliferation: relevance in cancer prognosis","author":"Garc\u00eda-V\u00e1zquez","year":"2024"},{"key":"10.1016\/j.drup.2026.101355_bib225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.drup.2026.101355_bib226","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40265-015-0537-0","article-title":"Necitumumab: first global approval","volume":"76","author":"Garnock-Jones","year":"2016","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.drup.2026.101355_bib227","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1182\/blood.V99.4.1314","article-title":"The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism","volume":"99","author":"Geisler","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101355_bib228","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.canlet.2015.01.031","article-title":"EZH2 promotes tumor progression via regulating VEGF-A\/AKT signaling in non-small cell lung cancer","volume":"359","author":"Geng","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.drup.2026.101355_bib229","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1177\/1947601911407325","article-title":"PTEN tumor suppressor network in PI3K-Akt pathway control","volume":"1","author":"Georgescu","year":"2010","journal-title":"Genes Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib230","doi-asserted-by":"crossref","first-page":"4233s","DOI":"10.1158\/1078-0432.CCR-040005","article-title":"The role of gefitinib in lung cancer treatment","volume":"10","author":"Giaccone","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101355_bib231","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14103574","article-title":"Exploring the potential of digital twins in cancer treatment: a narrative review of reviews","volume":"14","author":"Giansanti","year":"2025","journal-title":"J. Clin. Med"},{"key":"10.1016\/j.drup.2026.101355_bib232","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1038\/jid.2011.239","article-title":"SPARC promotes cathepsin B-mediated melanoma invasiveness through a collagen I\/\u03b12\u03b21 integrin axis","volume":"131","author":"Girotti","year":"2011","journal-title":"J. Invest Dermatol."},{"key":"10.1016\/j.drup.2026.101355_bib233","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102980","article-title":"Overcoming resistance to CDK4\/6 inhibitors in hormone receptor positive, HER2 negative breast cancer: innovative combinations and emerging strategies","volume":"139","author":"Giugliano","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.drup.2026.101355_bib234","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1158\/1078-0432.CCR-07-1354","article-title":"U.S. food and drug administration approval: panitumumab for epidermal growth factor receptor\u2013expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens","volume":"14","author":"Giusti","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101355_bib235","doi-asserted-by":"crossref","first-page":"7319","DOI":"10.1158\/0008-5472.CAN-06-4625","article-title":"Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation","volume":"67","author":"Godin-Heymann","year":"2007","journal-title":"Cancer Res"},{"issue":"20","key":"10.1016\/j.drup.2026.101355_bib236","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1182\/blood-2013-05-504043","article-title":"Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab","volume":"122","author":"Golay","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101355_bib237","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.3390\/ijms24043590","article-title":"HER2 Amplification level predicts pathological complete response in the neoadjuvant setting of HER2-Overexpressing breast cancer: a meta-analysis and systematic review","volume":"24","author":"Gonullu","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib238","doi-asserted-by":"crossref","first-page":"14120","DOI":"10.1038\/s41598-021-93561-6","article-title":"EGR1 and RXRA transcription factors link TGF-\u03b2 pathway and CCL2 expression in triple negative breast cancer cells","volume":"11","author":"Gorbacheva","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drup.2026.101355_bib239","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1080\/01635581.2020.1792946","article-title":"Leptin promotes prostate cancer proliferation and migration by stimulating STAT3 pathway","volume":"73","author":"Gorrab","year":"2021","journal-title":"Nutr. Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib240","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1158\/2767-9764.CRC-24-0247","article-title":"A kinome-wide synthetic lethal CRISPR\/Cas9 screen reveals that mTOR inhibition prevents adaptive resistance to CDK4\/CDK6 blockade in HNSCC","volume":"4","author":"Goto","year":"2024","journal-title":"Cancer Res Commun."},{"key":"10.1016\/j.drup.2026.101355_bib241","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1158\/1078-0432.CCR-21-3874","article-title":"A phase Ib\/II randomized study of RO4929097, a gamma-secretase or Notch inhibitor with or without vismodegib, a hedgehog inhibitor, in advanced sarcoma","volume":"28","author":"Gounder","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101355_bib242","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/1476-4598-9-305","article-title":"Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation","volume":"9","author":"Gravina","year":"2010","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib243","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.4161\/cc.10.13.16244","article-title":"LKB1\/AMPK\/mTOR signaling pathway in hematological malignancies: from metabolism to cancer cell biology","volume":"10","author":"Green","year":"2011","journal-title":"Cell Cycle"},{"key":"10.1016\/j.drup.2026.101355_bib244","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2023.107468","article-title":"Off-target pharmacological activity at various kinases: potential functional and pathological side effects","volume":"123","author":"Green","year":"2023","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.drup.2026.101355_bib245","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1158\/1535-7163.MCT-11-0989","article-title":"Combinations of BRAF, MEK, and PI3K\/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations","volume":"11","author":"Greger","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drup.2026.101355_bib246","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1634\/theoncologist.12-2-191","article-title":"Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer","volume":"12","author":"Gridelli","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.drup.2026.101355_bib247","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.3324\/haematol.2019.217430","article-title":"HIF-1\u03b1 is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia","volume":"105","author":"Griggio","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.drup.2026.101355_bib248","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.12419","article-title":"Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAF V600E targeted inhibition in a novel syngeneic murine glioma model","volume":"7","author":"Grossauer","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.drup.2026.101355_bib249","first-page":"67","article-title":"Cabozantinib: multi-kinase inhibitor of MET, AXL, RET, and VEGFR2, recent results in cancer research","volume":"211","author":"Gr\u00fcllich","year":"2018","journal-title":"Fortschr. der Krebsforsch. Prog. dans Les. Rech. sur Le. Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib250","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02759","article-title":"More than just attractive: how CCL2 influences myeloid cell behavior beyond chemotaxis","volume":"10","author":"Gschwandtner","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.drup.2026.101355_bib251","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12967-024-04870-z","article-title":"Hypoxia upregulating ACSS2 enhances lipid metabolism reprogramming through HMGCS1 mediated PI3K\/AKT\/mTOR pathway to promote the progression of pancreatic neuroendocrine neoplasms","volume":"22","author":"Gu","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.drup.2026.101355_bib252","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.intonc.2025.02.001","article-title":"Artificial intelligence in tumor drug resistance: mechanisms and treatment prospects","volume":"1","author":"Gu","year":"2025","journal-title":"Intell. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib253","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1111\/cas.16091","article-title":"SIRT7 promotes Hippo\/YAP activation and cancer cell proliferation in hepatocellular carcinoma via suppressing MST1","volume":"115","author":"Gu","year":"2024","journal-title":"Cancer Sci."},{"key":"10.1016\/j.drup.2026.101355_bib254","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.3390\/cancers15174252","article-title":"IGF1R contributes to cell proliferation in ALK-mutated neuroblastoma with preference for activating the PI3K-AKT signaling pathway","volume":"15","author":"Guan","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2026.101355_bib255","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3233\/CBM-170431","article-title":"Knockdown of lncRNA GHET1 suppresses cell proliferation, invasion and LATS1\/YAP pathway in non small cell lung cancer","volume":"21","author":"Guan","year":"2018","journal-title":"Cancer Biomark."},{"key":"10.1016\/j.drup.2026.101355_bib256","doi-asserted-by":"crossref","first-page":"a026187","DOI":"10.1101\/cshperspect.a026187","article-title":"Inherited TP53 mutations and the Li\u2013Fraumeni syndrome","volume":"7","author":"Guha","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.drup.2026.101355_bib257","doi-asserted-by":"crossref","first-page":"E3729","DOI":"10.1073\/pnas.1703096114","article-title":"Hippo pathway mediates resistance to cytotoxic drugs","volume":"114","author":"Gujral","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib258","article-title":"Blocking tumoral angiogenesis VEGF\/VEGFR pathway: bevacizumab\u201420 years of therapeutic success and controversy","volume":"17","author":"Gullo","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2026.101355_bib259","doi-asserted-by":"crossref","unstructured":"O. Gumusay, P.P. Vitiello, C. Wabl, R.B. Corcoran, A. Bardelli and H.S. Rugo, Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology, American Society of Clinical Oncology Educational Book, pp. e292-e308.","DOI":"10.1200\/EDBK_280845"},{"key":"10.1016\/j.drup.2026.101355_bib260","article-title":"Targeting UPR signaling pathway by dasatinib as a promising therapeutic approach in chronic myeloid leukemia","volume":"39","author":"Gunel","year":"2022","journal-title":"Med. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib261","first-page":"3703","article-title":"Long non-coding RNA MALAT1 regulates ovarian cancer cell proliferation, migration and apoptosis through Wnt\/\u03b2-catenin signaling pathway","volume":"22","author":"Guo","year":"2018","journal-title":"Eur. Rev. Med Pharm. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib262","doi-asserted-by":"crossref","first-page":"7643","DOI":"10.12998\/wjcc.v9.i26.7643","article-title":"Combined targeted therapy and immunotherapy for cancer treatment","volume":"9","author":"Guo","year":"2021","journal-title":"World J. Clin. Cases"},{"key":"10.1016\/j.drup.2026.101355_bib263","first-page":"4090","article-title":"LncRNA NEAT1 regulates cervical carcinoma proliferation and invasion by targeting AKT\/PI3K","volume":"22","author":"Guo","year":"2018","journal-title":"Eur. Rev. Med Pharm. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib264","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0328-x","article-title":"Silencing of long noncoding RNA HOXA11-AS inhibits the Wnt signaling pathway via the upregulation of HOXA11 and thereby inhibits the proliferation, invasion, and self-renewal of hepatocellular carcinoma stem cells","volume":"51","author":"Guo","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.drup.2026.101355_bib265","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13046-022-02266-9","article-title":"HDAC7 promotes NSCLC proliferation and metastasis via stabilization by deubiquitinase USP10 and activation of \u03b2-catenin-FGF18 pathway","volume":"41","author":"Guo","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101355_bib266","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12032-024-02328-2","article-title":"IL-6 regulates epithelial ovarian cancer EMT, invasion, and metastasis by modulating Let-7c and miR-200c through the STAT3\/HIF-1\u03b1 pathway","volume":"41","author":"Guo","year":"2024","journal-title":"Med. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib267","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.7150\/ijbs.25720","article-title":"Effect of stromal cells in tumor microenvironment on metastasis initiation","volume":"14","author":"Guo","year":"2018","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib268","article-title":"LncRNA HOXA11-AS promotes migration and invasion through modulating miR-148a\/WNT1\/\u03b2-catenin pathway in gastric cancer","volume":"67","author":"Guo","year":"2020","journal-title":"Neoplasma"},{"key":"10.1016\/j.drup.2026.101355_bib269","first-page":"1997","article-title":"ERK\/MAPK signalling pathway and tumorigenesis (Review)","volume":"19","author":"Guo","year":"2020","journal-title":"Exp. Ther. Med"},{"key":"10.1016\/j.drup.2026.101355_bib270","doi-asserted-by":"crossref","first-page":"55","DOI":"10.5858\/2010-0454-RAR.1","article-title":"HER2: biology, detection, and clinical implications","volume":"135","author":"Gutierrez","year":"2011","journal-title":"Arch. Pathol. Lab Med"},{"key":"10.1016\/j.drup.2026.101355_bib271","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s43018-021-00221-9","article-title":"Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma","volume":"2","author":"Haas","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib272","first-page":"1188","article-title":"Larotrectinib for newly diagnosed infantile fibrosarcoma and other pediatric NTRK fusion\u2013positive solid tumors (Children's oncology group ADVL1823)","volume":"43","author":"Hall","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib273","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.drup.2026.101355_bib274","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41419-022-04751-7","article-title":"Class I HDAC overexpression promotes temozolomide resistance in glioma cells by regulating RAD18 expression","volume":"13","author":"Hanisch","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.drup.2026.101355_bib275","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1111\/1759-7714.14891","article-title":"Tumor-derived exosomal miR-148b-3p mediates M2 macrophage polarization via TSC2\/mTORC1 to promote breast cancer migration and invasion","volume":"14","author":"Hao","year":"2023","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib276","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3892\/ol.2022.13542","article-title":"BANCR positively regulates the HIF\u20111\u03b1\/VEGF\u2011C\/VEGFR\u20113 pathway in a hypoxic microenvironment to promote lymphangiogenesis in pancreatic cancer cells","volume":"24","author":"Hao","year":"2022","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.drup.2026.101355_bib277","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41698-019-0092-3","article-title":"Engineered models to parse apart the metastatic cascade","volume":"3","author":"Hapach","year":"2019","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib278","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/s41467-021-21247-8","article-title":"Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteome","volume":"12","author":"Hartlieb","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101355_bib279","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0002-9440(10)65006-7","article-title":"Openings between defective endothelial cells explain tumor vessel leakiness","volume":"156","author":"Hashizume","year":"2000","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.drup.2026.101355_bib280","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/978-1-4615-1809-9_2","article-title":"The role of RB in cell cycle control","volume":"1","author":"Hatakeyama","year":"1995","journal-title":"Prog. Cell Cycle Res"},{"key":"10.1016\/j.drup.2026.101355_bib281","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nchembio.332","article-title":"A chemical and phosphoproteomic characterization of dasatinib action in lung cancer","volume":"6","author":"Haura","year":"2010","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.drup.2026.101355_bib282","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1038\/sj.onc.1208474","article-title":"Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities","volume":"24","author":"He","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.drup.2026.101355_bib283","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3892\/ol.2020.11958","article-title":"Long non\u2011coding RNA CCAT2 promotes prostate cancer cell proliferation and invasion by regulating the Wnt\/\u03b2\u2011catenin signaling pathway","volume":"20","author":"He","year":"2020","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.drup.2026.101355_bib284","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.biopha.2017.08.057","article-title":"LncRNA FEZF1-AS1 enhances epithelial-mesenchymal transition (EMT) through suppressing E-cadherin and regulating WNT pathway in non-small cell lung cancer (NSCLC)","volume":"95","author":"He","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.drup.2026.101355_bib285","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","article-title":"Targeting PI3K\/Akt signal transduction for cancer therapy","volume":"6","author":"He","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.drup.2026.101355_bib286","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1016\/j.bbrc.2018.06.159","article-title":"Downregulation of RASSF6 promotes breast cancer growth and chemoresistance through regulation of Hippo signaling","volume":"503","author":"He","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.drup.2026.101355_bib287","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3389\/fmolb.2019.00160","article-title":"Extracellular matrix in the tumor microenvironment and its impact on cancer therapy","volume":"6","author":"Henke","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.drup.2026.101355_bib288","article-title":"Abstract 1914: amivantamab efficacy in wildtype EGFR NSCLC tumors correlates with levels of ligand expression","author":"Henley","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2026.101355_bib289","doi-asserted-by":"crossref","first-page":"10026","DOI":"10.1073\/pnas.170290997","article-title":"Contact with fibrillar collagen inhibits melanoma cell proliferation by up-regulating p27KIP1","volume":"97","author":"Henriet","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.drup.2026.101355_bib290","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1080\/14737140.2021.1963235","article-title":"Avapritinib in unresectable or metastatic gastrointestinal stromal tumor with PDGFRA exon 18 mutation: safety and efficacy","volume":"21","author":"Henriques-Abreu","year":"2021","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.drup.2026.101355_bib291","doi-asserted-by":"crossref","first-page":"278","DOI":"10.18632\/genesandcancer.120","article-title":"Dual function of MDM2 and MDMX toward the tumor suppressors p53 and RB","volume":"7","author":"Hern\u00e1ndez-Monge","year":"2016","journal-title":"Genes Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib292","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1158\/2326-6066.CIR-22-0426","article-title":"Hedgehog signaling regulates treg to Th17 conversion through metabolic rewiring in breast cancer","volume":"11","author":"Hinshaw","year":"2023","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.drup.2026.101355_bib293","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1158\/2159-8290.CD-19-1006","article-title":"Atypical KRAS(G12R) mutant is impaired in PI3K signaling and macropinocytosis in pancreatic cancer","volume":"10","author":"Hobbs","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drup.2026.101355_bib294","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A landscape of driver mutations in melanoma","volume":"150","author":"Hodis","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.drup.2026.101355_bib295","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrc3037","article-title":"PTEN loss in the continuum of common cancers, rare syndromes and mouse models","volume":"11","author":"Hollander","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib296","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s40425-018-0356-4","article-title":"Targeting the TGF\u03b2 pathway with galunisertib, a TGF\u03b2RI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade","volume":"6","author":"Holmgaard","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib297","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.1158\/0008-5472.CAN-22-0736","article-title":"PRC2-mediated epigenetic suppression of Type I IFN-STAT2 signaling impairs antitumor immunity in luminal breast cancer","volume":"82","author":"Hong","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2026.101355_bib298","first-page":"2135","article-title":"Notch signaling at a glance","volume":"126","author":"Hori","year":"2013","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.drup.2026.101355_bib299","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1230062","article-title":"TERT promoter mutations in familial and sporadic melanoma","volume":"339","author":"Horn","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.drup.2026.101355_bib300","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41575-020-0300-1","article-title":"Pancreatic cancer stroma: an update on therapeutic targeting strategies","volume":"17","author":"Hosein","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.drup.2026.101355_bib301","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/(SICI)1098-2264(199805)22:1<66::AID-GCC9>3.0.CO;2-5","article-title":"Mechanism of cyclin D1 (CCND1, PRAD1) overexpression in human cancer cells: analysis of allele-specific expression","volume":"22","author":"Hosokawa","year":"1998","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib302","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3389\/fonc.2018.00575","article-title":"Notch signaling regulates mitochondrial metabolism and NF-\u03baB activity in triple-negative breast cancer cells via IKK\u03b1-dependent non-canonical pathways","volume":"8","author":"Hossain","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib303","doi-asserted-by":"crossref","DOI":"10.3390\/cells10112916","article-title":"Suppression of PI3K\/Akt\/mTOR\/c-Myc\/mtp53 positive feedback loop induces cell cycle arrest by Dual PI3K\/mTOR inhibitor PQR309 in endometrial cancer cell lines","author":"Hsin","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.drup.2026.101355_bib304","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.lungcan.2011.07.001","article-title":"Mesenchymal stem cells enhance lung cancer initiation through activation of IL-6\/JAK2\/STAT3 pathway","volume":"75","author":"Hsu","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib305","doi-asserted-by":"crossref","first-page":"410","DOI":"10.21037\/atm-21-698","article-title":"PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K\/AKT\/mTOR signaling pathway","volume":"9","author":"Hu","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.drup.2026.101355_bib306","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.drup.2026.101355_bib307","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215867","article-title":"FGFR1\/MAPK-directed brachyury activation drives PD-L1-mediated immune evasion to promote lung cancer progression","volume":"547","author":"Hu","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.drup.2026.101355_bib308","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1111\/jgh.15362","article-title":"Long noncoding RNA TMPO-AS1\/miR-126-5p\/BRCC3 axis accelerates gastric cancer progression and angiogenesis via activating PI3K\/Akt\/mTOR pathway","volume":"36","author":"Hu","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.drup.2026.101355_bib309","article-title":"MiR-99a antitumor activity in human breast cancer cells through targeting of mTOR expression","volume":"9","author":"Hu","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.drup.2026.101355_bib310","first-page":"5049","article-title":"Long noncoding RNA HOXD-AS1 regulates proliferation of cervical cancer cells by activating Ras\/ERK signaling pathway","volume":"21","author":"Hu","year":"2017","journal-title":"Eur. Rev. Med Pharm. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib311","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0754-1","article-title":"Targeting mTOR for cancer therapy","volume":"12","author":"Hua","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib312","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317711314","article-title":"Long non-coding RNA CCAT2 promotes cell proliferation and invasion through regulating Wnt\/\u03b2-catenin signaling pathway in clear cell renal cell carcinoma","volume":"39","author":"Huang","year":"2017","journal-title":"Tumor Biol."},{"key":"10.1016\/j.drup.2026.101355_bib313","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12967-021-02954-8","article-title":"SRPK1\/AKT axis promotes oxaliplatin-induced anti-apoptosis via NF-\u03baB activation in colon cancer","volume":"19","author":"Huang","year":"2021","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.drup.2026.101355_bib314","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2023.113585","article-title":"FTO promotes cervical cancer cell proliferation, colony formation, migration and invasion via the regulation of the BMP4\/Hippo\/YAP1\/TAZ pathway","volume":"427","author":"Huang","year":"2023","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.drup.2026.101355_bib315","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12964-023-01455-z","article-title":"The immune checkpoint TIGIT\/CD155 promotes the exhaustion of CD8+ T cells in TNBC through glucose metabolic reprogramming mediated by PI3K\/AKT\/mTOR signaling","volume":"22","author":"Huang","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.drup.2026.101355_bib316","doi-asserted-by":"crossref","first-page":"319","DOI":"10.21037\/tcr.2019.01.19","article-title":"State of the art of overcoming efflux transporter mediated multidrug resistance of breast cancer","volume":"8","author":"Huang","year":"2019","journal-title":"Transl. Cancer Res"},{"key":"10.1016\/j.drup.2026.101355_bib317","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1111\/cas.70134","article-title":"PRRX2 regulates GLI2 to promote proliferation, invasion, and metastasis by inhibiting senescence via hedgehog signaling","volume":"116","author":"Huang","year":"2025","journal-title":"Cancer Sci."},{"key":"10.1016\/j.drup.2026.101355_bib318","doi-asserted-by":"crossref","first-page":"6693","DOI":"10.1074\/jbc.RA118.001689","article-title":"Wnt7a activates canonical Wnt signaling, promotes bladder cancer cell invasion, and is suppressed by miR-370-3p","volume":"293","author":"Huang","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drup.2026.101355_bib319","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3390\/ijms25010616","article-title":"Attenuation of PI3K-Akt-mTOR pathway to reduce cancer stemness on chemoresistant lung cancer cells by shikonin and synergy with BEZ235 inhibitor","author":"Huang","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib320","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12967-024-04934-0","article-title":"Wnt\/\u03b2-catenin signalling activates IMPDH2-mediated purine metabolism to facilitate oxaliplatin resistance by inhibiting caspase-dependent apoptosis in colorectal cancer","volume":"22","author":"Huang","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.drup.2026.101355_bib321","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1186\/s13046-021-02188-y","article-title":"HIF-1\u03b1 switches the functionality of TGF-\u03b2 signaling via changing the partners of smads to drive glucose metabolic reprogramming in non-small cell lung cancer","volume":"40","author":"Huang","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101355_bib322","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1172\/JCI200421358","article-title":"NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression","volume":"114","author":"Huber","year":"2004","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.drup.2026.101355_bib323","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13046-018-0996-8","article-title":"Hypoxia-induced Slug SUMOylation enhances lung cancer metastasis","volume":"38","author":"Hung","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101355_bib324","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41419-025-07457-8","article-title":"Transcription factor ONECUT3 regulates HDAC6\/HIF-1\u03b1 activity to promote the Warburg effect and tumor growth in colorectal cancer","volume":"16","author":"Huo","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.drup.2026.101355_bib325","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.3390\/encyclopedia2040111","article-title":"Apoptosis regulators Bcl-2 and Caspase-3","author":"Hussar","year":"2022","journal-title":"Encyclopedia"},{"issue":"20","key":"10.1016\/j.drup.2026.101355_bib326","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.16350","article-title":"IGF1R depletion facilitates MET-amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells","volume":"8","author":"Hussmann","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.drup.2026.101355_bib327","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1186\/s12885-024-12482-5","article-title":"Clinical application of targeted tumour sequencing tests for detecting ERBB2 amplification and optimizing anti-HER2 therapy in gastric cancer","volume":"24","author":"Ichikawa","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib328","doi-asserted-by":"crossref","first-page":"478","DOI":"10.2174\/1566524023666230509161645","article-title":"The mTOR signaling pathway and mTOR inhibitors in cancer: next-generation inhibitors and approaches","volume":"24","author":"Ihlamur","year":"2024","journal-title":"Curr. Mol. Med"},{"key":"10.1016\/j.drup.2026.101355_bib329","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/1097-0142(20010801)92:3<488::AID-CNCR1347>3.0.CO;2-F","article-title":"The association of k-ras gene mutation and vascular endothelial growth factor gene expression in pancreatic carcinoma","volume":"92","author":"Ikeda","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib330","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1158\/1078-0432.CCR-16-1417","article-title":"Atezolizumab: A PD-L1\u2013blocking antibody for bladder cancer","volume":"23","author":"Inman","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101355_bib331","doi-asserted-by":"crossref","DOI":"10.3390\/medicina58070903","article-title":"The angiogenic balance and its implications in cancer and cardiovascular diseases: an overview","author":"Ionescu","year":"2022","journal-title":"Medicina"},{"key":"10.1016\/j.drup.2026.101355_bib332","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s12935-021-01981-1","article-title":"Clinical applications of artificial intelligence and machine learning in cancer diagnosis: looking into the future","volume":"21","author":"Iqbal","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.drup.2026.101355_bib333","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.trecan.2024.11.009","article-title":"KRAS inhibitors: resistance drivers and combinatorial strategies","volume":"11","author":"Isermann","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib334","article-title":"Trastuzumab emtansine: mechanisms of action and drug resistance","volume":"16","author":"Isola","year":"2014","journal-title":"Breast Cancer Res.: BCR"},{"key":"10.1016\/j.drup.2026.101355_bib335","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41379-021-00918-3","article-title":"An unusual phenotype occurs in 15% of mismatch repair-deficient tumors and is associated with non-colorectal cancers and genetic syndromes","volume":"35","author":"Jaffrelot","year":"2022","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.drup.2026.101355_bib336","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41388-024-03227-6","article-title":"Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms","volume":"44","author":"Jain","year":"2025","journal-title":"Oncogene"},{"key":"10.1016\/j.drup.2026.101355_bib337","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nrurol.2018.9","article-title":"Clinical implications of PTEN loss in prostate cancer","volume":"15","author":"Jamaspishvili","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.drup.2026.101355_bib338","doi-asserted-by":"crossref","first-page":"12465","DOI":"10.1038\/srep12465","article-title":"Blockade of Wnt\/\u03b2-catenin signaling suppresses breast cancer metastasis by inhibiting CSC-like phenotype","volume":"5","author":"Jang","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drup.2026.101355_bib339","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/hmg\/7.5.767","article-title":"The BCR gene recombines preferentially with Alu elements in complex BCR-ABL translocations of chronic myeloid leukaemia","volume":"7","author":"Jeffs","year":"1998","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.drup.2026.101355_bib340","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.imbio.2015.11.010","article-title":"Tumor associated macrophages provide the survival resistance of tumor cells to hypoxic microenvironmental condition through IL-6 receptor-mediated signals","volume":"222","author":"Jeong","year":"2017","journal-title":"Immunobiology"},{"key":"10.1016\/j.drup.2026.101355_bib341","first-page":"7369","article-title":"miR-126 suppresses epithelial-to-mesenchymal transition and metastasis by targeting PI3K\/AKT\/Snail signaling of lung cancer cells","volume":"15","author":"Jia","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.drup.2026.101355_bib342","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s13578-022-00855-x","article-title":"Anti-tumor effects of dual PI3K-HDAC inhibitor CUDC-907 on activation of ROS-IRE1\u03b1-JNK-mediated cytotoxic autophagy in esophageal cancer","volume":"12","author":"Jian","year":"2022","journal-title":"Cell Biosci."},{"key":"10.1016\/j.drup.2026.101355_bib343","doi-asserted-by":"crossref","first-page":"860","DOI":"10.21037\/atm-21-1908","article-title":"CircRNA HIPK3 promotes the progression of oral squamous cell carcinoma through upregulation of the NUPR1\/PI3K\/AKT pathway by sponging miR-637","volume":"9","author":"Jiang","year":"2021","journal-title":"Ann. Transl. Med"},{"key":"10.1016\/j.drup.2026.101355_bib344","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13045-022-01252-0","article-title":"Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy","volume":"15","author":"Jiang","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib345","doi-asserted-by":"crossref","first-page":"1447678","DOI":"10.3389\/fonc.2024.1447678","article-title":"Research progress on the role of bypass activation mechanisms in resistance to tyrosine kinase inhibitors in non-small cell lung cancer","volume":"14","author":"Jiang","year":"2024","journal-title":"Front Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib346","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1186\/s12885-016-2904-y","article-title":"Let-7 inhibits self-renewal of hepatocellular cancer stem-like cells through regulating the epithelial-mesenchymal transition and the Wnt signaling pathway","volume":"16","author":"Jin","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib347","first-page":"3176","article-title":"LncRNA MALAT1 promotes proliferation and metastasis in epithelial ovarian cancer via the PI3K-AKT pathway","volume":"21","author":"Jin","year":"2017","journal-title":"Eur. Rev. Med Pharm. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib348","first-page":"3311","article-title":"Hsa_circ_0005075 predicts a poor prognosis and acts as an oncogene in colorectal cancer via activating Wnt\/\u03b2-catenin pathway","volume":"23","author":"Jin","year":"2019","journal-title":"Eur. Rev. Med Pharm. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib349","doi-asserted-by":"crossref","first-page":"9137","DOI":"10.1038\/s41598-019-45537-w","article-title":"Circulating pro- and anti-angiogenic factors in multi-stage liver disease and hepatocellular carcinoma progression","volume":"9","author":"Joo","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drup.2026.101355_bib350","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/sj.bjc.6601908","article-title":"Assessment of vascular reactivity in rat brain glioma by measuring regional blood volume during graded hypoxic hypoxia","volume":"91","author":"Julien","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib351","doi-asserted-by":"crossref","first-page":"10921","DOI":"10.1038\/s41598-017-11094-3","article-title":"CG200745, an HDAC inhibitor, induces anti-tumour effects in cholangiocarcinoma cell lines via miRNAs targeting the Hippo pathway","volume":"7","author":"Jung","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drup.2026.101355_bib352","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10549-010-1090-x","article-title":"Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer","volume":"128","author":"Junttila","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.drup.2026.101355_bib353","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/14712598.2021.1884677","article-title":"Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma","volume":"21","author":"Jurczak","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.drup.2026.101355_bib354","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41419-025-07887-4","article-title":"Inhibition of the Caveolin-1 pathway promotes apoptosis and overcomes pan-tyrosine kinase inhibitor resistance in hepatocellular carcinoma","volume":"16","author":"Kabir","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.drup.2026.101355_bib355","first-page":"50","article-title":"TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer Patients1","volume":"6","author":"Kandioler-Eckersberger","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101355_bib356","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s40265-022-01793-1","article-title":"Teclistamab: first approval","volume":"82","author":"Kang","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.drup.2026.101355_bib357","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1365-2559.2012.04274.x","article-title":"Notch3 and Jagged2 contribute to gastric cancer development and to glandular differentiation associated with MUC2 and MUC5AC expression","volume":"61","author":"Kang","year":"2012","journal-title":"Histopathology"},{"key":"10.1016\/j.drup.2026.101355_bib358","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14225681","article-title":"Endothelial-specific molecule 1 inhibition lessens productive angiogenesis and tumor metastasis to overcome bevacizumab resistance","author":"Kang","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2026.101355_bib359","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41419-020-03144-y","article-title":"Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance","volume":"11","author":"Kapoor","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.drup.2026.101355_bib360","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.2147\/OTT.S174548","article-title":"Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives","volume":"12","author":"Karachaliou","year":"2019","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.drup.2026.101355_bib361","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.3389\/fonc.2021.624780","article-title":"Adverse events following administration of anti-CTLA4 antibody ipilimumab","volume":"11","author":"Karimi","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib362","doi-asserted-by":"crossref","first-page":"eaau8544","DOI":"10.1126\/scisignal.aau8544","article-title":"Chronic TGF-\u03b2 exposure drives stabilized EMT, tumor stemness, and cancer drug resistance with vulnerability to bitopic mTOR inhibition","volume":"12","author":"Katsuno","year":"2019","journal-title":"Sci. Signal."},{"key":"10.1016\/j.drup.2026.101355_bib363","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13058-023-01675-8","article-title":"Targeting the oncogenic transcription factor FOXM1 to improve outcomes in all subtypes of breast cancer","volume":"25","author":"Katzenellenbogen","year":"2023","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.drup.2026.101355_bib364","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12040827","article-title":"Decoding tumor angiogenesis for therapeutic advancements: mechanistic insights","author":"Kaur","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.drup.2026.101355_bib365","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40265-022-01827-8","article-title":"Tremelimumab: first approval","volume":"83","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.drup.2026.101355_bib366","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1023\/A:1006458407515","article-title":"Inhibition of NF-\u03baB activity enhances trail mediated apoptosis in breast cancer cell lines","volume":"64","author":"Keane","year":"2000","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.drup.2026.101355_bib367","doi-asserted-by":"crossref","first-page":"4494","DOI":"10.1021\/acs.molpharmaceut.5c00473","article-title":"Translational insights into stimuli-responsive magnetic nanoparticles for breast cancer treatment","volume":"22","author":"Khan","year":"2025","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.drup.2026.101355_bib368","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103819","article-title":"Unravelling the potential of mitochondria-targeted liposomes for enhanced cancer treatment","volume":"29","author":"Khan","year":"2024","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drup.2026.101355_bib369","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.145766","article-title":"Exosome-mediated communication in pancreatic cancer: From molecular crosstalk to clinical translation","volume":"320","author":"Khan","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.drup.2026.101355_bib370","doi-asserted-by":"crossref","DOI":"10.3390\/jpm15020050","article-title":"Targeting metabolic vulnerabilities to combat drug resistance in cancer therapy","volume":"15","author":"Khan","year":"2025","journal-title":"J. Pers. Med"},{"key":"10.1016\/j.drup.2026.101355_bib371","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1158\/0008-5472.CAN-12-2149","article-title":"Autocrine motility factor promotes HER2 cleavage and signaling in breast cancer cells","volume":"73","author":"Kho","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101355_bib372","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10112988","article-title":"Cancer metastasis and treatment resistance: mechanistic insights and therapeutic targeting of cancer stem cells and the tumor microenvironment","volume":"10","author":"Kilmister","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.drup.2026.101355_bib373","doi-asserted-by":"crossref","first-page":"10597","DOI":"10.1038\/s41598-020-67325-7","article-title":"TGF-\u03b2 induced EMT and stemness characteristics are associated with epigenetic regulation in lung cancer","volume":"10","author":"Kim","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drup.2026.101355_bib374","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s00018-016-2412-x","article-title":"Role of YAP\/TAZ transcriptional regulators in resistance to anti-cancer therapies","volume":"74","author":"Kim","year":"2017","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.drup.2026.101355_bib375","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1158\/0008-5472.CAN-22-1559","article-title":"A cell-fate reprogramming strategy reverses epithelial-to-mesenchymal transition of lung cancer cells while avoiding hybrid states","volume":"83","author":"Kim","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2026.101355_bib376","article-title":"Impact of complex apoptotic signaling pathways on cancer cell sensitivity to therapy","author":"Kim","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2026.101355_bib377","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/s41388-021-02141-5","article-title":"p53 partial loss-of-function mutations sensitize to chemotherapy","volume":"41","author":"Klimovich","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.drup.2026.101355_bib378","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.trecan.2016.11.006","article-title":"The strange case of CDK4\/6 inhibitors: mechanisms, resistance, and combination strategies","volume":"3","author":"Knudsen","year":"2017","journal-title":"Trends Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib379","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188572","article-title":"The case for AI-driven cancer clinical trials - the efficacy arm in silico","volume":"1876","author":"Kolla","year":"2021","journal-title":"Biochim Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib380","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1210\/endrev\/bnad001","article-title":"Recent advances in the role of autophagy in endocrine-dependent tumors","volume":"44","author":"Komarla","year":"2023","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.drup.2026.101355_bib381","doi-asserted-by":"crossref","first-page":"66051","DOI":"10.18632\/oncotarget.11800","article-title":"MiR-155 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells through the activation of PI3K\/SGK3\/\u03b2-catenin signaling pathways","volume":"7","author":"Kong","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.drup.2026.101355_bib382","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.ccell.2018.03.025","article-title":"A convergence-based framework for cancer drug resistance","volume":"33","author":"Konieczkowski","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2026.101355_bib383","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.21873\/anticanres.14622","article-title":"Role of oncogenes and tumor-suppressor genes in carcinogenesis: a review","volume":"40","author":"Kontomanolis","year":"2020","journal-title":"Anticancer Res."},{"key":"10.1016\/j.drup.2026.101355_bib384","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.4_suppl.339","article-title":"DNA methyl-transferases (DNMTs) as potential therapeutic vulnerability in prostate cancer","volume":"42","author":"Koul","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib385","doi-asserted-by":"crossref","first-page":"17796","DOI":"10.1021\/acs.jmedchem.4c01817","article-title":"Hydrazide-based class I selective HDAC inhibitors completely reverse chemoresistance synergistically in platinum-resistant solid cancer cells","volume":"67","author":"Kraft","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drup.2026.101355_bib386","doi-asserted-by":"crossref","unstructured":"I.E. Krop, N. Masuda, T. Mukohara, S. Takahashi, T. Nakayama, K. Inoue, H. Iwata, T. Toyama, Y. Yamamoto, D.M. Hansra, M. Takahashi, A. Osaki, K. Koyama, T. Inoue, T. Yonekura, J. Mostillo, S. Ohwada, Y. Tanaka, D.W. Sternberg and K. Yonemori, Results from the phase 1\/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC), Journal of Clinical Oncology 40, pp. 1002-1002.","DOI":"10.1200\/JCO.2022.40.16_suppl.1002"},{"key":"10.1016\/j.drup.2026.101355_bib387","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijsu.2005.05.002","article-title":"An introduction to death receptors in apoptosis","volume":"3","author":"Kumar","year":"2005","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.drup.2026.101355_bib388","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ccr.2011.09.009","article-title":"Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis","volume":"20","author":"Labelle","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2026.101355_bib389","article-title":"AMPK-Fyn signaling promotes Notch1 stability to potentiate hypoxia-induced breast cancer stemness and drug resistance","author":"Lahiry","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.drup.2026.101355_bib390","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s40265-017-0802-5","article-title":"Inotuzumab ozogamicin: first global approval","volume":"77","author":"Lamb","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.drup.2026.101355_bib391","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.drup.2026.101355_bib392","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1158\/0008-5472.CAN-14-3256","article-title":"Redundancy: a critical obstacle to improving cancer therapy","volume":"75","author":"Lavi","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2026.101355_bib393","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12885-019-5424-8","article-title":"Alternative lengthening of telomeres (ALT) influences survival in soft tissue sarcomas: a systematic review with meta-analysis","volume":"19","author":"Lawlor","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib394","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1158\/0008-5472.CAN-05-0551","article-title":"TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers","volume":"65","author":"Le Calvez","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2026.101355_bib395","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.3389\/fonc.2021.704001","article-title":"TPL inhibits the invasion and migration of drug-resistant ovarian cancer by targeting the PI3K\/AKT\/NF-\u03baB-signaling pathway to inhibit the polarization of M2 TAMs","volume":"11","author":"Le","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib396","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s40265-020-01302-2","article-title":"Cemiplimab: a review in advanced cutaneous squamous cell carcinoma","volume":"80","author":"Lee","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.drup.2026.101355_bib397","article-title":"Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1\/2 study","author":"Lee","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib398","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1016\/j.ymthe.2024.09.026","article-title":"PD-L1: from cancer immunotherapy to therapeutic implications in multiple disorders","volume":"32","author":"Lee","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drup.2026.101355_bib399","doi-asserted-by":"crossref","first-page":"36746","DOI":"10.18632\/oncotarget.5479","article-title":"Adiponectin promotes VEGF-A-dependent angiogenesis in human chondrosarcoma through PI3K, Akt, mTOR, and HIF-\u03b1 pathway","volume":"6","author":"Lee","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.drup.2026.101355_bib400","doi-asserted-by":"crossref","first-page":"7335","DOI":"10.4049\/jimmunol.172.12.7335","article-title":"Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients","volume":"172","author":"Lee","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.drup.2026.101355_bib401","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12931-015-0285-4","article-title":"Autophagy contributes to the chemo-resistance of non-small cell lung cancer in hypoxic conditions","volume":"16","author":"Lee","year":"2015","journal-title":"Respir. Res."},{"key":"10.1016\/j.drup.2026.101355_bib402","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/sj.onc.1209163","article-title":"The JAK2 V617F mutation in de novo acute myelogenous leukemias","volume":"25","author":"Lee","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.drup.2026.101355_bib403","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41586-019-1004-y","article-title":"Hepatocytes direct the formation of a pro-metastatic niche in the liver","volume":"567","author":"Lee","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101355_bib404","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1158\/1535-7163.MCT-19-0873","article-title":"Preclinical activity of HER2-selective tyrosine kinase inhibitor tucatinib as a single agent or in combination with trastuzumab or docetaxel in solid tumor models","volume":"19","author":"Lee","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drup.2026.101355_bib405","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12102256","article-title":"CDKN2A homozygous deletion is a stronger predictor of outcome than IDH1\/2-Mutation in CNS WHO grade 4 gliomas","author":"Lee","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.drup.2026.101355_bib406","doi-asserted-by":"crossref","first-page":"15061","DOI":"10.1038\/ncomms15061","article-title":"Mechanism of SOS PR-domain autoinhibition revealed by single-molecule assays on native protein from lysate","volume":"8","author":"Lee","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101355_bib407","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41392-022-01190-w","article-title":"Signaling pathways and therapeutic interventions in gastric cancer","volume":"7","author":"Lei","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.drup.2026.101355_bib408","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10585-024-10288-0","article-title":"Cancer metastasis through the lymphatic versus blood vessels","volume":"41","author":"Leong","year":"2024","journal-title":"Clin. Exp. Metastas-.-."},{"key":"10.1016\/j.drup.2026.101355_bib409","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/sj.bjc.6604470","article-title":"The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma","volume":"99","author":"Lesueur","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib410","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/15384047.2019.1665956","article-title":"Mutated TP53 is a marker of increased VEGF expression: analysis of 7,525 pan-cancer tissues","volume":"21","author":"Li","year":"2020","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.drup.2026.101355_bib411","first-page":"2944","article-title":"MicroRNA\u2011145 inhibits migration and induces apoptosis in human non\u2011small cell lung cancer cells through regulation of the EGFR\/PI3K\/AKT signaling pathway","author":"Li","year":"2018","journal-title":"Oncol. Rep. 40"},{"key":"10.1016\/j.drup.2026.101355_bib412","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cbi.2017.08.014","article-title":"miR-221\/222 promote cancer stem-like cell properties and tumor growth of breast cancer via targeting PTEN and sustained Akt\/NF-\u03baB\/COX-2 activation","volume":"277","author":"Li","year":"2017","journal-title":"Chem. -Biol. Interact."},{"key":"10.1016\/j.drup.2026.101355_bib413","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1080\/1061186X.2019.1585437","article-title":"NEAT1 mediates paclitaxel-resistance of non-small cell of lung cancer through activation of Akt\/mTOR signalling pathway","volume":"27","author":"Li","year":"2019","journal-title":"J. Drug Target."},{"key":"10.1016\/j.drup.2026.101355_bib414","doi-asserted-by":"crossref","first-page":"93476","DOI":"10.18632\/oncotarget.19281","article-title":"Dysregulated lncRNA-UCA1 contributes to the progression of gastric cancer through regulation of the PI3K-Akt-mTOR signaling pathway","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.drup.2026.101355_bib415","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3892\/etm.2021.10390","article-title":"FOXP3 facilitates the invasion and metastasis of non\u2011small cell lung cancer cells through regulating VEGF, EMT and the Notch1\/Hes1 pathway","volume":"22","author":"Li","year":"2021","journal-title":"Exp. Ther. Med"},{"key":"10.1016\/j.drup.2026.101355_bib416","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.yexcr.2019.03.038","article-title":"IL-10 in vitro could enhance IFN\u03b3 expression and suppress PD-1 expression in CD8 T cells from esophageal cancer patients","volume":"379","author":"Li","year":"2019","journal-title":"Exp. Cell Res"},{"key":"10.1016\/j.drup.2026.101355_bib417","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41420-023-01336-x","article-title":"Cancer-associated fibroblast-secreted IGFBP7 promotes gastric cancer by enhancing tumor associated macrophage infiltration via FGF2\/FGFR1\/PI3K\/AKT axis","volume":"9","author":"Li","year":"2023","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.drup.2026.101355_bib418","doi-asserted-by":"crossref","DOI":"10.15252\/embj.201796659","article-title":"ATRX loss induces telomere dysfunction and necessitates induction of alternative lengthening of telomeres during human cell immortalization","volume":"38","author":"Li","year":"2019","journal-title":"Embo J."},{"key":"10.1016\/j.drup.2026.101355_bib419","doi-asserted-by":"crossref","first-page":"9667920","DOI":"10.1155\/2023\/9667920","article-title":"Long non-coding RNA HOTAIR promotes human osteosarcoma proliferation, migration through activation of the Wnt\/b-catenin signaling pathway","volume":"2023","author":"Li","year":"2023","journal-title":"J. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib420","first-page":"5865","article-title":"The relationship between MMP-2 and MMP-9 expression levels with breast cancer incidence and prognosis","volume":"14","author":"Li","year":"2017","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.drup.2026.101355_bib421","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","article-title":"Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.drup.2026.101355_bib422","doi-asserted-by":"crossref","first-page":"15923","DOI":"10.1039\/C8RA00549D","article-title":"Long non-coding RNA CASC2 enhanced cisplatin-induced viability inhibition of non-small cell lung cancer cells by regulating the PTEN\/PI3K\/Akt pathway through down-regulation of miR-18a and miR-21","volume":"8","author":"Li","year":"2018","journal-title":"RSC Adv."},{"key":"10.1016\/j.drup.2026.101355_bib423","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.3892\/ol.2016.5110","article-title":"The Ras\/Raf\/MEK\/ERK signaling pathway and its role in the occurrence and development of HCC (Review)","volume":"12","author":"Li","year":"2016","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.drup.2026.101355_bib424","article-title":"DNA repair pathways in cancer therapy and resistance","volume":"11","author":"Li","year":"2020","journal-title":"Front Pharm."},{"key":"10.1016\/j.drup.2026.101355_bib425","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2021.114689","article-title":"Curcumin inhibits the invasion and metastasis of triple negative breast cancer via Hedgehog\/Gli1 signaling pathway","volume":"283","author":"Li","year":"2022","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.drup.2026.101355_bib426","first-page":"3522","article-title":"Long non-coding RNA CASC2 suppresses the proliferation of gastric cancer cells by regulating the MAPK signaling pathway","volume":"8","author":"Li","year":"2016","journal-title":"Am. J. Transl. Res"},{"key":"10.1016\/j.drup.2026.101355_bib427","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41392-024-01953-7","article-title":"Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.drup.2026.101355_bib428","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s43556-022-00110-2","article-title":"Targeting the PI3K\/AKT\/mTOR and RAF\/MEK\/ERK pathways for cancer therapy","volume":"3","author":"Li","year":"2022","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.drup.2026.101355_bib429","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s43556-022-00110-2","article-title":"Targeting the PI3K\/AKT\/mTOR and RAF\/MEK\/ERK pathways for cancer therapy","volume":"3","author":"Li","year":"2022","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.drup.2026.101355_bib430","first-page":"3740","article-title":"MiR-145 inhibits cervical cancer progression and metastasis by targeting WNT2B by Wnt\/\u03b2-catenin pathway","volume":"12","author":"Li","year":"2019","journal-title":"Int J. Clin. Exp. Pathol."},{"key":"10.1016\/j.drup.2026.101355_bib431","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s12094-019-02223-7","article-title":"Long noncoding RNA CASC2c inhibited cell proliferation in hepatocellular carcinoma by inactivated ERK1\/2 and Wnt\/\u03b2-catenin signaling pathway","volume":"22","author":"Li","year":"2020","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib432","article-title":"Relatlimab: a novel drug targeting immune checkpoint LAG-3 in melanoma therapy","volume":"14","author":"Li","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.drup.2026.101355_bib433","article-title":"Long non-coding RNA BANCR promotes proliferation in malignant melanoma by regulating MAPK pathway activation","volume":"9","author":"Li","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.drup.2026.101355_bib434","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1038\/s41598-018-36963-3","article-title":"Induction of MET receptor tyrosine kinase down-regulation through antibody-mediated receptor clustering","volume":"9","author":"Li","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drup.2026.101355_bib435","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1038\/onc.2011.426","article-title":"Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance","volume":"31","author":"Li","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.drup.2026.101355_bib436","doi-asserted-by":"crossref","DOI":"10.3390\/cells13221922","article-title":"BCL2i-based therapies and emerging resistance in chronic lymphocytic leukemia","volume":"13","author":"Li","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.drup.2026.101355_bib437","first-page":"1863","article-title":"Long non\u2011coding RNA H19 knockdown inhibits the cell viability and promotes apoptosis of thyroid cancer cells through regulating the PI3K\/AKT pathway","author":"Li","year":"2019","journal-title":"Exp. Ther. Med 18"},{"key":"10.1016\/j.drup.2026.101355_bib438","first-page":"3366","article-title":"Enhanced expression of circular RNA hsa_circ_000984 promotes cells proliferation and metastasis in non-small cell lung cancer by modulating Wnt\/\u03b2-catenin pathway","volume":"23","author":"Li","year":"2019","journal-title":"Eur. Rev. Med Pharm. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib439","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.21037\/tlcr-21-299","article-title":"Let-7b-3p inhibits tumor growth and metastasis by targeting the BRF2-mediated MAPK\/ERK pathway in human lung adenocarcinoma","volume":"10","author":"Li","year":"2021","journal-title":"Transl. Lung Cancer Res"},{"key":"10.1016\/j.drup.2026.101355_bib440","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1007\/s10620-017-4831-4","article-title":"The GAS5\/miR-222 axis regulates proliferation of gastric cancer cells through the PTEN\/Akt\/mTOR pathway","volume":"62","author":"Li","year":"2017","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib441","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3892\/ol.2020.12357","article-title":"Effect of let\u20117c on the PI3K\/Akt\/FoxO signaling pathway in hepatocellular carcinoma","volume":"21","author":"Li","year":"2021","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.drup.2026.101355_bib442","doi-asserted-by":"crossref","first-page":"4516","DOI":"10.7150\/thno.54549","article-title":"LncRNA PRADX-mediated recruitment of PRC2\/DDX5 complex suppresses UBXN1 expression and activates NF-\u03baB activity, promoting tumorigenesis","volume":"11","author":"Li","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.drup.2026.101355_bib443","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12964-023-01082-8","article-title":"Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer","volume":"21","author":"Li","year":"2023","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.drup.2026.101355_bib444","first-page":"435","article-title":"Knockdown of lncRNA\u2011HOTAIR downregulates the drug\u2011resistance of breast cancer cells to doxorubicin via the PI3K\/AKT\/mTOR signaling pathway","volume":"18","author":"Li","year":"2019","journal-title":"Exp. Ther. Med"},{"key":"10.1016\/j.drup.2026.101355_bib445","doi-asserted-by":"crossref","DOI":"10.1177\/1533033819849068","article-title":"Colon cancer cell secretes EGF to promote M2 polarization of TAM through EGFR\/PI3K\/AKT\/mTOR pathway","volume":"18","author":"Lian","year":"2019","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.drup.2026.101355_bib446","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12943-023-01929-1","article-title":"JAK\/STAT in leukemia: a clinical update","volume":"23","author":"Liang","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib447","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/jop.12466","article-title":"MALAT1 induces tongue cancer cells' EMT and inhibits apoptosis through Wnt\/\u03b2-catenin signaling pathway","volume":"46","author":"Liang","year":"2017","journal-title":"J. Oral. Pathol. Med."},{"key":"10.1016\/j.drup.2026.101355_bib448","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.847","article-title":"Clinical implications of EGFR-associated MAPK\/ERK pathway in multiple primary lung cancer","volume":"12","author":"Liang","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.drup.2026.101355_bib449","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41416-023-02495-5","article-title":"MET exon 14 skipping mutation drives cancer progression and recurrence via activation of SMAD2 signalling","volume":"130","author":"Liang","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib450","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s44385-024-00003-9","article-title":"Application of artificial intelligence in drug-target interactions prediction: a review","volume":"2","author":"Liao","year":"2025","journal-title":"npj Biomed. Innov."},{"key":"10.1016\/j.drup.2026.101355_bib451","first-page":"7313","article-title":"Downregulation of lncRNA H19 inhibits the migration and invasion of melanoma cells by inactivating the NF\u2011\u03baB and PI3K\/Akt signaling pathways","volume":"17","author":"Liao","year":"2018","journal-title":"Mol. Med Rep."},{"key":"10.1016\/j.drup.2026.101355_bib452","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/978-3-319-42118-6_3","article-title":"Metabolic reprogramming by the PI3K-Akt-mTOR pathway in cancer","volume":"207","author":"Lien","year":"2016","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.drup.2026.101355_bib453","article-title":"Molecular mechanism of PD-1\/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab","volume":"7","author":"Lim","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drup.2026.101355_bib454","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1038\/sj.bjc.6605335","article-title":"Mutant p53 mediates survival of breast cancer cells","volume":"101","author":"Lim","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib455","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1158\/0008-5472.CAN-16-1297","article-title":"Adhere, degrade, and move: the three-step model of invasion","volume":"76","author":"Liotta","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101355_bib456","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105997","article-title":"Clinical experience with CTLA-4 blockade for cancer immunotherapy: from the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment","volume":"175","author":"Lisi","year":"2022","journal-title":"Pharm. Res"},{"key":"10.1016\/j.drup.2026.101355_bib457","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3389\/fphar.2022.1108776","article-title":"The role of metabolic reprogramming in pancreatic cancer chemoresistance","volume":"13","author":"Liu","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.drup.2026.101355_bib458","article-title":"Bone marrow adipocytes, adipocytokines, and breast cancer cells: novel implications in bone metastasis of breast cancer","volume":"10","author":"Liu","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib459","first-page":"4149","article-title":"miR-21 regulates the proliferation and apoptosis of ovarian cancer cells through PTEN\/PI3K\/AKT","volume":"23","author":"Liu","year":"2019","journal-title":"Eur. Rev. Med Pharm. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib460","doi-asserted-by":"crossref","DOI":"10.1177\/0963689720953093","article-title":"LncRNA GAS5 suppresses the proliferation and invasion of osteosarcoma cells via the miR-23a-3p\/PTEN\/PI3K\/AKT pathway","volume":"29","author":"Liu","year":"2020","journal-title":"Cell Transplant."},{"key":"10.1016\/j.drup.2026.101355_bib461","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.canlet.2013.12.025","article-title":"Tumor suppressor p53 and its mutants in cancer metabolism","volume":"356","author":"Liu","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.drup.2026.101355_bib462","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/kjm2.12696","article-title":"LDLR promotes autophagy-mediated cisplatin resistance in ovarian cancer associated with the PI3K\/AKT\/mTOR signaling pathway","volume":"39","author":"Liu","year":"2023","journal-title":"Kaohsiung J. Med. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib463","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2023.110892","article-title":"ZNF746 promotes M2 macrophage polarisation and favours tumour progression in breast cancer via the Jagged1\/Notch pathway","volume":"112","author":"Liu","year":"2023","journal-title":"Cell. Signal."},{"key":"10.1016\/j.drup.2026.101355_bib464","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110225","article-title":"Inhibition of Wnt\/\u03b2-catenin pathway reverses multi-drug resistance and EMT in Oct4+\/Nanog+ NSCLC cells","volume":"127","author":"Liu","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.drup.2026.101355_bib465","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/nm.2402","article-title":"Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway\u2013dependent and PI3K pathway\u2013independent mechanisms","volume":"17","author":"Liu","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2026.101355_bib466","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317712445","article-title":"Targeting interlukin-6 to relieve immunosuppression in tumor microenvironment","volume":"39","author":"Liu","year":"2017","journal-title":"Tumor Biol."},{"key":"10.1016\/j.drup.2026.101355_bib467","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41419-020-02998-6","article-title":"PI3K\/AKT pathway as a key link modulates the multidrug resistance of cancers","volume":"11","author":"Liu","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.drup.2026.101355_bib468","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1186\/s12964-024-01812-6","article-title":"Interactions between hedgehog signaling pathway and the complex tumor microenvironment in breast cancer: current knowledge and therapeutic promises","volume":"22","author":"Liu","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.drup.2026.101355_bib469","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41392-020-00436-9","article-title":"Targeting TGF\u03b2 signal transduction for cancer therapy","volume":"6","author":"Liu","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.drup.2026.101355_bib470","doi-asserted-by":"crossref","first-page":"7541","DOI":"10.1002\/jcp.29656","article-title":"lncRNA SNHG11 promotes lung cancer cell proliferation and migration via activation of Wnt\/\u03b2-catenin signaling pathway","volume":"235","author":"Liu","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.drup.2026.101355_bib471","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.102027","article-title":"AKR1C3 promotes progression and mediates therapeutic resistance by inducing epithelial-mesenchymal transition and angiogenesis in small cell lung cancer","volume":"47","author":"Liu","year":"2024","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib472","doi-asserted-by":"crossref","DOI":"10.1177\/1533033821990074","article-title":"Upregulation of long noncoding RNA_GAS5 suppresses cell proliferation and metastasis in laryngeal cancer via regulating PI3K\/AKT\/mTOR signaling pathway","volume":"20","author":"Liu","year":"2021","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.drup.2026.101355_bib473","first-page":"7905","article-title":"Upregulation of circHIPK3 promotes the progression of gastric cancer via Wnt\/\u03b2-catenin pathway and indicates a poor prognosis","volume":"23","author":"Liu","year":"2019","journal-title":"Eur. Rev. Med Pharm. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib474","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.3724\/abbs.2023082","article-title":"Angiopoietin-1 promotes triple-negative breast cancer cell proliferation by upregulating carboxypeptidase A4","volume":"55","author":"Liu","year":"2023","journal-title":"Acta Biochim Biophys. Sin. (Shanghai)"},{"key":"10.1016\/j.drup.2026.101355_bib475","doi-asserted-by":"crossref","first-page":"9169","DOI":"10.1158\/0008-5472.CAN-05-0939","article-title":"Decoy receptor 2 (DcR2) Is a p53 target gene and regulates chemosensitivity","volume":"65","author":"Liu","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2026.101355_bib476","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.23834","article-title":"Let-7 reduces the proliferation and migration of oral cancer cells via PI3K\/AKT signaling pathway","volume":"38","author":"Liu","year":"2024","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"10.1016\/j.drup.2026.101355_bib477","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2024.5684","article-title":"Drug resistance and tumor immune microenvironment: an overview of current understandings (Review)","volume":"65","author":"Liu","year":"2024","journal-title":"Int J. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib478","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.drup.2026.101355_bib479","article-title":"LncRNA GHET1 promotes cervical cancer progression through regulating AKT\/mTOR and Wnt\/\u03b2-catenin signaling pathways","volume":"40","author":"Liu","year":"2020","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.drup.2026.101355_bib480","article-title":"Tumor-stroma-inflammation networks promote pro-metastatic chemokines and aggressiveness characteristics in triple-negative breast cancer","volume":"10","author":"Liubomirski","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.drup.2026.101355_bib481","doi-asserted-by":"crossref","first-page":"6893","DOI":"10.1038\/s41467-021-27223-6","article-title":"The telomere length landscape of prostate cancer","volume":"12","author":"Livingstone","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101355_bib482","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0002-9440(10)65277-7","article-title":"p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers","volume":"154","author":"Lloyd","year":"1999","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.drup.2026.101355_bib483","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12943-022-01543-7","article-title":"Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments","volume":"21","author":"Lone","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib484","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40262-016-0452-x","article-title":"Population pharmacokinetics of necitumumab in cancer patients","volume":"56","author":"Long","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.drup.2026.101355_bib485","doi-asserted-by":"crossref","unstructured":"V. Long Georgina, D. Stroyakovskiy, H. Gogas, E. Levchenko, F. de Braud, J. Larkin, C. Garbe, T. Jouary, A. Hauschild, J. Grob Jean, V. Chiarion Sileni, C. Lebbe, M. Mandal\u00e0, M. Millward, A. Arance, I. Bondarenko, B.A.G. Haanen John, J. Hansson, J. Utikal, V. Ferraresi, N. Kovalenko, P. Mohr, V. Probachai, D. Schadendorf, P. Nathan, C. Robert, A. Ribas, J. DeMarini Douglas, G. Irani Jhangir, M. Casey, D. Ouellet, A.-M. Martin, N. Le, K. Patel and K. Flaherty, Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma, New England Journal of Medicine 371, pp. 1877-1888.","DOI":"10.1056\/NEJMoa1406037"},{"key":"10.1016\/j.drup.2026.101355_bib486","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/annonc\/mdx176","article-title":"Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study","volume":"28","author":"Long","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib487","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1186\/s13046-019-1329-2","article-title":"Long non-coding RNA GAS5 inhibits DDP-resistance and tumor progression of epithelial ovarian cancer via GAS5-E2F4-PARP1-MAPK axis","volume":"38","author":"Long","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101355_bib488","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40164-024-00505-7","article-title":"Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion","volume":"13","author":"Lu","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib489","doi-asserted-by":"crossref","first-page":"200","DOI":"10.14715\/cmb\/2023.69.11.30","article-title":"Detection of TP53 gene mutation in blood of breast cancer patients based on circulating tumor DNA and its application in prognosis","volume":"69","author":"Lu","year":"2023","journal-title":"Cell. Mol. Biol."},{"key":"10.1016\/j.drup.2026.101355_bib490","first-page":"7633","article-title":"MiR-155 affects osteosarcoma cell proliferation and invasion through regulating NF-\u03baB signaling pathway","volume":"22","author":"Lu","year":"2018","journal-title":"Eur. Rev. Med Pharm. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib491","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s11912-021-01096-w","article-title":"Alternative lengthening of telomeres (ALT) in pancreatic neuroendocrine tumors: ready for prime-time in clinical practice?","volume":"23","author":"Luchini","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.drup.2026.101355_bib492","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/s41419-021-04285-4","article-title":"Venetoclax imparts distinct cell death sensitivity and adaptivity patterns in T cells","volume":"12","author":"Ludwig","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.drup.2026.101355_bib493","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00018-019-03351-7","article-title":"Tumor angiogenesis: causes, consequences, challenges and opportunities","volume":"77","author":"Lugano","year":"2020","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.drup.2026.101355_bib494","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1038\/s41591-023-02593-0","article-title":"The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial","volume":"29","author":"Luke","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2026.101355_bib495","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00432-024-05877-1","article-title":"LncRNA ZFAS1 regulates ATIC transcription and promotes the proliferation and migration of hepatocellular carcinoma through the PI3K\/AKT signaling pathway","volume":"150","author":"Luo","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib496","doi-asserted-by":"crossref","DOI":"10.1016\/j.cytogfr.2025.05.004","article-title":"TGF-\u03b2-driven EMT in cancer progression and drug resistance","author":"Luo","year":"2025","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.drup.2026.101355_bib497","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.109880","article-title":"MiR-155-5p exerts tumor-suppressing functions in Wilms tumor by targeting IGF2 via the PI3K signaling pathway","volume":"125","author":"Luo","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.drup.2026.101355_bib498","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11081076","article-title":"PTEN tumor-suppressor: the dam of stemness in cancer","volume":"11","author":"Luongo","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drup.2026.101355_bib499","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0145-2023","article-title":"CDK4\/6 inhibitors in lung cancer: current practice and future directions","volume":"33","author":"Lv","year":"2024","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.drup.2026.101355_bib500","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2019.100228","article-title":"Long noncoding RNA UCA1 promotes osteosarcoma metastasis through CREB1-mediated epithelial-mesenchymal transition and activating PI3K\/AKT\/mTOR pathway","volume":"16","author":"Ma","year":"2019","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib501","doi-asserted-by":"crossref","first-page":"eadk8958","DOI":"10.1126\/sciadv.adk8958","article-title":"Tumor suppressor FRMD3 controls mammary epithelial cell fate determination via notch signaling pathway","volume":"10","author":"Ma","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.drup.2026.101355_bib502","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s11010-009-0154-x","article-title":"PTEN regulate angiogenesis through PI3K\/Akt\/VEGF signaling pathway in human pancreatic cancer cells","volume":"331","author":"Ma","year":"2009","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.drup.2026.101355_bib503","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12943-024-02218-1","article-title":"The roles of KRAS in cancer metabolism, tumor microenvironment and clinical therapy","volume":"24","author":"Ma","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib504","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1016\/j.biopha.2018.10.011","article-title":"The lncRNA LINC00675 regulates cell proliferation, migration, and invasion by affecting Wnt\/\u03b2-catenin signaling in cervical cancer","volume":"108","author":"Ma","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.drup.2026.101355_bib505","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/s41419-021-03762-0","article-title":"Fatostatin reverses progesterone resistance by inhibiting the SREBP1-NF-\u03baB pathway in endometrial carcinoma","volume":"12","author":"Ma","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.drup.2026.101355_bib506","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.bbrc.2013.11.010","article-title":"MiR-34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K\/Akt\/Bad pathway","volume":"441","author":"Ma","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.drup.2026.101355_bib507","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.neuint.2018.03.011","article-title":"Long noncoding RNA DANCR mediates cisplatin resistance in glioma cells via activating AXL\/PI3K\/Akt\/NF-\u03baB signaling pathway","volume":"118","author":"Ma","year":"2018","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.drup.2026.101355_bib508","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13143540","article-title":"Trastuzumab mechanism of action; 20 years of research to unravel a dilemma","volume":"13","author":"Maadi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drup.2026.101355_bib509","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/2040620716652862","article-title":"Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment","volume":"7","author":"Magen","year":"2016","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.drup.2026.101355_bib510","doi-asserted-by":"crossref","DOI":"10.1172\/JCI197764","article-title":"NR2F1 and mTORC1 provide the bridge between melanoma dormancy and therapeutic resistance","volume":"135","author":"Mamidi","year":"2025","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.drup.2026.101355_bib511","article-title":"Obinutuzumab activates CD64 more potently than other anti-CD20 antibodies in chronic lymphocytic leukemia (CLL)","volume":"130","author":"Mandelboim","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101355_bib512","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1158\/1078-0432.CCR-22-0713","article-title":"Microsatellite instability\u2013high endometrial cancers with MLH1 promoter hypermethylation have distinct molecular and clinical profiles","volume":"28","author":"Manning-Geist","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101355_bib513","doi-asserted-by":"crossref","first-page":"339","DOI":"10.15171\/apb.2017.041","article-title":"The different mechanisms of cancer drug resistance: a brief review","volume":"7","author":"Mansoori","year":"2017","journal-title":"Adv. Pharm. Bull."},{"key":"10.1016\/j.drup.2026.101355_bib514","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41418-018-0246-9","article-title":"Mutant p53 as a guardian of the cancer cell","volume":"26","author":"Mantovani","year":"2019","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.drup.2026.101355_bib515","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109771","article-title":"Circular RNA CDR1-AS contributes to pemetrexed and cisplatin chemoresistance through EGFR\/PI3K signaling pathway in lung adenocarcinoma","volume":"123","author":"Mao","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.drup.2026.101355_bib516","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1186\/s12935-021-02396-8","article-title":"p53 signaling in cancer progression and therapy","volume":"21","author":"Marei","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.drup.2026.101355_bib517","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1038\/s41598-024-53211-z","article-title":"Clinical trials are becoming more complex: a machine learning analysis of data from over 16,000 trials","volume":"14","author":"Markey","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drup.2026.101355_bib518","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s40265-018-1012-5","article-title":"Cemiplimab: first global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.drup.2026.101355_bib519","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1126\/science.7761852","article-title":"Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability","volume":"268","author":"Markowitz","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.drup.2026.101355_bib520","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.2217\/epi-2016-0110","article-title":"Epigenetic control of the tumor microenvironment","volume":"8","author":"Marks","year":"2016","journal-title":"Epigenomics"},{"key":"10.1016\/j.drup.2026.101355_bib521","article-title":"L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: comparison of osimertinib vs. cetuximab","volume":"4","author":"Marrocco","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.drup.2026.101355_bib522","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104355","article-title":"Trastuzumab deruxtecan in breast cancer","author":"Mart\u00edn","year":"2024","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"key":"10.1016\/j.drup.2026.101355_bib523","article-title":"Abstract GS02-01: randomized phase 3 study of datopotamab deruxtecan vs chemotherapy for patients with previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer: results from TROPION-Breast01","author":"Mart\u00ednez-Ja\u00f1ez","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2026.101355_bib524","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13058-020-01284-9","article-title":"Frequency and spectrum of PIK3CA somatic mutations in breast cancer","volume":"22","author":"Mart\u00ednez-S\u00e1ez","year":"2020","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.drup.2026.101355_bib525","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.7150\/thno.81847","article-title":"Role of p53 in breast cancer progression: an insight into p53 targeted therapy","volume":"13","author":"Marvalim","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.drup.2026.101355_bib526","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065303","article-title":"The effect of belantamab mafodotin on primary myeloma\u2013stroma co-cultures: asymmetrical mitochondrial transfer between myeloma cells and autologous bone marrow stromal cells","volume":"24","author":"Matula","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib527","series-title":"Pediatric Surgical Oncology","first-page":"1","article-title":"Cancer development and progression and the \u201challmarks of cancer\u201d","author":"Mazingi","year":"2023"},{"key":"10.1016\/j.drup.2026.101355_bib528","doi-asserted-by":"crossref","first-page":"E2939","DOI":"10.1073\/pnas.1206400109","article-title":"Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy","volume":"109","author":"McAuliffe","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib529","first-page":"1061","article-title":"Comprehensive genomic characterization defines human glioblastoma genes and core pathways","volume":"455","author":"McLendon","year":"2008"},{"key":"10.1016\/j.drup.2026.101355_bib530","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/hem.V19.2.202221","article-title":"STAMPing on BCR-ABL1: asciminib approved for chronic myeloid leukemia","volume":"19","author":"McMahon","year":"2022","journal-title":"Hematologist"},{"issue":"24","key":"10.1016\/j.drup.2026.101355_bib531","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","article-title":"Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5","volume":"66","author":"McNabola","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2026.101355_bib532","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.clbc.2021.10.013","article-title":"A phase Ib dose escalation trial of RO4929097 (a \u03b3-secretase inhibitor) in combination with exemestane in patients with ER+ metastatic breast cancer (MBC)","volume":"22","author":"Means-Powell","year":"2022","journal-title":"Clin. Breast Cancer"},{"issue":"8","key":"10.1016\/j.drup.2026.101355_bib533","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.clinthera.2008.08.008","article-title":"Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases","volume":"30","author":"Medina","year":"2008","journal-title":"Clin. Ther."},{"key":"10.1016\/j.drup.2026.101355_bib534","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0014124","article-title":"Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo","volume":"5","author":"Meng","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.drup.2026.101355_bib535","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.semcancer.2003.09.016","article-title":"Autocrine signaling in carcinoma: VEGF and the \u03b16\u03b24 integrin","volume":"14","author":"Mercurio","year":"2004","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.drup.2026.101355_bib536","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2147\/CMAR.S269679","article-title":"LncRNA BANCR attenuates the killing capacity of cisplatin on gastric cancer cell through the ERK1\/2 pathway","volume":"13","author":"Miao","year":"2021","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.drup.2026.101355_bib537","doi-asserted-by":"crossref","first-page":"156","DOI":"10.36849\/JDD.5657","article-title":"A review of hedgehog inhibitors sonidegib and vismodegib for treatment of advanced basal cell carcinoma","volume":"20","author":"Michael Migden","year":"2021","journal-title":"J. Drugs Dermatol."},{"key":"10.1016\/j.drup.2026.101355_bib538","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1073\/pnas.1417320112","article-title":"Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients","volume":"112","author":"Michielin","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib539","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.htct.2023.06.006","article-title":"All about blinatumomab: the bispecific T cell engager immunotherapy for B cell acute lymphoblastic leukemia","volume":"46","author":"Mirfakhraie","year":"2024","journal-title":"Hematol., Transfus. Cell Ther."},{"key":"10.1016\/j.drup.2026.101355_bib540","doi-asserted-by":"crossref","DOI":"10.1177\/20503121211069012","article-title":"Tumor promoting roles of IL-10, TGF-\u03b2, IL-4, and IL-35: Its implications in cancer immunotherapy","volume":"10","author":"Mirlekar","year":"2022","journal-title":"SAGE Open Med"},{"key":"10.1016\/j.drup.2026.101355_bib541","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib542","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/14737140.2017.1364995","article-title":"Anti-GD2 immunotherapy for neuroblastoma","volume":"17","author":"Modak","year":"2017","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.drup.2026.101355_bib543","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1158\/1078-0432.CCR-13-2391","article-title":"Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non\u2013small cell lung cancer","volume":"20","author":"Molina-Vila","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101355_bib544","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biocel.2018.03.015","article-title":"Blockade of nuclear factor-\u03baB (NF-\u03baB) pathway inhibits growth and induces apoptosis in chemoresistant ovarian carcinoma cells","volume":"99","author":"Momeny","year":"2018","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.drup.2026.101355_bib545","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/cdd.2017.183","article-title":"Why do BCL-2 inhibitors work and where should we use them in the clinic?","volume":"25","author":"Montero","year":"2018","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.drup.2026.101355_bib546","article-title":"Trastuzumab mechanism of action; 20 years of research to unravel a dilemma","volume":"13","author":"Moshtaghian","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2026.101355_bib547","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.727306","article-title":"Calmodulin 2 facilitates angiogenesis and metastasis of gastric cancer via STAT3\/HIF-1A\/VEGF-A mediated macrophage polarization","volume":"11","author":"Mu","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib548","doi-asserted-by":"crossref","DOI":"10.1097\/MPA.0000000000001828","article-title":"Hypoxia promotes pancreatic cancer cell dedifferentiation to stem-like cell phenotypes with high tumorigenic potential by the HIF-1\u03b1\/Notch signaling pathway","volume":"50","author":"Mu","year":"2021","journal-title":"Pancreas"},{"key":"10.1016\/j.drup.2026.101355_bib549","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1038\/s41388-024-03165-3","article-title":"The T\u03b2RI promotes migration and metastasis through thrombospondin 1 and ITGAV in prostate cancer cells","volume":"43","author":"Mu","year":"2024","journal-title":"Oncogene"},{"key":"10.1016\/j.drup.2026.101355_bib550","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1750-2187-5-8","article-title":"EGFR\/Met association regulates EGFR TKI resistance in breast cancer","volume":"5","author":"Mueller","year":"2010","journal-title":"J. Mol. Signal"},{"key":"10.1016\/j.drup.2026.101355_bib551","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100100","article-title":"p53 expression in luminal breast cancer correlates with TP53 mutation and primary endocrine resistance","volume":"36","author":"Mueller","year":"2023","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.drup.2026.101355_bib552","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/onco.13715","article-title":"Effects of ado-trastuzumab emtansine and fam-trastuzumab deruxtecan on metastatic breast cancer harboring HER2 amplification and the L755S mutation","volume":"26","author":"Mukohara","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.drup.2026.101355_bib553","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000346837","article-title":"HER2 dimerization inhibitor pertuzumab - mode of action and clinical data in breast cancer","volume":"8","author":"M\u00fcller","year":"2013","journal-title":"Breast Care"},{"key":"10.1016\/j.drup.2026.101355_bib554","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.01088","article-title":"A comparative analysis of individual RAS mutations in cancer biology","volume":"9","author":"Mu\u00f1oz-Maldonado","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib555","first-page":"457","article-title":"Drug resistance mechanisms of cancer stem-like cells and their therapeutic potential as drug targets","volume":"2","author":"Murayama","year":"2019","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.drup.2026.101355_bib556","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16132479","article-title":"Overcoming chemoresistance in cancer: the promise of crizotinib","volume":"16","author":"Musa","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2026.101355_bib557","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.3390\/cells13221838","article-title":"Apoptosis: a comprehensive overview of signaling pathways, morphological changes, and physiological significance and therapeutic implications","volume":"13","author":"Mustafa","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.drup.2026.101355_bib558","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.3389\/fonc.2018.00016","article-title":"Role of BRCA mutations in the modulation of response to platinum therapy","volume":"8","author":"Mylavarapu","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib559","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/jb\/mvq119","article-title":"Alternative lengthening of telomeres pathway: recombination-mediated telomere maintenance mechanism in human cells","volume":"149","author":"Nabetani","year":"2011","journal-title":"J. Biochem."},{"key":"10.1016\/j.drup.2026.101355_bib560","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ccr.2004.06.022","article-title":"PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients","volume":"6","author":"Nagata","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2026.101355_bib561","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/cgt.2010.16","article-title":"Targeting MMP-9, uPAR, and cathepsin B inhibits invasion, migration and activates apoptosis in prostate cancer cells","volume":"17","author":"Nalla","year":"2010","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.drup.2026.101355_bib562","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2019.00086","article-title":"The role of the extracellular matrix in cancer stemness","volume":"7","author":"Nallanthighal","year":"2019","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.drup.2026.101355_bib563","doi-asserted-by":"crossref","first-page":"eadw3231","DOI":"10.1126\/scisignal.adw3231","article-title":"MAPK and mTORC1 signaling converge to drive cyclin D1 protein production to enable cell cycle reentry in melanoma persister cells","volume":"18","author":"Nangia","year":"2025","journal-title":"Sci. Signal."},{"key":"10.1016\/j.drup.2026.101355_bib564","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1007\/s10528-023-10592-6","article-title":"LncRNA MALAT1 expression regulates breast cancer progression via PI3K\/AKT\/mTOR pathway modulation","volume":"62","author":"Naveed","year":"2024","journal-title":"Biochem. Genet."},{"key":"10.1016\/j.drup.2026.101355_bib565","first-page":"2220","article-title":"Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy, Blood","volume":"111","author":"Nefedova","year":"2008","journal-title":"J. Am. Soc. Hematol."},{"key":"10.1016\/j.drup.2026.101355_bib566","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41698-022-00341-0","article-title":"BRAF v600E\u2013mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study","volume":"7","author":"Nelson","year":"2023","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib567","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/oncolo\/oyae119","article-title":"Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G","volume":"29","author":"Nelson","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.drup.2026.101355_bib568","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13174363","article-title":"Apoptosis deregulation and the development of cancer multi-drug resistance","author":"Neophytou","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2026.101355_bib569","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23010146","article-title":"Matrix metalloproteinases shape the tumor microenvironment in cancer progression","volume":"23","author":"Niland","year":"2021","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib570","first-page":"27","article-title":"Acquired resistance to molecularly targeted therapies for cancer","volume":"8","author":"Nolan","year":"2025","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.drup.2026.101355_bib571","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jamaoncol.2024.0584","article-title":"Gefitinib vs gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-variant lung cancer\u2014long-term results of a randomized clinical trial","volume":"10","author":"Noronha","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib572","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082276","article-title":"Targeting multiple signaling pathways in cancer: the rutin therapeutic approach","volume":"12","author":"Nouri","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drup.2026.101355_bib573","article-title":"P16-CD8-Ki67 triple algorithm for prediction of CDKN2A mutations in patients with multiple primary and familial melanoma","volume":"14","author":"Nurla","year":"2024","journal-title":"Diagn. (Basel)"},{"key":"10.1016\/j.drup.2026.101355_bib574","article-title":"Understanding apoptosis in sickle cell anemia patients: mechanisms and implications","volume":"103","author":"Obeagu","year":"2024","journal-title":"Medicine"},{"key":"10.1016\/j.drup.2026.101355_bib575","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114971","article-title":"Recent advances in PI3K\/PKB\/mTOR inhibitors as new anticancer agents","volume":"246","author":"Occhiuzzi","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.drup.2026.101355_bib576","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.jtho.2023.12.019","article-title":"Prevalence and therapeutic targeting of high-level ERBB2 amplification in NSCLC","volume":"19","author":"Odintsov","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib577","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.trecan.2022.03.004","article-title":"The interactive role of inflammatory mediators and metabolic reprogramming in pancreatic cancer","volume":"8","author":"Ohara","year":"2022","journal-title":"Trends Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib578","doi-asserted-by":"crossref","first-page":"a001008","DOI":"10.1101\/cshperspect.a001008","article-title":"TP53 mutations in human cancers: origins, consequences, and clinical use","volume":"2","author":"Olivier","year":"2010","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.drup.2026.101355_bib579","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101355_bib580","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4049\/jimmunol.1501351","article-title":"The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fc\u03b3 receptor-mediated cross-linking","volume":"197","author":"Overdijk","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.drup.2026.101355_bib581","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11122002","article-title":"JAK-STAT signaling: a double-edged sword of immune regulation and cancer progression","volume":"11","author":"Owen","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drup.2026.101355_bib582","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/cr.2008.316","article-title":"Roles of TGF\u03b2 in metastasis","volume":"19","author":"Padua","year":"2009","journal-title":"Cell Res."},{"key":"10.1016\/j.drup.2026.101355_bib583","doi-asserted-by":"crossref","first-page":"19003","DOI":"10.1038\/s41598-024-69435-y","article-title":"Gypenoside inhibits gastric cancer proliferation by suppressing glycolysis via the Hippo pathway","volume":"14","author":"Pan","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drup.2026.101355_bib584","doi-asserted-by":"crossref","first-page":"2206792","DOI":"10.1002\/advs.202206792","article-title":"EHBP1L1 Drives Immune Evasion in renal cell carcinoma through binding and stabilizing JAK1","volume":"10","author":"Pan","year":"2023","journal-title":"Adv. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib585","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Pandey","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2026.101355_bib586","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/cbf.3446","article-title":"Cancer-associated fibroblasts promote malignancy of gastric cancer cells via Nodal signalling","volume":"38","author":"Pang","year":"2020","journal-title":"Cell Biochem Funct."},{"key":"10.1016\/j.drup.2026.101355_bib587","doi-asserted-by":"crossref","first-page":"7139","DOI":"10.1158\/0008-5472.CAN-07-0778","article-title":"KRAS, and HRAS exhibit different leukemogenic potentials in mice","volume":"67","author":"Parikh","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101355_bib588","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8060842","article-title":"Indoleamine-2,3-dioxygenase in thyroid cancer cells suppresses natural killer cell function by inhibiting NKG2D and NKp46 expression via STAT signaling pathways","author":"Park","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.drup.2026.101355_bib589","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/1873-3468.12061","article-title":"p53 as guardian of the mitochondrial genome","volume":"590","author":"Park","year":"2016","journal-title":"FEBS Lett."},{"key":"10.1016\/j.drup.2026.101355_bib590","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3892\/or.2022.8377","article-title":"Leptin stimulates migration and invasion and maintains cancer stem\u2011like properties in gastric cancer cells","volume":"48","author":"Park","year":"2022","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.drup.2026.101355_bib591","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1038\/s41598-020-59899-z","article-title":"APC controls Wnt-induced \u03b2-catenin destruction complex recruitment in human colonocytes","volume":"10","author":"Parker","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drup.2026.101355_bib592","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.critrevonc.2017.02.009","article-title":"EGFR inhibition in NSCLC: new findings\u2026. and opened questions?","volume":"112","author":"Passiglia","year":"2017","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"key":"10.1016\/j.drup.2026.101355_bib593","doi-asserted-by":"crossref","first-page":"vdaa025","DOI":"10.1093\/noajnl\/vdaa025","article-title":"TERT, a promoter of CNS malignancies","volume":"2","author":"Patel","year":"2020","journal-title":"Neuro-Oncol. Adv."},{"key":"10.1016\/j.drup.2026.101355_bib594","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrclinonc.2016.168","article-title":"PD-1\u2013PD-L1 immune-checkpoint blockade in B-cell lymphomas","volume":"14","author":"Patel","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib595","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231205848","article-title":"CDK4\/6 inhibitors: basics, pros, and major cons in breast cancer treatment with specific regard to cardiotoxicity\u2013a narrative review","volume":"15","author":"Pavlovic","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib596","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2217\/fon.13.7","article-title":"Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer","volume":"9","author":"Peddi","year":"2013","journal-title":"Future Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib597","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.yexcr.2016.03.022","article-title":"Down-regulation of hTERT and Cyclin D1 transcription via PI3K\/Akt and TGF-\u03b2 pathways in MCF-7 Cancer cells with PX-866 and Raloxifene","volume":"344","author":"Peek","year":"2016","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.drup.2026.101355_bib598","doi-asserted-by":"crossref","first-page":"18145","DOI":"10.18632\/oncotarget.15210","article-title":"Down-regulation of lncRNA CASC2 promotes cell proliferation and metastasis of bladder cancer by activation of the Wnt\/\u03b2-catenin signaling pathway","volume":"8","author":"Pei","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.drup.2026.101355_bib599","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12943-022-01569-x","article-title":"Targeting TGF-\u03b2 signal transduction for fibrosis and cancer therapy","volume":"21","author":"Peng","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib600","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s41392-022-01110-y","article-title":"Regulated cell death (RCD) in cancer: key pathways and targeted therapies","volume":"7","author":"Peng","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.drup.2026.101355_bib601","doi-asserted-by":"crossref","first-page":"17443","DOI":"10.1038\/s41598-020-74452-8","article-title":"Cir-ITCH inhibits gastric cancer migration, invasion and proliferation by regulating the Wnt\/\u03b2-catenin pathway","volume":"10","author":"Peng","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drup.2026.101355_bib602","article-title":"PI3K\/Akt\/mTOR pathway and its role in cancer therapeutics: are we making headway?","volume":"12","author":"Peng","year":"2022","journal-title":"Front Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib603","article-title":"Circular RNA hsa_circ_0010882 promotes the progression of gastric cancer via regulation of the PI3K\/Akt\/mTOR signaling pathway","volume":"24","author":"Peng","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib604","doi-asserted-by":"crossref","unstructured":"V. Penugurti, R.K. Manne, L. Bai, R. Kant and H.-K. Lin, AMPK: The energy sensor at the crossroads of aging and cancer. Elsevier, pp. 15-27.","DOI":"10.1016\/j.semcancer.2024.08.002"},{"key":"10.1016\/j.drup.2026.101355_bib605","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1200\/JCO.23.00205","article-title":"Targeting NRAS mutations in advanced melanoma","volume":"41","author":"Phadke","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib606","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13046-021-02223-y","article-title":"Adiponectin triggers breast cancer cell death via fatty acid metabolic reprogramming","volume":"41","author":"Pham","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101355_bib607","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2309701","article-title":"Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma","volume":"20","author":"Pirosa","year":"2024","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.drup.2026.101355_bib608","doi-asserted-by":"crossref","first-page":"603","DOI":"10.18632\/aging.100934","article-title":"Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies","volume":"8","author":"Pistritto","year":"2016","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.drup.2026.101355_bib609","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/cncr.11197","article-title":"Microsatellite instability and expression of MLH1 and MSH2 in carcinomas of the small intestine","volume":"97","author":"Planck","year":"2003","journal-title":"Cancer: Interdiscip. Int. J. Am. Cancer Soc."},{"key":"10.1016\/j.drup.2026.101355_bib610","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/s41467-018-03264-2","article-title":"MYC-driven epigenetic reprogramming favors the onset of tumorigenesis by inducing a stem cell-like state","volume":"9","author":"Poli","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101355_bib611","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14010238","article-title":"The functional role of extracellular matrix proteins in cancer","volume":"14","author":"Popova","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drup.2026.101355_bib612","first-page":"236","article-title":"PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter","volume":"63","author":"Pore","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2026.101355_bib613","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1073\/pnas.1216013110","article-title":"Combined targeting of MEK and PI3K\/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo","volume":"110","author":"Posch","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib614","doi-asserted-by":"crossref","DOI":"10.1016\/j.inoche.2024.112114","article-title":"Advances in erlotinib delivery systems: addressing challenges and exploring opportunities in EGFR-targeted cancer therapies","volume":"161","author":"Pourmadadi","year":"2024","journal-title":"Inorg. Chem. Commun."},{"key":"10.1016\/j.drup.2026.101355_bib615","first-page":"1","article-title":"Efficacy and safety of BRAF\/MEK inhibitors in BRAFV600E-mutated anaplastic thyroid cancer: a systematic review and meta-analysis","author":"Priantti","year":"2024","journal-title":"Endocrine"},{"key":"10.1016\/j.drup.2026.101355_bib616","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-11-2612","article-title":"A comprehensive survey of Ras mutations in cancer","volume":"72","author":"Prior","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101355_bib617","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Prior","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101355_bib618","article-title":"Tumor-associated macrophages increase COX-2 expression promoting endocrine resistance in breast cancer via the PI3K\/Akt\/mTOR pathway","volume":"68","author":"Qi","year":"2021","journal-title":"Neoplasma"},{"key":"10.1016\/j.drup.2026.101355_bib619","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1089\/cbr.2019.3468","article-title":"LncRNA FENDRR upregulation promotes hepatic carcinoma cells apoptosis by targeting miR-362-5p Via NPR3 and p38-MAPK pathway","volume":"35","author":"Qian","year":"2020","journal-title":"Cancer Biotherapy Radiopharm."},{"key":"10.1016\/j.drup.2026.101355_bib620","article-title":"Circular RNA hsa_circ_0000285 acts as an oncogene in laryngocarcinoma by inducing Wnt\/\u03b2-catenin signaling pathway","volume":"23","author":"Qin","year":"2019","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib621","first-page":"1842","article-title":"FDA approval summary: alpelisib plus fulvestrant for patients with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer","volume":"27","author":"Qiu","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101355_bib622","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.3892\/ol.2014.1828","article-title":"Wnt\/\u03b2\u2011catenin signaling pathway may regulate the expression of angiogenic growth factors in hepatocellular carcinoma","volume":"7","author":"Qu","year":"2014","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.drup.2026.101355_bib623","article-title":"and Shun, penpulimab, an Fc-engineered IgG1 Anti-PD-1 antibody, with improved efficacy and low incidence of immune-related adverse events","volume":"13","author":"Qu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.drup.2026.101355_bib624","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat. Med"},{"key":"10.1016\/j.drup.2026.101355_bib625","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aai7911","article-title":"Platelets subvert T cell immunity against cancer via GARP-TGF\u03b2 axis","volume":"2","author":"Rachidi","year":"2017","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.drup.2026.101355_bib626","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1042\/BCJ20220325","article-title":"The mTORC2 signaling network: targets and cross-talks","volume":"481","author":"Ragupathi","year":"2024","journal-title":"Biochem. J."},{"key":"10.1016\/j.drup.2026.101355_bib627","article-title":"Abstract A059: uncovering bystander killing mechanisms of trastuzumab deruxtecan (T-DXd): effective extracellular payload release via cathepsin L in HER2-low breast cancer","author":"Ragusa","year":"2024","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.drup.2026.101355_bib628","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1158\/2326-6066.CIR-22-0057","article-title":"Preclinical characterization of relatlimab, a human LAG-3\u2013blocking antibody, alone or in combination with nivolumab","volume":"10","author":"Rak","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.drup.2026.101355_bib629","first-page":"4575","article-title":"Mutant ras oncogenes upregulate VEGF\/VPF expression: implications for induction and inhibition of tumor angiogenesis","volume":"55","author":"Rak","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101355_bib630","doi-asserted-by":"crossref","DOI":"10.1039\/D3MD00145H","article-title":"MEK inhibitors in cancer treatment: structural insights, regulation, recent advances and future perspectives","author":"Ram","year":"2023","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.drup.2026.101355_bib631","first-page":"263","article-title":"BRCA1 and BRCA2 point mutations and large rearrangements in breast and ovarian cancer families in Northern Poland","volume":"19","author":"Ratajska","year":"2008","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.drup.2026.101355_bib632","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.2020009984","article-title":"A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs","volume":"138","author":"R\u00e9a","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101355_bib633","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14051321","article-title":"Direct targeting KRAS mutation in non-small cell lung cancer: focus on resistance","volume":"14","author":"Reita","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drup.2026.101355_bib634","first-page":"5512","article-title":"MiR-200c promotes proliferation of papillary thyroid cancer cells via Wnt\/\u03b2-catenin signaling pathway","volume":"24","author":"Ren","year":"2020","journal-title":"Eur. Rev. Med Pharm. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib635","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122528","article-title":"Cell-mediated barriers in cancer immunosurveillance","volume":"342","author":"Rezaie","year":"2024","journal-title":"Life Sci."},{"key":"10.1016\/j.drup.2026.101355_bib636","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4062\/biomolther.2022.063","article-title":"Snail promotes cancer cell proliferation via its interaction with the BIRC3","volume":"30","author":"Rho","year":"2022","journal-title":"Biomol. Ther. (Seoul. )"},{"key":"10.1016\/j.drup.2026.101355_bib637","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.3892\/ijo.2015.3119","article-title":"Deficient mismatch repair: read all about it (Review)","volume":"47","author":"Richman","year":"2015","journal-title":"Int J. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib638","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1053\/j.semdp.2015.02.010","article-title":"BRAF V600E mutation-specific antibody: a review","volume":"32","author":"Ritterhouse","year":"2015","journal-title":"Semin Diagn. Pathol."},{"issue":"12","key":"10.1016\/j.drup.2026.101355_bib639","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","article-title":"Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets","volume":"110","author":"Rix","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101355_bib640","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1158\/1078-0432.CCR-12-0563","article-title":"Combined PI3K\/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models","volume":"18","author":"Roberts","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101355_bib641","article-title":"Viral manipulation of STAT3: evade, exploit, and injure","volume":"14","author":"Suarez","year":"2018","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.drup.2026.101355_bib642","doi-asserted-by":"crossref","unstructured":"A.S. Rolig, X. Peng, E.R. Sturgill, N. Holay, M. Kasiewicz, C. Mick, G.H. McGee, W. Miller, Y. Koguchi, J. Kaufmann, N. Yanamandra, S. Griffin, J. Smothers, M. Adamow, J. Lee, R. Shen, M.K. Callahan and W.L. Redmond, The response to anti\u2013PD-1 and anti\u2013LAG-3 checkpoint blockade is associated with regulatory T cell reprogramming, Science Translational Medicine 17, p. eadk3702.","DOI":"10.1126\/scitranslmed.adk3702"},{"key":"10.1016\/j.drup.2026.101355_bib643","doi-asserted-by":"crossref","first-page":"9875","DOI":"10.18632\/oncotarget.23986","article-title":"RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases","volume":"9","author":"Romei","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.drup.2026.101355_bib644","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib645","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa0904554","article-title":"Screening for epidermal growth factor receptor mutations in lung cancer","volume":"361","author":"Rosell","year":"2009","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.drup.2026.101355_bib646","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-018-0624-2","article-title":"Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy","volume":"11","author":"Rossari","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib647","doi-asserted-by":"crossref","first-page":"10","DOI":"10.5826\/dpc.0901a03","article-title":"Familial melanoma: diagnostic and management implications","volume":"9","author":"Rossi","year":"2019","journal-title":"Dermatol. Pr. Concept"},{"key":"10.1016\/j.drup.2026.101355_bib648","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nm.4494","article-title":"Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling","volume":"24","author":"Roswall","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2026.101355_bib649","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41420-025-02713-4","article-title":"Adipocyte-derived IL6 and triple-negative breast cancer cell-derived CXCL1 co-activate STAT3\/NF-\u03baB pathway to mediate the crosstalk between adipocytes and triple-negative breast cancer cells","volume":"11","author":"Ruan","year":"2025","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.drup.2026.101355_bib650","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1016\/j.bbagen.2018.08.013","article-title":"Dual blockade of VEGFR1 and VEGFR2 by a novel peptide abrogates VEGF-driven angiogenesis, tumor growth, and metastasis through PI3K\/AKT and MAPK\/ERK1\/2 pathway","volume":"1862","author":"Sadremomtaz","year":"2018","journal-title":"Biochim. Et. Biophys. Acta (BBA) - Gen. Subj."},{"key":"10.1016\/j.drup.2026.101355_bib651","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1615\/CritRevOncog.2016016976","article-title":"Resistance to cell death and its modulation in cancer stem cells","volume":"21","author":"Safa","year":"2016","journal-title":"Crit. Rev. Oncog."},{"key":"10.1016\/j.drup.2026.101355_bib652","doi-asserted-by":"crossref","first-page":"1170264","DOI":"10.3389\/fonc.2023.1170264","article-title":"The role of tumor microenvironment in drug resistance: emerging technologies to unravel breast cancer heterogeneity","volume":"13","author":"Salemme","year":"2023","journal-title":"Front Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib653","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.150348","article-title":"Role of Wnt\/\u03b2-catenin pathway in cancer drug resistance: Insights into molecular aspects of major solid tumors","volume":"729","author":"Samant","year":"2024","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.drup.2026.101355_bib654","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.adengl.2021.01.029","article-title":"Sonidegib in the treatment of locally advanced basal cell carcinoma","volume":"112","author":"San Mart\u00edn","year":"2021","journal-title":"Actas Dermo-Sifiliogr. \u00e1ficas (Engl. Ed. )"},{"key":"10.1016\/j.drup.2026.101355_bib655","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic signaling pathways in the cancer genome atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.drup.2026.101355_bib656","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.108143","article-title":"PTEN loss in glioma cell lines leads to increased extracellular vesicle biogenesis and PD-L1 cargo in a PI3K-dependent manner","volume":"301","author":"Sanchez","year":"2025","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drup.2026.101355_bib657","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.cels.2018.03.003","article-title":"Pan-cancer alterations of the MYC oncogene and its proximal network across the cancer genome atlas","volume":"6","author":"Schaub","year":"2018","journal-title":"Cell Syst."},{"key":"10.1016\/j.drup.2026.101355_bib658","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1038\/sj.onc.1204493","article-title":"Alternative lengthening of telomeres is associated with chromosomal instability in osteosarcomas","volume":"20","author":"Scheel","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.drup.2026.101355_bib659","doi-asserted-by":"crossref","first-page":"1170115","DOI":"10.3389\/fonc.2023.1170115","article-title":"Editorial: hallmark of cancer: evasion of growth suppressors","volume":"13","author":"Scheel","year":"2023","journal-title":"Front Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib660","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1634\/theoncologist.2010-0079","article-title":"Commentary: tackling the challenges of developing targeted therapies for cancer","volume":"15","author":"Schilsky","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.drup.2026.101355_bib661","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.508","article-title":"HER2\/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer","volume":"5","author":"Schulz","year":"2014","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.drup.2026.101355_bib662","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ccr.2012.11.014","article-title":"Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors","volume":"23","author":"Schwitalla","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2026.101355_bib663","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s40265-015-0383-0","article-title":"Lenvatinib: first global approval","volume":"75","author":"Scott","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.drup.2026.101355_bib664","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s13058-023-01746-w","article-title":"HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results","volume":"25","author":"Seo","year":"2023","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.drup.2026.101355_bib665","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a022277","article-title":"TGF-\u03b2 family signaling in tumor suppression and cancer progression","volume":"9","author":"Seoane","year":"2017","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.drup.2026.101355_bib666","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.molmed.2007.10.002","article-title":"The HER family and cancer: emerging molecular mechanisms and therapeutic targets","volume":"13","author":"Sergina","year":"2007","journal-title":"Trends Mol. Med"},{"key":"10.1016\/j.drup.2026.101355_bib667","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006098","article-title":"Signal transduction in cancer","volume":"5","author":"Sever","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med"},{"key":"10.1016\/j.drup.2026.101355_bib668","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2174\/1389450116666151001104133","article-title":"Targeting receptor tyrosine kinases using monoclonal antibodies: the most specific tools for targeted-based cancer therapy","volume":"17","author":"Shabani","year":"2016","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.drup.2026.101355_bib669","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.gendis.2016.02.002","article-title":"Cancer stem cells and HER2 positive breast cancer: the story so far","volume":"3","author":"Shah","year":"2016","journal-title":"Genes Dis."},{"key":"10.1016\/j.drup.2026.101355_bib670","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.biopha.2018.02.123","article-title":"Long non-coding RNA Linc00675 suppresses cell proliferation and metastasis in colorectal cancer via acting on miR-942 and Wnt\/\u03b2-catenin signaling","volume":"101","author":"Shan","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.drup.2026.101355_bib671","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13045-025-01684-4","article-title":"Unraveling the triad of hypoxia, cancer cell stemness, and drug resistance","volume":"18","author":"Shang","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib672","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.2174\/0929867328666201207202012","article-title":"Targeting the JAK\/STAT signaling pathway for breast cancer","volume":"28","author":"Shao","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.drup.2026.101355_bib673","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1172\/JCI9054","article-title":"Anticancer drug targets: cell cycle and checkpoint control","volume":"104","author":"Shapiro","year":"1999","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.drup.2026.101355_bib674","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003065","article-title":"Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling","volume":"3","author":"She","year":"2008","journal-title":"PloS One"},{"key":"10.1016\/j.drup.2026.101355_bib675","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2147\/OTT.S493643","article-title":"Exploring TGF-\u03b2 signaling in cancer progression: prospects and therapeutic strategies","volume":"18","author":"Sheikh","year":"2025","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.drup.2026.101355_bib676","doi-asserted-by":"crossref","first-page":"2293273","DOI":"10.1080\/21623945.2023.2293273","article-title":"Leptin secreted by adipocytes promotes EMT transition and endometrial cancer progression via the JAK2\/STAT3 signalling pathway","volume":"13","author":"Shen","year":"2024","journal-title":"Adipocyte"},{"key":"10.1016\/j.drup.2026.101355_bib677","doi-asserted-by":"crossref","first-page":"14895","DOI":"10.1007\/s13277-016-5372-8","article-title":"Novel long non-coding RNA GACAT3 promotes gastric cancer cell proliferation through the IL-6\/STAT3 signaling pathway","volume":"37","author":"Shen","year":"2016","journal-title":"Tumor Biol."},{"key":"10.1016\/j.drup.2026.101355_bib678","first-page":"1258","article-title":"MiR-221 affects the proliferation and apoptosis of laryngeal cancer cells through the PI3K\/AKT signaling pathway","volume":"24","author":"Shi","year":"2020","journal-title":"Eur. Rev. Med Pharm. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib679","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1111\/1759-7714.15427","article-title":"miR-30c-5p inhibits esophageal squamous cell carcinoma progression by repressing the PI3K\/AKT signaling pathway","volume":"15","author":"Shi","year":"2024","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib680","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41392-024-01828-x","article-title":"Notch signaling pathway in cancer: from mechanistic insights to targeted therapies","volume":"9","author":"Shi","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.drup.2026.101355_bib681","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-023-01383-x","article-title":"Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies","volume":"8","author":"Shi","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.drup.2026.101355_bib682","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.7150\/thno.52190","article-title":"Hypoxia-induced Nur77 activates PI3K\/Akt signaling via suppression of Dicer\/let-7i-5p to induce epithelial-to-mesenchymal transition","volume":"11","author":"Shi","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.drup.2026.101355_bib683","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1158\/1078-0432.CCR-11-2381","article-title":"The clinical effect of the dual-targeting strategy involving PI3K\/AKT\/mTOR and RAS\/MEK\/ERK pathways in patients with advanced cancer","volume":"18","author":"Shimizu","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101355_bib684","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12935-022-02570-6","article-title":"Exosomal miR-301a-3p from esophageal squamous cell carcinoma cells promotes angiogenesis by inducing M2 polarization of macrophages via the PTEN\/PI3K\/AKT signaling pathway","volume":"22","author":"Shou","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.drup.2026.101355_bib685","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.659260","article-title":"BCAT1 activates PI3K\/AKT\/mTOR pathway and contributes to the angiogenesis and tumorigenicity of gastric cancer","volume":"9","author":"Shu","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.drup.2026.101355_bib686","doi-asserted-by":"crossref","first-page":"9864","DOI":"10.1038\/s41467-024-54223-z","article-title":"Base-excision repair pathway shapes 5-methylcytosine deamination signatures in pan-cancer genomes","volume":"15","author":"Silveira","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101355_bib687","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1158\/2159-8290.CD-21-1494","article-title":"A Structure is worth a thousand words: new insights for RAS and RAF regulation","volume":"12","author":"Simanshu","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drup.2026.101355_bib688","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/IOP.0000000000002464","article-title":"Review of targeted therapy, vismodegib, for the treatment of periocular basal cell carcinoma","volume":"40","author":"Singalavanija","year":"2024","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"key":"10.1016\/j.drup.2026.101355_bib689","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112560","article-title":"5-Azacytidine- and retinoic-acid-induced reprogramming of DCCs into dormancy suppresses metastasis via restored TGF-\u03b2-SMAD4 signaling","volume":"42","author":"Singh","year":"2023","journal-title":"Cell Rep."},{"issue":"6","key":"10.1016\/j.drup.2026.101355_bib690","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1634\/theoncologist.2009-0274","article-title":"Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor","volume":"15","author":"Sleijfer","year":"2010","journal-title":"oncologist"},{"key":"10.1016\/j.drup.2026.101355_bib691","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1182\/bloodadvances.2019000702","article-title":"Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting","volume":"3","author":"Slomp","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.drup.2026.101355_bib692","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/B978-0-12-380888-2.00003-0","article-title":"The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer","volume":"108","author":"Smith","year":"2010","journal-title":"Adv. Cancer Res"},{"key":"10.1016\/j.drup.2026.101355_bib693","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.immuni.2018.01.006","article-title":"Interleukin-10 directly inhibits CD8(+) T cell function by enhancing N-glycan branching to decrease antigen sensitivity","volume":"48","author":"Smith","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.drup.2026.101355_bib694","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","article-title":"Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance","volume":"22","author":"Smith","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.drup.2026.101355_bib695","article-title":"Safety and efficacy of pralsetinib in RET fusion-positive non-small cell lung cancer including as first-line therapy: update from the ARROW trial","author":"Smoljanovi\u0107","year":"2022","journal-title":"Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib696","doi-asserted-by":"crossref","DOI":"10.2217\/fon-2020-0348","article-title":"Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors","author":"Smrke","year":"2020","journal-title":"Future Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib697","doi-asserted-by":"crossref","DOI":"10.3390\/biom9110668","article-title":"FDA- and EMA-approved tyrosine kinase inhibitors in advanced EGFR-mutated non-small cell lung cancer: safety, tolerability, plasma concentration monitoring, and management","volume":"9","author":"Solassol","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.drup.2026.101355_bib698","doi-asserted-by":"crossref","first-page":"13066","DOI":"10.1002\/jcb.28578","article-title":"Long noncoding RNA SNHG12 promotes cell proliferation and activates Wnt\/\u03b2-catenin signaling in prostate cancer through sponging microRNA-195","volume":"120","author":"Song","year":"2019","journal-title":"J. Cell Biochem"},{"key":"10.1016\/j.drup.2026.101355_bib699","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005414","article-title":"Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model","volume":"10","author":"Sov\u00e9","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib700","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3390\/biomedicines3010071","article-title":"HGF\/c-MET axis in tumor microenvironment and metastasis formation","volume":"3","author":"Spina","year":"2015","journal-title":"Biomedicines"},{"key":"10.1016\/j.drup.2026.101355_bib701","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ccell.2023.11.008","article-title":"B3GALT6 promotes dormant breast cancer cell survival and recurrence by enabling heparan sulfate-mediated FGF signaling","volume":"42","author":"Sreekumar","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2026.101355_bib702","doi-asserted-by":"crossref","first-page":"192","DOI":"10.18632\/aging.100296","article-title":"Roles of the Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging","volume":"3","author":"Steelman","year":"2011","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.drup.2026.101355_bib703","doi-asserted-by":"crossref","first-page":"10260","DOI":"10.3390\/ijms221910260","article-title":"Growth factors, PI3K\/AKT\/mTOR and MAPK signaling pathways in colorectal cancer pathogenesis: where are we now?","volume":"22","author":"Stefani","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib704","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/260170a0","article-title":"DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA","volume":"260","author":"Stehelin","year":"1976","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101355_bib705","doi-asserted-by":"crossref","first-page":"dev146589","DOI":"10.1242\/dev.146589","article-title":"Wnt signaling in development and tissue homeostasis","volume":"145","author":"Steinhart","year":"2018","journal-title":"Development"},{"key":"10.1016\/j.drup.2026.101355_bib706","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-22-0423","article-title":"JAK\u2013STAT signaling in inflammatory breast cancer enables chemotherapy-resistant cell states","volume":"83","author":"Stevens","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2026.101355_bib707","first-page":"1024","article-title":"MYC, metabolism, and cancer, cancer discov","volume":"5","author":"Stine","year":"2015"},{"key":"10.1016\/j.drup.2026.101355_bib708","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2015-446","article-title":"Abstract 446: reciprocal paracrine signaling between epithelial and stromal cells alters the pancreatic tumor microenvironment","volume":"75","author":"Stout","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2026.101355_bib709","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1002\/ijc.21535","article-title":"Silencing of APAF-1 in B-CLL results in poor prognosis in the case of concomitant p53 mutation","volume":"118","author":"Sturm","year":"2006","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib710","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jds.2023.08.013","article-title":"MiR-34a functions as a tumor suppressor in oral cancer through the inhibition of the Axl\/Akt\/GSK-3\u03b2 pathway","volume":"19","author":"Su","year":"2024","journal-title":"J. Dent. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib711","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116047","article-title":"TP53R175H mutation promotes breast cancer cell proliferation through CORO1A\u2013P38 MAPK pathway regulation","volume":"221","author":"Su","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.drup.2026.101355_bib712","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1158\/2767-9764.CRC-22-0260","article-title":"Phase I study of mTORC1\/2 inhibitor sapanisertib (CB-228\/TAK-228) in combination with metformin in patients with mTOR\/AKT\/PI3K pathway alterations and advanced solid malignancies","volume":"4","author":"Subbiah","year":"2024","journal-title":"Cancer Res Commun."},{"key":"10.1016\/j.drup.2026.101355_bib713","article-title":"Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers","volume":"15","author":"Subbiah","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib714","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.trecan.2021.07.003","article-title":"Precision therapy for RET-altered cancers with RET inhibitors","volume":"7","author":"Subbiah","year":"2021","journal-title":"Trends Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib715","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.772510","article-title":"Receptor tyrosine kinases and their signaling pathways as therapeutic targets of curcumin in cancer","volume":"12","author":"Sudhesh Dev","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.drup.2026.101355_bib716","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.3892\/mmr.2016.5656","article-title":"Let\u20117 miRNAs sensitize breast cancer stem cells to radiation\u2011induced repression through inhibition of the cyclin D1\/Akt1\/Wnt1 signaling pathway","volume":"14","author":"Sun","year":"2016","journal-title":"Mol. Med Rep."},{"key":"10.1016\/j.drup.2026.101355_bib717","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216747","article-title":"CD63+ cancer-associated fibroblasts confer CDK4\/6 inhibitor resistance to breast cancer cells by exosomal miR-20","volume":"588","author":"Sun","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.drup.2026.101355_bib718","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1261820","article-title":"Editorial: cancer cell-intrinsic and -extrinsic factors affecting tumor immune evasion","volume":"14","author":"Sun","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.drup.2026.101355_bib719","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.7150\/jca.19142","article-title":"HES1 promotes colorectal cancer cell resistance To 5-Fu by inducing Of EMT and ABC transporter proteins","volume":"8","author":"Sun","year":"2017","journal-title":"J. Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib720","first-page":"504","article-title":"Long non-coding RNA NEAT1 acts as oncogene in NSCLC by regulating the Wnt signaling pathway","volume":"21","author":"Sun","year":"2017","journal-title":"Eur. Rev. Med Pharm. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib721","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/aps.2015.92","article-title":"Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment","volume":"36","author":"Sun","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.drup.2026.101355_bib722","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.drup.2026.101355_bib723","doi-asserted-by":"crossref","DOI":"10.1177\/1073274818789361","article-title":"Lenvatinib","volume":"25","author":"Suyama","year":"2018","journal-title":"Cancer Control.: J. Moffitt Cancer Cent."},{"key":"10.1016\/j.drup.2026.101355_bib724","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s40265-021-01561-7","article-title":"Amivantamab: first approval","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.drup.2026.101355_bib725","doi-asserted-by":"crossref","first-page":"5547","DOI":"10.1038\/s41467-021-25865-0","article-title":"Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy","volume":"12","author":"Takamatsu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101355_bib726","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174415","article-title":"Angiotensin II promotes primary tumor growth and metastasis formation of murine TNBC 4T1 cells through the fibroblasts around cancer cells","volume":"909","author":"Takiguchi","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.drup.2026.101355_bib727","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/pros.21029","article-title":"Adiponectin increases motility of human prostate cancer cells via adipoR, p38, AMPK, and NF-\u03baB pathways","volume":"69","author":"Tang","year":"2009","journal-title":"Prostate"},{"key":"10.1016\/j.drup.2026.101355_bib728","first-page":"7","article-title":"Assessment and prognostic analysis of EGFR, HER2, and HER3 protein expression in surgically resected gastric adenocarcinomas","volume":"8","author":"Tang","year":"2015","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.drup.2026.101355_bib729","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1158\/0008-5472.CAN-21-0753","article-title":"Hypoxia promotes breast cancer cell growth by activating a glycogen metabolic program","volume":"81","author":"Tang","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2026.101355_bib730","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41392-020-00449-4","article-title":"Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy","volume":"6","author":"Tang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.drup.2026.101355_bib731","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.2147\/CMAR.S265578","article-title":"Silencing of long non-coding RNA HOTAIR alleviates epithelial\u2013mesenchymal transition in pancreatic cancer via the Wnt\/\u03b2-catenin signaling pathway","volume":"13","author":"Tang","year":"2021","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.drup.2026.101355_bib732","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13046-023-02726-w","article-title":"AXL in cancer: a modulator of drug resistance and therapeutic target","volume":"42","author":"Tang","year":"2023","journal-title":"J. Exp. Clin. Cancer Res"},{"key":"10.1016\/j.drup.2026.101355_bib733","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1093\/emboj\/19.16.4298","article-title":"Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein","volume":"19","author":"Tanimoto","year":"2000","journal-title":"Embo J."},{"key":"10.1016\/j.drup.2026.101355_bib734","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2022.115927","article-title":"Breast cancer cells-derived Von Willebrand Factor promotes VEGF-A-related angiogenesis through PI3K\/Akt-miR-205-5p signaling pathway","volume":"440","author":"Tao","year":"2022","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.drup.2026.101355_bib735","first-page":"758","article-title":"LncRNA SNHG11 promotes malignant progression of colorectal cancer cells through the PI3K\/Akt\/mTOR signaling pathway","volume":"104","author":"Tao","year":"2024","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"10.1016\/j.drup.2026.101355_bib736","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/modpathol.3800729","article-title":"Close association between HER-2 amplification and overexpression in human tumors of non-breast origin","volume":"20","author":"Tapia","year":"2007","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.drup.2026.101355_bib737","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00428-009-0855-2","article-title":"DcR1 expression in endometrial carcinomas","volume":"456","author":"Tarragona","year":"2010","journal-title":"Virchows Arch."},{"key":"10.1016\/j.drup.2026.101355_bib738","article-title":"MicroRNA-34a enhances immune response and suppresses PI3K\/AKT signaling through targeting PD-L1 in triple-negative breast cancer","volume":"40","author":"Tavakolpour","year":"2025","journal-title":"Gene Rep."},{"key":"10.1016\/j.drup.2026.101355_bib739","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.3390\/jcm8101658","article-title":"Wnt signaling in ovarian cancer stemness, EMT, and therapy resistance","volume":"8","author":"Teeuwssen","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.drup.2026.101355_bib740","first-page":"4598476","article-title":"Hypoxia impairs NK cell cytotoxicity through SHP-1-mediated attenuation of STAT3 and ERK signaling pathways","author":"Teng","year":"2020","journal-title":"J. Immunol. Res. 2020"},{"key":"10.1016\/j.drup.2026.101355_bib741","first-page":"2700","article-title":"Endothelial progenitor cells are clonal and exhibit the JAK2 V617F mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms, Blood","volume":"117","author":"Teofili","year":"2011","journal-title":"J. Am. Soc. Hematol."},{"key":"10.1016\/j.drup.2026.101355_bib742","article-title":"FDA approval summary: teclistamab - a bispecific CD3 T-cell engager for patients with relapsed or refractory multiple myeloma","author":"Theoret","year":"2024","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.drup.2026.101355_bib743","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41698-024-00758-9","article-title":"Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations","volume":"8","author":"Thomas","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib744","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccr.2005.10.012","article-title":"TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance","volume":"8","author":"Thomas","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2026.101355_bib745","doi-asserted-by":"crossref","first-page":"150","DOI":"10.20517\/2394-4722.2017.38","article-title":"TGF-\u03b2 stimulation of EMT programs elicits non-genomic ER-\u03b1 activity and anti-estrogen resistance in breast cancer cells","volume":"3","author":"Tian","year":"2017","journal-title":"J. Cancer Metastas-.-. Treat."},{"key":"10.1016\/j.drup.2026.101355_bib746","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12935-020-1139-9","article-title":"Long non-coding RNA DANCR promotes cervical cancer growth via activation of the Wnt\/\u03b2-catenin signaling pathway","volume":"20","author":"Tian","year":"2020","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.drup.2026.101355_bib747","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.omtn.2021.03.016","article-title":"miR-144 delivered by nasopharyngeal carcinoma-derived EVs stimulates angiogenesis through the FBXW7\/HIF-1\u03b1\/VEGF-A axis","volume":"24","author":"Tian","year":"2021","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.drup.2026.101355_bib748","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.101978","article-title":"TCF19 promotes cell proliferation and tumor formation in lung cancer by activating the Raf\/MEK\/ERK signaling pathway","volume":"45","author":"Tian","year":"2024","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib749","doi-asserted-by":"crossref","unstructured":"J. Tol, M. Koopman, A. Cats, J. Rodenburg Cees, J.M. Creemers Geert, G. Schrama Jolanda, L.G. Erdkamp Frans, H. Vos Allert, J. van Groeningen Cees, A.M. Sinnige Harm, J. Richel Dirk, E. Voest Emile, R. Dijkstra Jeroen, E. Vink-B\u00f6rger Marianne, F. Antonini Ninja, L. Mol, H.J.M. van Krieken Johan, O. Dalesio and J.A. Punt Cornelis, Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer, New England Journal of Medicine 360, pp. 563-572.","DOI":"10.1056\/NEJMoa0808268"},{"key":"10.1016\/j.drup.2026.101355_bib750","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1200\/JCO.23.01909","article-title":"Datopotamab deruxtecan in advanced or metastatic HR+\/HER2\u2013 and triple-negative breast cancer: results from the phase I TROPION-PanTumor01 study","volume":"42","author":"Tolcher","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib751","article-title":"Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met\u2013overexpressing (OE) advanced non-small cell lung cancer (NSCLC)","author":"Tomasini","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib752","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.1038\/sj.onc.1210399","article-title":"Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer","volume":"26","author":"Tomlinson","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.drup.2026.101355_bib753","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1286683","article-title":"Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations","volume":"11","author":"Tornesello","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"issue":"3","key":"10.1016\/j.drup.2026.101355_bib754","article-title":"Potential of Akt mediated DNA repair in radioresistance of solid tumors overexpressing erbB-PI3K-Akt pathway","volume":"2","author":"Toulany","year":"2013","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.drup.2026.101355_bib755","article-title":"Autophagy and cancer: modulation of cell death pathways and cancer cell adaptations","volume":"219","author":"Towers","year":"2019","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.drup.2026.101355_bib756","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s12079-017-0441-3","article-title":"Mechanistic regulation of epithelial-to-mesenchymal transition through RAS signaling pathway and therapeutic implications in human cancer","volume":"12","author":"Tripathi","year":"2018","journal-title":"J. Cell Commun. Signal"},{"key":"10.1016\/j.drup.2026.101355_bib757","doi-asserted-by":"crossref","DOI":"10.3390\/cells13171484","article-title":"HOTAIR promotes the hyperactivation of PI3K\/Akt and Wnt\/\u03b2-catenin signaling pathways via PTEN hypermethylation in cervical cancer","author":"Trujano-Camacho","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.drup.2026.101355_bib758","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0144462","article-title":"Curcumin inhibits non-small cell lung cancer cells metastasis through the adiponectin\/NF-\u03bab\/MMPs signaling pathway","volume":"10","author":"Tsai","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.drup.2026.101355_bib759","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.155636","article-title":"Trastuzumab\/pertuzumab combination therapy stimulates antitumor responses through complement-dependent cytotoxicity and phagocytosis","volume":"7","author":"Tsao","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.drup.2026.101355_bib760","doi-asserted-by":"crossref","first-page":"46717","DOI":"10.18632\/oncotarget.8773","article-title":"Kirsten Ras* oncogene: significance of its discovery in human cancer research","volume":"7","author":"Tsuchida","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.drup.2026.101355_bib761","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.canlet.2012.06.006","article-title":"STAT3 activation by IL-6 from mesenchymal stem cells promotes the proliferation and metastasis of osteosarcoma","volume":"325","author":"Tu","year":"2012","journal-title":"Cancer Lett."},{"key":"10.1016\/j.drup.2026.101355_bib762","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12967-023-04841-w","article-title":"Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway","volume":"22","author":"Tufail","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.drup.2026.101355_bib763","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.109979","article-title":"Hallmarks of cancer resistance","volume":"27","author":"Tufail","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.drup.2026.101355_bib764","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41392-025-02280-1","article-title":"Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches","volume":"10","author":"Tufail","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.drup.2026.101355_bib765","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12943-025-02306-w","article-title":"Wnt signaling in cancer: from biomarkers to targeted therapies and clinical translation","volume":"24","author":"Tufail","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib766","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2024.111055","article-title":"Targeting PI3K\/AKT\/mTOR signaling to overcome drug resistance in cancer","volume":"396","author":"Tufail","year":"2024","journal-title":"Chem. -Biol. Interact."},{"key":"10.1016\/j.drup.2026.101355_bib767","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22020977","article-title":"Autocrine TGF-\u03b2 in cancer: review of the literature and caveats in experimental analysis","volume":"22","author":"Ungefroren","year":"2021","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib768","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2026849118","article-title":"Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance","volume":"118","author":"Upton","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib769","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112748","article-title":"EGFR in cancer: signaling mechanisms, drugs, and acquired resistance","volume":"13","author":"Uribe","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drup.2026.101355_bib770","article-title":"CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance","volume":"9","author":"Usmani","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.drup.2026.101355_bib771","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41698-025-00939-0","article-title":"Computationally integrating radiology and pathology image features for predicting treatment benefit and outcome in lung cancer","volume":"9","author":"Vaidya","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib772","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4161\/mabs.20230","article-title":"Brentuximab vedotin","volume":"4","author":"van de Donk","year":"2012","journal-title":"MAbs"},{"key":"10.1016\/j.drup.2026.101355_bib773","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1158\/1541-7786.620.2.11","article-title":"Bcl-2 overexpression leads to increases in suppressor of cytokine signaling-3 expression in B Cells and De novo follicular Lymphoma1","volume":"2","author":"Vanasse","year":"2004","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.drup.2026.101355_bib774","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/humu.10185","article-title":"Germline TP53 mutations and Li-Fraumeni syndrome","volume":"21","author":"Varley","year":"2003","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.drup.2026.101355_bib775","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1158\/0008-5472.CAN-11-3594","article-title":"HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation","volume":"72","author":"Vaught","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101355_bib776","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918789364","article-title":"Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy","volume":"10","author":"Vaval\u00e0","year":"2018","journal-title":"Ther. Adv. Med Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib777","doi-asserted-by":"crossref","first-page":"6779","DOI":"10.1038\/s41467-024-51156-5","article-title":"Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes","volume":"15","author":"Venkadakrishnan","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101355_bib778","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","article-title":"Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1","volume":"17","author":"Verhaak","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2026.101355_bib779","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3389\/fonc.2022.992636","article-title":"Precision oncology for RET-related tumors","volume":"12","author":"Verrienti","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib780","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082296","article-title":"Transcription factors in cancer development and therapy","volume":"12","author":"Vishnoi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drup.2026.101355_bib781","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103334","article-title":"PI3K inhibition in breast cancer: identifying and overcoming different flavors of resistance","volume":"162","author":"Vitale","year":"2021","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"issue":"5 2","key":"10.1016\/j.drup.2026.101355_bib782","first-page":"15","article-title":"Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers","volume":"20","author":"Vokes","year":"2006","journal-title":"Oncology"},{"key":"10.1016\/j.drup.2026.101355_bib783","doi-asserted-by":"crossref","first-page":"4958","DOI":"10.1158\/1078-0432.CCR-23-1122","article-title":"ATM mutations associate with distinct co-mutational patterns and therapeutic vulnerabilities in NSCLC","volume":"29","author":"Vokes","year":"2023","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.drup.2026.101355_bib784","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-019-0038-9","article-title":"Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer","volume":"4","author":"Vyse","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.drup.2026.101355_bib785","first-page":"45","article-title":"PTEN May involve in regulation of PD-L1 expression in triple negative breast carcinoma","volume":"1","author":"Wai","year":"2021","journal-title":"Open J. Med. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib786","doi-asserted-by":"crossref","unstructured":"C. Wan, S. Mahara, C. Sun, A. Doan, H.K. Chua, D. Xu, J. Bian, Y. Li, D. Zhu, D. Sooraj, T. Cierpicki, J. Grembecka and R. Firestein, Genome-scale CRISPR-Cas9 screen of Wnt\/\u03b2-catenin signaling identifies therapeutic targets for colorectal cancer, Science Advances 7, p. eabf2567.","DOI":"10.1126\/sciadv.abf2567"},{"key":"10.1016\/j.drup.2026.101355_bib787","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.2147\/OTT.S297855","article-title":"Consequences of mutations and abnormal expression of SMAD4 in tumors and T cells","volume":"14","author":"Wan","year":"2021","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.drup.2026.101355_bib788","first-page":"9860","article-title":"MiR-200b-5p inhibits proliferation of ovarian cancer cells by targeting ATAD2 and regulating PI3K\/AKT signaling pathway","volume":"24","author":"Wang","year":"2020","journal-title":"Eur. Rev. Med Pharm. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib789","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/s41419-022-04620-3","article-title":"Bevacizumab attenuates osteosarcoma angiogenesis by suppressing MIAT encapsulated by serum-derived extracellular vesicles and facilitating miR-613-mediated GPR158 inhibition","volume":"13","author":"Wang","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.drup.2026.101355_bib790","first-page":"3369","article-title":"Long non-coding RNA CCAT2 promotes epithelial-mesenchymal transition involving Wnt\/\u03b2-catenin pathway in epithelial ovarian carcinoma cells","volume":"15","author":"Wang","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.drup.2026.101355_bib791","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2015.11.049","article-title":"Aurora-B and HDAC synergistically regulate survival and proliferation of lymphoma cell via AKT, mTOR and Notch pathways","volume":"779","author":"Wang","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.drup.2026.101355_bib792","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2147\/DDDT.S443107","article-title":"Understanding sorafenib-induced cardiovascular toxicity: mechanisms and treatment implications","volume":"18","author":"Wang","year":"2024","journal-title":"Drug Des., Dev. Ther."},{"key":"10.1016\/j.drup.2026.101355_bib793","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2023.109783","article-title":"LncRNA UCA1 promotes pancreatic cancer cell migration by regulating mitochondrial dynamics via the MAPK pathway","volume":"748","author":"Wang","year":"2023","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.drup.2026.101355_bib794","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-023-01347-1","article-title":"Targeting p53 pathways: mechanisms, structures and advances in therapy","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.drup.2026.101355_bib795","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.7150\/jca.81320","article-title":"Hypoxia-elicited exosomes promote the chemoresistance of pancreatic cancer cells by transferring LncROR via hippo signaling","volume":"14","author":"Wang","year":"2023","journal-title":"J. Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib796","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41419-023-05763-7","article-title":"Aberrant Cyclin D1 splicing in cancer: from molecular mechanism to therapeutic modulation","volume":"14","author":"Wang","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.drup.2026.101355_bib797","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41392-019-0069-2","article-title":"Targeted therapeutic options and future perspectives for HER2-positive breast cancer","volume":"4","author":"Wang","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.drup.2026.101355_bib798","doi-asserted-by":"crossref","first-page":"568","DOI":"10.21037\/atm-20-7482","article-title":"Autocrined leptin promotes proliferation of non-small cell lung cancer (NSCLC) via PI3K\/AKT and p53 pathways","volume":"9","author":"Wang","year":"2021","journal-title":"Ann. Transl. Med"},{"key":"10.1016\/j.drup.2026.101355_bib799","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1007\/s12032-014-0934-3","article-title":"miR-99a and -99b inhibit cervical cancer cell proliferation and invasion by targeting mTOR signaling pathway","volume":"31","author":"Wang","year":"2014","journal-title":"Med. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib800","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/1759-7714.14244","article-title":"Efficacy and safety of anti-PD-1\/PD-L1 in combination with chemotherapy or not as first-line treatment for advanced non-small cell lung cancer: a systematic review and network meta-analysis","volume":"13","author":"Wang","year":"2022","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib801","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.bbrc.2018.08.175","article-title":"CircRNA circ-ITCH suppresses papillary thyroid cancer progression through miR-22-3p\/CBL\/\u03b2-catenin pathway","volume":"504","author":"Wang","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.drup.2026.101355_bib802","first-page":"7653","article-title":"MALAT1 promotes cisplatin resistance in cervical cancer by activating the PI3K\/AKT pathway","volume":"22","author":"Wang","year":"2018","journal-title":"Eur. Rev. Med Pharm. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib803","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.2147\/OTT.S92378","article-title":"Downregulation of microRNA-122 promotes proliferation, migration, and invasion of human hepatocellular carcinoma cells by activating epithelial-mesenchymal transition","volume":"9","author":"Wang","year":"2016","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.drup.2026.101355_bib804","doi-asserted-by":"crossref","first-page":"2333790","DOI":"10.1080\/19490976.2024.2333790","article-title":"Fusobacterium nucleatum induces chemoresistance in colorectal cancer by inhibiting pyroptosis via the Hippo pathway","volume":"16","author":"Wang","year":"2024","journal-title":"Gut Microbes"},{"key":"10.1016\/j.drup.2026.101355_bib805","doi-asserted-by":"crossref","first-page":"84086","DOI":"10.18632\/oncotarget.20475","article-title":"LncRNA SNHG12 contributes to multidrug resistance through activating the MAPK\/Slug pathway by sponging miR-181a in non-small cell lung cancer","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.drup.2026.101355_bib806","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1089\/dna.2017.3922","article-title":"miR-21 inhibitors modulate biological functions of gastric cancer cells via PTEN\/PI3K\/mTOR pathway","volume":"37","author":"Wang","year":"2017","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.drup.2026.101355_bib807","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.7150\/jca.91360","article-title":"AQP3 promotes the invasion and metastasis in cervical cancer by regulating NOX4-derived H(2)O(2) activation of Syk\/PI3K\/Akt signaling axis","volume":"15","author":"Wang","year":"2024","journal-title":"J. Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib808","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1186\/1471-2407-13-521","article-title":"The association of TP53 mutations with the resistance of colorectal carcinoma to the insulin-like growth factor-1 receptor inhibitor picropodophyllin","volume":"13","author":"Wang","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib809","first-page":"2023","article-title":"RB1 aberrations predict outcomes of immune checkpoint inhibitor combination therapy in NSCLC","volume":"13","author":"Wang","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib810","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1080\/09553002.2024.2324475","article-title":"Taraxasterol enhanced bladder cancer cells radiosensitivity via inhibiting the COX-2\/PGE2\/JAK2\/STAT3\/MMP pathway","volume":"100","author":"Wang","year":"2024","journal-title":"Int. J. Radiat. Biol."},{"key":"10.1016\/j.drup.2026.101355_bib811","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.2147\/NDT.S137171","article-title":"Long noncoding RNA CASC2 predicts the prognosis of glioma patients and functions as a suppressor for gliomas by suppressing Wnt\/\u03b2-catenin signaling pathway","volume":"13","author":"Wang","year":"2017","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.drup.2026.101355_bib812","article-title":"Cell death pathways: molecular mechanisms and therapeutic targets for cancer","volume":"5","author":"Wang","year":"2024","journal-title":"MedComm"},{"key":"10.1016\/j.drup.2026.101355_bib813","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s10142-022-00865-5","article-title":"CircPVT1 facilitates the progression of oral squamous cell carcinoma by regulating miR-143-3p\/SLC7A11 axis through MAPK signaling pathway","volume":"22","author":"Wang","year":"2022","journal-title":"Funct. Integr. Genom."},{"key":"10.1016\/j.drup.2026.101355_bib814","doi-asserted-by":"crossref","first-page":"232","DOI":"10.4149\/neo_2018_180710N460","article-title":"Circ-ITCH regulates triple-negative breast cancer progression through the Wnt\/\u03b2-catenin pathway","volume":"66","author":"Wang","year":"2019","journal-title":"Neoplasma"},{"key":"10.1016\/j.drup.2026.101355_bib815","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/1078-0432.CCR-22-2939","article-title":"The Oral PI3K\u03b4 inhibitor linperlisib for the treatment of relapsed and\/or refractory follicular lymphoma: a phase II, single-arm, open-label clinical trial","volume":"29","author":"Wang","year":"2023","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.drup.2026.101355_bib816","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1517\/13543784.2014.928283","article-title":"Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer","volume":"23","author":"Wang","year":"2014","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.drup.2026.101355_bib817","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100884","article-title":"Targeting feedback activation of signaling transduction pathways to overcome drug resistance in cancer","volume":"65","author":"Wang","year":"2022","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.drup.2026.101355_bib818","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3233\/CBM-182080","article-title":"LncRNA ZFAS1 promotes proliferation and migration and inhibits apoptosis in nasopharyngeal carcinoma via the PI3K\/AKT pathway in vitro","volume":"26","author":"Wang","year":"2019","journal-title":"Cancer Biomark."},{"key":"10.1016\/j.drup.2026.101355_bib819","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116711","article-title":"Novel EGFR inhibitors against resistant L858R\/T790M\/C797S mutant for intervention of non-small cell lung cancer","volume":"277","author":"Wang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.drup.2026.101355_bib820","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13046-018-0683-9","article-title":"TFAP2C promotes stemness and chemotherapeutic resistance in colorectal cancer via inactivating hippo signaling pathway","volume":"37","author":"Wang","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101355_bib821","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.imlet.2017.02.006","article-title":"Inflammatory cytokines IL-17 and TNF-\u03b1 up-regulate PD-L1 expression in human prostate and colon cancer cells","volume":"184","author":"Wang","year":"2017","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.drup.2026.101355_bib822","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41392-024-01797-1","article-title":"METTL14 downregulation drives S100A4+ monocyte-derived macrophages via MyD88\/NF-\u03baB pathway to promote MAFLD progression","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.drup.2026.101355_bib823","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1111\/jcmm.17268","article-title":"Overexpression of FOXD2-AS1 enhances proliferation and impairs differentiation of glioma stem cells by activating the NOTCH pathway via TAF-1","volume":"26","author":"Wang","year":"2022","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.drup.2026.101355_bib824","first-page":"15708","article-title":"CHEK2 mutation and risk of prostate cancer: a systematic review and meta-analysis","volume":"8","author":"Wang","year":"2015","journal-title":"Int J. Clin. Exp. Med"},{"key":"10.1016\/j.drup.2026.101355_bib825","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10456-004-8272-2","article-title":"Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro","volume":"7","author":"Wang","year":"2004","journal-title":"Angiogenesis"},{"key":"10.1016\/j.drup.2026.101355_bib826","first-page":"859","article-title":"Long non-coding RNA BANCR regulates cancer stem cell markers in papillary thyroid cancer via the RAF\/MEK\/ERK signaling pathway","volume":"40","author":"Wang","year":"2018","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.drup.2026.101355_bib827","doi-asserted-by":"crossref","first-page":"24606","DOI":"10.1038\/srep24606","article-title":"Twist-mediated Epithelial-mesenchymal transition promotes breast tumor cell invasion via inhibition of hippo pathway","volume":"6","author":"Wang","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drup.2026.101355_bib828","first-page":"2021","article-title":"LncRNA GHET1 promotes hypoxia-induced glycolysis, proliferation, and invasion in triple-negative breast cancer through the hippo\/YAP signaling pathway","volume":"9","author":"Wang","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.drup.2026.101355_bib829","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1083\/jcb.201105153","article-title":"Invasive matrix degradation at focal adhesions occurs via protease recruitment by a FAK-p130Cas complex","volume":"196","author":"Wang","year":"2012","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.drup.2026.101355_bib830","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/s41419-022-05393-5","article-title":"LncRNA HOXA11-AS promotes glioma malignant phenotypes and reduces its sensitivity to ROS via Tpl2-MEK1\/2-ERK1\/2 pathway","volume":"13","author":"Wei","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.drup.2026.101355_bib831","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10456-005-9010-0","article-title":"Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro","volume":"8","author":"Weigand","year":"2005","journal-title":"Angiogenesis"},{"key":"10.1016\/j.drup.2026.101355_bib832","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1158\/0008-5472.CAN-19-0458","article-title":"Defining the hallmarks of metastasis","volume":"79","author":"Welch","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101355_bib833","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.3390\/cancers14225489","article-title":"Triple combination of immune checkpoint inhibitors and BRAF\/MEK inhibitors in BRAF V600 melanoma: current status and future perspectives","volume":"14","author":"Welti","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2026.101355_bib834","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1159\/000464429","article-title":"Hypoxia enhances immunosuppression by inhibiting CD4+ effector T cell function and promoting treg activity","volume":"41","author":"Westendorf","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.drup.2026.101355_bib835","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","article-title":"Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors","volume":"62","author":"Williams","year":"2018","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.drup.2026.101355_bib836","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1158\/1535-7163.MCT-16-0194","article-title":"Inhibition of breast cancer metastasis by presurgical treatment with an oral matrix metalloproteinase inhibitor: a preclinical proof-of-principle study","volume":"15","author":"Winer","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drup.2026.101355_bib837","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1152\/physiol.00045.2009","article-title":"Roles for growth factors in cancer progression","volume":"25","author":"Witsch","year":"2010","journal-title":"Physiology"},{"key":"10.1016\/j.drup.2026.101355_bib838","doi-asserted-by":"crossref","first-page":"16369","DOI":"10.1073\/pnas.1113483108","article-title":"Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation","volume":"108","author":"Wong","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.drup.2026.101355_bib839","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.semcancer.2022.08.003","article-title":"STAT family of transcription factors in breast cancer: pathogenesis and therapeutic opportunities and challenges","volume":"86","author":"Wong","year":"2022","journal-title":"Semin Cancer Biol."},{"key":"10.1016\/j.drup.2026.101355_bib840","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15061899","article-title":"Cancer-associated fibroblasts: master tumor microenvironment modifiers","volume":"15","author":"Wright","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drup.2026.101355_bib841","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.3389\/fneur.2020.00297","article-title":"miR-155 regulates the proliferation of glioma cells through PI3K\/AKT signaling","volume":"11","author":"Wu","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.drup.2026.101355_bib842","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1007\/s12094-023-03093-w","article-title":"Hypoxia promotes conversion to a stem cell phenotype in prostate cancer cells by activating HIF-1\u03b1\/Notch1 signaling pathway","volume":"25","author":"Wu","year":"2023","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib843","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107443","article-title":"PD-1\/PD-L1 enhanced cisplatin resistance in gastric cancer through PI3K\/AKT mediated P-gp expression","volume":"94","author":"Wu","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.drup.2026.101355_bib844","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2023.100624","article-title":"EGFR-T790M mutation\u2013derived interactome rerouted EGFR translocation contributing to gefitinib resistance in non-small cell lung cancer","volume":"22","author":"Wu","year":"2023","journal-title":"Mol. Cell. Proteom."},{"key":"10.1016\/j.drup.2026.101355_bib845","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108708","article-title":"Collagen facilitates the colorectal cancer stemness and metastasis through an integrin\/PI3K\/AKT\/Snail signaling pathway","volume":"114","author":"Wu","year":"2019","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.drup.2026.101355_bib846","doi-asserted-by":"crossref","DOI":"10.1177\/1533033819887962","article-title":"LncRNA BANCR promotes pancreatic cancer tumorigenesis via modulating MiR-195-5p\/Wnt\/\u03b2-catenin signaling pathway","volume":"18","author":"Wu","year":"2019","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.drup.2026.101355_bib847","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.biopha.2017.11.113","article-title":"Long noncoding RNA FEZF1-AS1 indicates a poor prognosis of gastric cancer and promotes tumorigenesis via activation of Wnt signaling pathway","volume":"96","author":"Wu","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.drup.2026.101355_bib848","doi-asserted-by":"crossref","first-page":"12061","DOI":"10.1007\/s13277-016-5074-2","article-title":"MicroRNA-21 promotes cell proliferation, migration, and resistance to apoptosis through PTEN\/PI3K\/AKT signaling pathway in esophageal cancer","volume":"37","author":"Wu","year":"2016","journal-title":"Tumor Biol."},{"key":"10.1016\/j.drup.2026.101355_bib849","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/nature08878","article-title":"Therapeutic antibody targeting of individual Notch receptors","volume":"464","author":"Wu","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101355_bib850","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1158\/1541-7786.MCR-12-0155-T","article-title":"Expression of Wnt3 activates Wnt\/\u03b2-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells","volume":"10","author":"Wu","year":"2012","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.drup.2026.101355_bib851","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/ijlh.13742","article-title":"Circ_0009910 sponges miR-491-5p to promote acute myeloid leukemia progression through modulating B4GALT5 expression and PI3K\/AKT signaling pathway","volume":"44","author":"Wu","year":"2022","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/j.drup.2026.101355_bib852","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/annonc\/mdv270","article-title":"First-line erlotinib versus gemcitabine\/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study","volume":"26","author":"Wu","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib853","doi-asserted-by":"crossref","first-page":"8367","DOI":"10.18632\/aging.204974","article-title":"The novel angiogenesis regulator circFAM169A promotes the metastasis of colorectal cancer through the angiopoietin-2 signaling axis","volume":"15","author":"Wu","year":"2023","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.drup.2026.101355_bib854","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1158\/2326-6066.CIR-14-0112","article-title":"NF-\u03baB, an active player in human cancers","volume":"2","author":"Xia","year":"2014","journal-title":"Cancer Immunol. Res"},{"key":"10.1016\/j.drup.2026.101355_bib855","first-page":"2819","article-title":"LncRNA UCA1 promotes epithelial-mesenchymal transition (EMT) of breast cancer cells via enhancing Wnt\/beta-catenin signaling pathway","volume":"20","author":"Xiao","year":"2016","journal-title":"Eur. Rev. Med Pharm. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib856","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.648407","article-title":"Clinically-relevant ABC transporter for anti-cancer drug resistance","volume":"12","author":"Xiao","year":"2021","journal-title":"Front Pharm."},{"key":"10.1016\/j.drup.2026.101355_bib857","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1089\/thy.2023.0157","article-title":"Methylation-mediated silencing of ATF3 promotes thyroid cancer progression by regulating prognostic genes in the MAPK and PI3K\/AKT pathways","volume":"33","author":"Xiao","year":"2023","journal-title":"Thyroid\u00ae"},{"key":"10.1016\/j.drup.2026.101355_bib858","first-page":"3405","article-title":"SHMT2 promotes tumor growth through VEGF and MAPK signaling pathway in breast cancer","volume":"12","author":"Xie","year":"2022","journal-title":"Am. J. Cancer Res"},{"key":"10.1016\/j.drup.2026.101355_bib859","doi-asserted-by":"crossref","first-page":"5114","DOI":"10.7150\/jca.58049","article-title":"ADNP prompts the cisplatin-resistance of bladder cancer via TGF-\u03b2-mediated epithelial-mesenchymal transition (EMT) pathway","volume":"12","author":"Xie","year":"2021","journal-title":"J. Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib860","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/s41420-021-00679-7","article-title":"Emerging roles of the Hedgehog signalling pathway in inflammatory bowel disease","volume":"7","author":"Xie","year":"2021","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.drup.2026.101355_bib861","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.3892\/ijmm.2020.4761","article-title":"Knockdown of long non\u2011coding RNA CCAT2 suppresses the progression of thyroid cancer by inhibiting the Wnt\/\u03b2\u2011catenin pathway","volume":"46","author":"Xin","year":"2020","journal-title":"Int J. Mol. Med"},{"key":"10.1016\/j.drup.2026.101355_bib862","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3892\/ijo.2012.1707","article-title":"MiR-21 regulates biological behavior through the PTEN\/PI-3 K\/Akt signaling pathway in human colorectal cancer cells","volume":"42","author":"Xiong","year":"2013","journal-title":"Int J. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib863","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/s41419-023-05944-4","article-title":"BCKDK regulates breast cancer cell adhesion and tumor metastasis by inhibiting TRIM21 ubiquitinate talin1","volume":"14","author":"Xu","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.drup.2026.101355_bib864","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/cr.2007.52","article-title":"Apoptosis signaling pathways and lymphocyte homeostasis","volume":"17","author":"Xu","year":"2007","journal-title":"Cell Res."},{"key":"10.1016\/j.drup.2026.101355_bib865","first-page":"6403","article-title":"NEAT1 promotes cell proliferation in multiple myeloma by activating PI3K\/AKT pathway","volume":"22","author":"Xu","year":"2018","journal-title":"Eur. Rev. Med Pharm. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib866","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13560","article-title":"CCL2 promotes metastasis and epithelial\u2013mesenchymal transition of non-small cell lung cancer via PI3K\/Akt\/mTOR and autophagy pathways","volume":"57","author":"Xu","year":"2024","journal-title":"Cell Prolif."},{"key":"10.1016\/j.drup.2026.101355_bib867","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/s41419-022-04935-1","article-title":"Cancer associated fibroblast\u2013derived CCL5 promotes hepatocellular carcinoma metastasis through activating HIF1\u03b1\/ZEB1 axis","volume":"13","author":"Xu","year":"2022","journal-title":"Cell death Dis."},{"key":"10.1016\/j.drup.2026.101355_bib868","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3233\/CBM-182293","article-title":"Hsa_circ_001569 is an unfavorable prognostic factor and promotes cell proliferation and metastasis by modulating PI3K-AKT pathway in breast cancer","volume":"25","author":"Xu","year":"2019","journal-title":"Cancer Biomark."},{"key":"10.1016\/j.drup.2026.101355_bib869","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/cr.2009.5","article-title":"TGF-beta-induced epithelial to mesenchymal transition","volume":"19","author":"Xu","year":"2009","journal-title":"Cell Res"},{"key":"10.1016\/j.drup.2026.101355_bib870","first-page":"52","article-title":"Combinatorial epigenetic regulation of non-coding RNAs has profound effects on oncogenic pathways in breast cancer subtypes","volume":"19","author":"Xu","year":"2018","journal-title":"Brief. Bioinforma."},{"key":"10.1016\/j.drup.2026.101355_bib871","article-title":"Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells","volume":"5","author":"Xu","year":"2010","journal-title":"PloS One"},{"key":"10.1016\/j.drup.2026.101355_bib872","doi-asserted-by":"crossref","first-page":"704","DOI":"10.7150\/thno.80184","article-title":"Battles against aberrant KEAP1-NRF2 signaling in lung cancer: intertwined metabolic and immune networks","volume":"13","author":"Xu","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.drup.2026.101355_bib873","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/1878-0261.12135","article-title":"Inhibition of IL-6-JAK\/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1\/NKG2D ligand levels","volume":"12","author":"Xu","year":"2018","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib874","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/pros.23479","article-title":"Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1\/NKG2D ligand levels in tumor cells","volume":"78","author":"Xu","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.drup.2026.101355_bib875","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12943-022-01670-1","article-title":"Targeting the tumor stroma for cancer therapy","volume":"21","author":"Xu","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib876","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1080\/09168451.2018.1431518","article-title":"Silencing of lncRNA ZFAS1 inhibits malignancies by blocking Wnt\/\u03b2-catenin signaling in gastric cancer cells","volume":"82","author":"Xu","year":"2018","journal-title":"Biosci., Biotechnol., Biochem."},{"key":"10.1016\/j.drup.2026.101355_bib877","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70281","article-title":"Transitional CXCL14(+) cancer-associated fibroblasts enhance tumour metastasis and confer resistance to EGFR-TKIs, revealing therapeutic vulnerability to filgotinib in lung adenocarcinoma","volume":"15","author":"Xu","year":"2025","journal-title":"Clin. Transl. Med"},{"key":"10.1016\/j.drup.2026.101355_bib878","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.bbrc.2018.05.139","article-title":"TGF-\u03b2 plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating stemness, EMT and apoptosis","volume":"502","author":"Xu","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.drup.2026.101355_bib879","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s13346-023-01505-6","article-title":"LINC00460 promotes neuroblastoma tumorigenesis and cisplatin resistance by targeting miR-149-5p\/DLL1 axis and activating Notch pathway in vitro and in vivo","volume":"14","author":"Xu","year":"2024","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.drup.2026.101355_bib880","article-title":"T790M mutation sensitizes non-small cell lung cancer cells to radiation via suppressing SPOCK1","volume":"38","author":"Xu","year":"2024","journal-title":"Biochem. Biophys. Rep."},{"key":"10.1016\/j.drup.2026.101355_bib881","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1002\/tox.23370","article-title":"LncRNA PSMA3-AS1 promotes cell proliferation, migration, and invasion in ovarian cancer by activating the PI3K\/Akt pathway via the miR-378a-3p\/GALNT3 axis","volume":"36","author":"Xu","year":"2021","journal-title":"Environ. Toxicol."},{"key":"10.1016\/j.drup.2026.101355_bib882","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","article-title":"Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer","volume":"8","author":"Xue","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.drup.2026.101355_bib883","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.canlet.2013.02.060","article-title":"Tumor-suppressive microRNA-145 targets catenin \u03b4-1 to regulate Wnt\/\u03b2-catenin signaling in human colon cancer cells","volume":"335","author":"Yamada","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.drup.2026.101355_bib884","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1158\/1078-0432.CCR-16-0520","article-title":"Loss of SMAD4 promotes lung metastasis of colorectal cancer by accumulation of CCR1+ tumor-associated neutrophils through CCL15-CCR1 axis","volume":"23","author":"Yamamoto","year":"2017","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.drup.2026.101355_bib885","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.3892\/ol.2017.6679","article-title":"Mode of action of pertuzumab in combination with trastuzumab plus docetaxel therapy in a HER2-positive breast cancer xenograft model","volume":"14","author":"Yamashita-Kashima","year":"2017","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.drup.2026.101355_bib886","doi-asserted-by":"crossref","first-page":"2304161","DOI":"10.1080\/15384047.2024.2304161","article-title":"Hypoxia promotes non-small cell lung cancer cell stemness, migration, and invasion via promoting glycolysis by lactylation of SOX9","volume":"25","author":"Yan","year":"2024","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.drup.2026.101355_bib887","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216263","article-title":"CXCL10 mediates CD8+ T cells to facilitate vessel normalization and improve the efficacy of cetuximab combined with PD-1 checkpoint inhibitors in colorectal cancer","volume":"567","author":"Yan","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.drup.2026.101355_bib888","doi-asserted-by":"crossref","first-page":"5942379","DOI":"10.1155\/2022\/5942379","article-title":"YAP overexpression in breast cancer cells promotes angiogenesis through activating YAP signaling in vascular endothelial cells","volume":"2022","author":"Yan","year":"2022","journal-title":"Anal. Cell. Pathol."},{"key":"10.1016\/j.drup.2026.101355_bib889","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.727464","article-title":"Anti-angiogenic agent combined with anti-PD-1 immunotherapy showed activity in patients with classical hodgkin lymphoma who have failed immunotherapy: a retrospective case report study","volume":"12","author":"Yan","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.drup.2026.101355_bib890","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s43556-025-00267-6","article-title":"TIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives","volume":"6","author":"Yan","year":"2025","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.drup.2026.101355_bib891","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s13046-021-02027-0","article-title":"Circular RNA circ_001422 promotes the progression and metastasis of osteosarcoma via the miR-195-5p\/FGF2\/PI3K\/Akt axis","volume":"40","author":"Yang","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101355_bib892","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41420-020-00390-z","article-title":"ABCA8-mediated efflux of taurocholic acid contributes to gemcitabine insensitivity in human pancreatic cancer via the S1PR2-ERK pathway","volume":"7","author":"Yang","year":"2021","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.drup.2026.101355_bib893","first-page":"2021","article-title":"CircHIPK3 promotes the tumorigenesis and development of gastric cancer through miR-637\/AKT1 pathway","volume":"11","author":"Yang","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib894","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s10456-024-09913-z","article-title":"Navigating tumor angiogenesis: therapeutic perspectives and myeloid cell regulation mechanism","volume":"27","author":"Yang","year":"2024","journal-title":"Angiogenesis"},{"key":"10.1016\/j.drup.2026.101355_bib895","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2025.117541","article-title":"Caulerpin suppresses tumor-associated angiogenesis and tumor growth via Hippo signaling in cervical cancer","volume":"504","author":"Yang","year":"2025","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.drup.2026.101355_bib896","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.3892\/etm.2020.8818","article-title":"TP53 mutation influences the efficacy of treatment of colorectal cancer cell lines with a combination of sirtuin inhibitors and chemotherapeutic agents","volume":"20","author":"Yang","year":"2020","journal-title":"Exp. Ther. Med"},{"key":"10.1016\/j.drup.2026.101355_bib897","first-page":"2025","article-title":"Reversal of ABCG2-mediated drug resistance by tinodasertib (ETC-206)","volume":"16","author":"Yang","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.drup.2026.101355_bib898","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41586-020-2394-6","article-title":"DNA of neutrophil extracellular traps promotes cancer metastasis via CCDC25","volume":"583","author":"Yang","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101355_bib899","doi-asserted-by":"crossref","first-page":"9107","DOI":"10.1158\/0008-5472.CAN-08-2556","article-title":"Transforming growth factor beta: tumor suppressor or promoter? Are host immune cells the answer?","volume":"68","author":"Yang","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101355_bib900","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.it.2010.04.002","article-title":"TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression","volume":"31","author":"Yang","year":"2010","journal-title":"Trends Immunol."},{"key":"10.1016\/j.drup.2026.101355_bib901","article-title":"Neratinib for HER2-positive breast cancer with an overlooked option","volume":"29","author":"Yang","year":"2023","journal-title":"Mol. Med."},{"key":"10.1016\/j.drup.2026.101355_bib902","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12943-019-0955-9","article-title":"Nuclear lncRNA HOXD-AS1 suppresses colorectal carcinoma growth and metastasis via inhibiting HOXD3-induced integrin \u03b23 transcriptional activating and MAPK\/AKT signalling","volume":"18","author":"Yang","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib903","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12944-022-01693-z","article-title":"Hypoxia-induced MIF induces dysregulation of lipid metabolism in Hep2 laryngocarcinoma through the IL-6\/JAK-STAT pathway","volume":"21","author":"Yang","year":"2022","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.drup.2026.101355_bib904","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13062-023-00376-8","article-title":"TM4SF1 upregulates MYH9 to activate the NOTCH pathway to promote cancer stemness and lenvatinib resistance in HCC","volume":"18","author":"Yang","year":"2023","journal-title":"Biol. Direct"},{"key":"10.1016\/j.drup.2026.101355_bib905","doi-asserted-by":"crossref","first-page":"9535","DOI":"10.18632\/oncotarget.14484","article-title":"HIF-1\u03b1 induces the epithelial-mesenchymal transition in gastric cancer stem cells through the Snail pathway","volume":"8","author":"Yang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.drup.2026.101355_bib906","first-page":"3365","article-title":"Long non\u2011coding RNA H19 promotes the migration and invasion of colon cancer cells via MAPK signaling pathway","volume":"16","author":"Yang","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.drup.2026.101355_bib907","unstructured":"Y. Yang, Z.-Y. Wang, Q. Liu, S. Sun, K. Wang, R. Chellappa, Z. Zhou, A. Yuille, L. Zhu and Y.-D. Zhang, Medical world model: Generative simulation of tumor evolution for treatment planning, arXiv preprint arXiv:2506.02327 (2025c)."},{"key":"10.1016\/j.drup.2026.101355_bib908","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.3349\/ymj.2015.56.6.1503","article-title":"Hypoxia induces epithelial-mesenchymal transition in follicular thyroid cancer: involvement of regulation of twist by hypoxia inducible factor-1\u03b1","volume":"56","author":"Yang","year":"2015","journal-title":"Yonsei Med J."},{"key":"10.1016\/j.drup.2026.101355_bib909","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/jop.12968","article-title":"Long non-coding RNA BANCR promotes proliferation and migration in oral squamous cell carcinoma via MAPK signaling pathway","volume":"50","author":"Yao","year":"2021","journal-title":"J. Oral. Pathol. Med."},{"key":"10.1016\/j.drup.2026.101355_bib910","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2024.156771","article-title":"Ang-1 promotes tumorigenesis and mediates the anti-cancer effects of Artesunate on Choroidal melanoma via the regulation of Akt\/mTOR signaling pathway","volume":"184","author":"Yao","year":"2024","journal-title":"Cytokine"},{"key":"10.1016\/j.drup.2026.101355_bib911","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20201389","article-title":"LncRNA UCA1 elevates the resistance of human leukemia cells to daunorubicin by the PI3K\/AKT pathway via sponging miR-613","volume":"41","author":"Yao","year":"2021","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.drup.2026.101355_bib912","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/s41416-022-01834-2","article-title":"Inhibition of PFKFB3 in HER2-positive gastric cancer improves sensitivity to trastuzumab by inducing tumour vessel normalisation","volume":"127","author":"Yao","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib913","doi-asserted-by":"crossref","first-page":"53839","DOI":"10.18632\/oncotarget.17809","article-title":"The role of Notch signaling in gastric carcinoma: molecular pathogenesis and novel therapeutic targets","volume":"8","author":"Yao","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.drup.2026.101355_bib914","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.2147\/CMAR.S199291","article-title":"MicroRNA-145 inhibits growth of laryngeal squamous cell carcinoma by targeting the PI3K\/Akt signaling pathway","volume":"11","author":"Ye","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.drup.2026.101355_bib915","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1080\/09553002.2021.1866225","article-title":"MiR-34a reverses radiation resistance on ECA-109 cells by inhibiting PI3K\/AKT\/mTOR signal pathway through downregulating the expression of SIRT1","volume":"97","author":"Ye","year":"2021","journal-title":"Int. J. Radiat. Biol."},{"key":"10.1016\/j.drup.2026.101355_bib916","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e36133","article-title":"CircRAPGEF5 acts as a modulator of RAS\/RAF\/MEK\/ERK signaling during colorectal carcinogenesis","volume":"10","author":"Yin","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.drup.2026.101355_bib917","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13215542","article-title":"CCR4 as a therapeutic target for cancer immunotherapy","volume":"13","author":"Yoshie","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2026.101355_bib918","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1089\/dna.2024.0109","article-title":"Innovating cancer treatment through cell cycle, telomerase, angiogenesis, and metastasis","volume":"43","author":"Yousefi","year":"2024","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.drup.2026.101355_bib919","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/bjc.2017.362","article-title":"Dual roles of tumour cells-derived matrix metalloproteinase 2 on brain tumour growth and invasion","volume":"117","author":"Yu","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib920","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jbo.2018.02.002","article-title":"Long non-coding RNA ANRIL is associated with a poor prognosis of osteosarcoma and promotes tumorigenesis via PI3K\/Akt pathway","volume":"11","author":"Yu","year":"2018","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib921","doi-asserted-by":"crossref","first-page":"CNS106","DOI":"10.2217\/cns-2023-0018","article-title":"Promising response to vemurafenib and cobimetinib treatment for BRAF V600E mutated craniopharyngioma: a case report and literature review","volume":"13","author":"Yu","year":"2024","journal-title":"CNS Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib922","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/jcb.24965","article-title":"miR-99a suppresses the metastasis of human non-small cell lung cancer cells by targeting AKT1 signaling pathway","volume":"116","author":"Yu","year":"2015","journal-title":"J. Cell Biochem"},{"key":"10.1016\/j.drup.2026.101355_bib923","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1007\/s11596-024-2949-0","article-title":"LncRNA H19 activates the RAS-MAPK signaling pathway via miR-140-5p\/SOS1 Axis in malignant liver tumors","volume":"44","author":"Yu","year":"2024","journal-title":"Curr. Med. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib924","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41419-021-04494-x","article-title":"ATF4\/CEMIP\/PKC\u03b1 promotes anoikis resistance by enhancing protective autophagy in prostate cancer cells","volume":"13","author":"Yu","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.drup.2026.101355_bib925","doi-asserted-by":"crossref","first-page":"14765","DOI":"10.1073\/pnas.93.25.14765","article-title":"Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor\/vascular permeability factor\u2009antibody","volume":"93","author":"Yuan","year":"1996","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib926","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41525-021-00232-6","article-title":"Loss of grand histone H3 lysine 27 trimethylation domains mediated transcriptional activation in esophageal squamous cell carcinoma","volume":"6","author":"Yuan","year":"2021","journal-title":"npj Genom. Med."},{"key":"10.1016\/j.drup.2026.101355_bib927","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.3892\/or.2016.4660","article-title":"Role of the tumor microenvironment in tumor progression and the clinical applications (Review)","volume":"35","author":"Yuan","year":"2016","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.drup.2026.101355_bib928","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s13643-022-02134-9","article-title":"Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis","volume":"11","author":"Yuan","year":"2022","journal-title":"Syst. Rev."},{"key":"10.1016\/j.drup.2026.101355_bib929","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat. Med"},{"key":"10.1016\/j.drup.2026.101355_bib930","doi-asserted-by":"crossref","first-page":"11795","DOI":"10.1080\/21655979.2021.2008639","article-title":"Circular RNA Pvt1 oncogene (CircPVT1) promotes the progression of papillary thyroid carcinoma by activating the Wnt\/\u03b2-catenin signaling pathway and modulating the ratio of microRNA-195 (miR-195) to vascular endothelial growth factor A (VEGFA) expression","volume":"12","author":"Zeng","year":"2021","journal-title":"Bioengineered"},{"key":"10.1016\/j.drup.2026.101355_bib931","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1053\/j.gastro.2009.11.004","article-title":"Antimetastatic role of Smad4 signaling in colorectal cancer","volume":"138","author":"Zhang","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drup.2026.101355_bib932","article-title":"The interplay between tumor suppressor p53 and hypoxia signaling pathways in cancer","volume":"9","author":"Zhang","year":"2021","journal-title":"Front Cell Dev. Biol."},{"key":"10.1016\/j.drup.2026.101355_bib933","first-page":"9233","article-title":"Long non-coding RNA MALAT1 regulates cell proliferation, invasion and apoptosis by modulating the Wnt signaling pathway in squamous cell carcinoma","volume":"13","author":"Zhang","year":"2021","journal-title":"Am. J. Transl. Res"},{"key":"10.1016\/j.drup.2026.101355_bib934","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00018-023-05068-0","article-title":"APC mutations disrupt \u03b2-catenin destruction complex condensates organized by Axin phase separation","volume":"81","author":"Zhang","year":"2024","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.drup.2026.101355_bib935","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.biopha.2016.11.058","article-title":"Long non-coding RNA ANRIL indicates a poor prognosis of cervical cancer and promotes carcinogenesis via PI3K\/Akt pathways","volume":"85","author":"Zhang","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.drup.2026.101355_bib936","first-page":"5856","article-title":"Expression of circ_001569 is upregulated in osteosarcoma and promotes cell proliferation and cisplatin resistance by activating the Wnt\/\u03b2\u2011catenin signaling pathway","volume":"16","author":"Zhang","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.drup.2026.101355_bib937","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.7150\/jca.20150","article-title":"Downregulation of BANCR promotes aggressiveness in papillary thyroid cancer via the MAPK and PI3K pathways","volume":"9","author":"Zhang","year":"2018","journal-title":"J. Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib938","first-page":"913","article-title":"miR-221\/222 promote malignant progression of glioma through activation of the Akt pathway","volume":"36","author":"Zhang","year":"2010","journal-title":"Int J. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib939","article-title":"Tucatinib has selective activity in HER2-positive cancers and significant combined activity with approved and novel breast cancer-targeted therapies","author":"Zhang","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drup.2026.101355_bib940","first-page":"357","article-title":"MALAT1 inhibits the Wnt\/\u03b2-catenin signaling pathway in colon cancer cells and affects cell proliferation and apoptosis","volume":"20","author":"Zhang","year":"2020","journal-title":"Bosn. J. Basic Med Sci."},{"key":"10.1016\/j.drup.2026.101355_bib941","first-page":"4663","article-title":"MiR-99a suppressed cell proliferation and invasion by directly targeting HOXA1 through regulation of the AKT\/mTOR signaling pathway and EMT in ovarian cancer","volume":"23","author":"Zhang","year":"2019","journal-title":"Eur. Rev. Med Pharm. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib942","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/s41419-023-06108-0","article-title":"Tumor-associated macrophages confer colorectal cancer 5-fluorouracil resistance by promoting MRP1 membrane translocation via an intercellular CXCL17\/CXCL22\u2013CCR4\u2013ATF6\u2013GRP78 axis","volume":"14","author":"Zhang","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.drup.2026.101355_bib943","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13045-018-0656-7","article-title":"The lncRNA NEAT1 activates Wnt\/\u03b2-catenin signaling and promotes colorectal cancer progression via interacting with DDX5","volume":"11","author":"Zhang","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib944","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.786728","article-title":"TGF-\u03b2 signaling and resistance to cancer therapy","volume":"9","author":"Zhang","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.drup.2026.101355_bib945","doi-asserted-by":"crossref","first-page":"eadi5174","DOI":"10.1126\/scisignal.adi5174","article-title":"The kinase PLK1 promotes Hedgehog signaling\u2013dependent resistance to the antiandrogen enzalutamide in metastatic prostate cancer","volume":"18","author":"Zhang","year":"2025","journal-title":"Sci. Signal."},{"key":"10.1016\/j.drup.2026.101355_bib946","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13046-019-1127-x","article-title":"Angiotensin II promotes ovarian cancer spheroid formation and metastasis by upregulation of lipid desaturation and suppression of endoplasmic reticulum stress","volume":"38","author":"Zhang","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101355_bib947","doi-asserted-by":"crossref","first-page":"10902","DOI":"10.18632\/aging.102493","article-title":"The long non-coding RNA SNHG12 promotes gastric cancer by activating the phosphatidylinositol 3-kinase\/AKT pathway","volume":"11","author":"Zhang","year":"2019","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.drup.2026.101355_bib948","first-page":"2021","article-title":"Long noncoding RNA SNHG12 promotes gastric cancer proliferation by binding to HuR and stabilizing YWHAZ expression through the AKT\/GSK-3\u03b2 pathway","volume":"11","author":"Zhang","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib949","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000519844","article-title":"LncRNA HOTAIR promotes chemoresistance by facilitating epithelial to mesenchymal transition through miR-29b\/PTEN\/PI3K signaling in cervical cancer","volume":"211","author":"Zhang","year":"2021","journal-title":"Cells Tissues Organs"},{"key":"10.1016\/j.drup.2026.101355_bib950","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.7150\/ijbs.66184","article-title":"Exosome-depleted MiR-148a-3p derived from hepatic stellate cells promotes tumor progression via ITGA5\/PI3K\/Akt Axis in hepatocellular carcinoma","volume":"18","author":"Zhang","year":"2022","journal-title":"Int J. Biol. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib951","article-title":"STK32C activated IL-6\/JAK2\/STAT3 signaling and promoted tumor angiogenesis","author":"Zhang","year":"2025","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.drup.2026.101355_bib952","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41419-021-03794-6","article-title":"Hsa_circ_0026628 promotes the development of colorectal cancer by targeting SP1 to activate the Wnt\/\u03b2-catenin pathway","volume":"12","author":"Zhang","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.drup.2026.101355_bib953","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1007\/s10147-017-1161-7","article-title":"PD-L1 induced by IFN-\u03b3 from tumor-associated macrophages via the JAK\/STAT3 and PI3K\/AKT signaling pathways promoted progression of lung cancer","volume":"22","author":"Zhang","year":"2017","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib954","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215917","article-title":"NEK2 inactivates the Hippo pathway to advance the proliferation of cervical cancer cells by cooperating with STRIPAK complexes","volume":"549","author":"Zhang","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.drup.2026.101355_bib955","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.biopha.2017.11.096","article-title":"LncRNA HOXD-AS1 promotes epithelial ovarian cancer cells proliferation and invasion by targeting miR-133a-3p and activating Wnt\/\u03b2-catenin signaling pathway","volume":"96","author":"Zhang","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.drup.2026.101355_bib956","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3892\/ol.2020.11687","article-title":"MicroRNA\u2011126 exerts antitumor functions in ovarian cancer by targeting EGFL7 and affecting epithelial\u2011to\u2011mesenchymal transition and ERK\/MAPK signaling pathway Retraction in","volume":"20","author":"Zhang","year":"2020","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.drup.2026.101355_bib957","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13045-020-00990-3","article-title":"Targeting the Wnt\/\u03b2-catenin signaling pathway in cancer","volume":"13","author":"Zhang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib958","first-page":"443","article-title":"LncRNA TUC338 promotes invasion of lung cancer by activating MAPK pathway","volume":"22","author":"Zhang","year":"2018","journal-title":"Eur. Rev. Med Pharm. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib959","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.3389\/fmolb.2020.627774","article-title":"CRISPR-Cas13-mediated knockdown of lncRNA-GACAT3 inhibited cell proliferation and motility, and induced apoptosis by increasing p21, Bax, and E-cadherin expression in bladder cancer","volume":"7","author":"Zhang","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.drup.2026.101355_bib960","first-page":"8412","article-title":"Effects of miR-126 on the STAT3 signaling pathway and the regulation of malignant behavior in lung cancer cells","volume":"15","author":"Zhang","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.drup.2026.101355_bib961","first-page":"4600","article-title":"Long non\u2011coding RNA\u2011CCAT2 promotes the occurrence of non\u2011small cell lung cancer by regulating the Wnt\/\u03b2\u2011catenin signaling pathway","volume":"16","author":"Zhao","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.drup.2026.101355_bib962","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1158\/0008-5472.CAN-13-3311-T","article-title":"miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt\/\u03b2-catenin\/BCL9 pathway","volume":"74","author":"Zhao","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2026.101355_bib963","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s12967-023-04063-0","article-title":"Mesenchymal stromal cells promote the drug resistance of gastrointestinal stromal tumors by activating the PI3K-AKT pathway via TGF-\u03b22","volume":"21","author":"Zhao","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.drup.2026.101355_bib964","first-page":"563","article-title":"LncRNA FENDRR affect proliferation, migration and apoptosis of lung squamous cell carcinoma H226 cells via ERK\/MAPK signaling pathway","volume":"49","author":"Zheng","year":"2022","journal-title":"Cancer Res. Prev. Treat."},{"key":"10.1016\/j.drup.2026.101355_bib965","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317705335","article-title":"Knockdown of long non-coding RNA HOXD-AS1 inhibits gastric cancer cell growth via inactivating the JAK2\/STAT3 pathway","volume":"39","author":"Zheng","year":"2017","journal-title":"Tumor Biol."},{"key":"10.1016\/j.drup.2026.101355_bib966","article-title":"Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?","volume":"8","author":"Zheng","year":"2018","journal-title":"Cell Biosci."},{"key":"10.1016\/j.drup.2026.101355_bib967","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s12935-019-0943-6","article-title":"miR-145 sensitizes esophageal squamous cell carcinoma to cisplatin through directly inhibiting PI3K\/AKT signaling pathway","volume":"19","author":"Zheng","year":"2019","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.drup.2026.101355_bib968","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12967-021-03226-1","article-title":"MiR-30c-5p loss-induced PELI1 accumulation regulates cell proliferation and migration via activating PI3K\/AKT pathway in papillary thyroid carcinoma","volume":"20","author":"Zheng","year":"2022","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.drup.2026.101355_bib969","doi-asserted-by":"crossref","first-page":"6163","DOI":"10.18632\/aging.204826","article-title":"PRMT5 facilitates angiogenesis and EMT via HIF-1\u03b1\/VEGFR\/Akt signaling axis in lung cancer","volume":"15","author":"Zheng","year":"2023","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.drup.2026.101355_bib970","first-page":"8288","article-title":"Long non-coding RNA LINC00675 inhibits tumorigenesis and EMT via repressing Wnt\/\u03b2-catenin signaling in esophageal squamous cell carcinoma","volume":"22","author":"Zhong","year":"2018","journal-title":"Eur. Rev. Med Pharm. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib971","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41392-022-00934-y","article-title":"Notch signaling pathway: architecture, disease, and therapeutics","volume":"7","author":"Zhou","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.drup.2026.101355_bib972","doi-asserted-by":"crossref","first-page":"13834","DOI":"10.1038\/srep13834","article-title":"Modeling the interplay between the HIF-1 and p53 pathways in hypoxia","volume":"5","author":"Zhou","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drup.2026.101355_bib973","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.biopha.2016.11.100","article-title":"miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K\/Akt signaling pathway and inhibites cell migration via targeting ZEB1","volume":"85","author":"Zhou","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.drup.2026.101355_bib974","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41392-020-00430-1","article-title":"Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents","volume":"6","author":"Zhou","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.drup.2026.101355_bib975","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1038\/s41388-023-02841-0","article-title":"GPR37 promotes colorectal cancer liver metastases by enhancing the glycolysis and histone lactylation via Hippo pathway","volume":"42","author":"Zhou","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.drup.2026.101355_bib976","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2217\/fon-2020-0273","article-title":"LncRNA PCAT7 promotes the malignant progression of breast cancer by regulating ErbB\/PI3K\/Akt pathway","volume":"17","author":"Zhou","year":"2021","journal-title":"Future Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib977","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12929-022-00818-x","article-title":"Post-translational modifications on the retinoblastoma protein","volume":"29","author":"Zhou","year":"2022","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib978","article-title":"Consensus on the lung cancer management after third-generation EGFR-TKI resistance","volume":"53","author":"Zhou","year":"2024","journal-title":"Lancet Reg. Health \u2013 West. Pac."},{"key":"10.1016\/j.drup.2026.101355_bib979","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.2147\/OTT.S144103","article-title":"Novel long noncoding RNA GACAT3 promotes colorectal cancer cell proliferation, invasion, and migration through miR-149","volume":"11","author":"Zhou","year":"2018","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.drup.2026.101355_bib980","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ccr.2012.12.001","article-title":"<em>NEK2<\/em> induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers","volume":"23","author":"Zhou","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2026.101355_bib981","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/jmcb\/mjy072","article-title":"Mutant p53 in cancer therapy\u2014the barrier or the path","volume":"11","author":"Zhou","year":"2019","journal-title":"J. Mol. Cell Biol."},{"key":"10.1016\/j.drup.2026.101355_bib982","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41420-022-01201-3","article-title":"MCM2 promotes the stemness and sorafenib resistance of hepatocellular carcinoma cells via hippo signaling","volume":"8","author":"Zhou","year":"2022","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.drup.2026.101355_bib983","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.3389\/fonc.2019.00350","article-title":"Long Non-coding RNA CASC2 enhances the antitumor activity of cisplatin through suppressing the Akt pathway by inhibition of miR-181a in esophageal squamous cell carcinoma cells","volume":"9","author":"Zhu","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.drup.2026.101355_bib984","first-page":"5335","article-title":"lncRNA MALAT1 overexpression promotes proliferation, migration and invasion of gastric cancer by activating the PI3K\/AKT pathway","volume":"17","author":"Zhu","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.drup.2026.101355_bib985","first-page":"2313","article-title":"LINC00675 suppresses proliferative, migration and invasion of clear cell renal cell carcinoma via the Wnt\/\u03b2-catenin pathway","volume":"24","author":"Zhu","year":"2020","journal-title":"Eur. Rev. Med Pharm. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib986","article-title":"Hypoxia\/inflammation-induced upregulation of HIF-1\u03b1 and C\/EBP\u03b2 promotes nephroblastoma cell EMT by improving HOXA11-AS transcription","volume":"10","author":"Zhu","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.drup.2026.101355_bib987","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1038\/s41467-018-03951-0","article-title":"Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1","volume":"9","author":"Zhu","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101355_bib988","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40257-021-00593-9","article-title":"Combining BRAF\/MEK inhibitors with immunotherapy in the treatment of metastatic melanoma","volume":"22","author":"Ziogas","year":"2021","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.drup.2026.101355_bib989","doi-asserted-by":"crossref","first-page":"E3395","DOI":"10.1073\/pnas.1217982109","article-title":"Stromal epigenetic dysregulation is sufficient to initiate mouse prostate cancer via paracrine Wnt signaling","volume":"109","author":"Zong","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.drup.2026.101355_bib990","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13578-020-00396-1","article-title":"mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges","volume":"10","author":"Zou","year":"2020","journal-title":"Cell Biosci."},{"key":"10.1016\/j.drup.2026.101355_bib991","first-page":"7935","article-title":"MiR-155 promotes proliferation and inhibits apoptosis of nasopharyngeal carcinoma cells through targeting PTEN-PI3K\/AKT pathway","volume":"23","author":"Zuo","year":"2019","journal-title":"Eur. Rev. Med Pharm. Sci."}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764626000063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764626000063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T02:40:53Z","timestamp":1773974453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368764626000063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":991,"alternative-id":["S1368764626000063"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2026.101355","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The hallmarks of oncogenic signaling: From pathways to resistance in cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Drug Resistance Updates","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drup.2026.101355","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101355"}}